Pyrazole derivatives as RET kinase inhibitors
Patent Information
- Application Number
- JP2023074122
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2023-04-28
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2041-11-05
AI Technical Summary
Current treatments for cancers and disorders associated with aberrant RET kinase activity, such as RET-related cancers and irritable bowel syndrome (IBS), are inadequate, particularly in cases where genetic alterations lead to overactive RET signaling or conformational changes in the kinase, rendering existing inhibitors less effective.
Development of novel pyrazole derivatives that act as RET kinase inhibitors, capable of targeting and inhibiting aberrant RET kinase activity, including mutations that confer resistance to other inhibitors, thereby providing therapeutic benefits for RET-related cancers and IBS.
The pyrazole derivatives effectively inhibit aberrant RET kinase activity, offering potent treatment options for RET-related cancers and IBS, even in cases with inhibitor-resistant mutations, by selectively targeting the kinase and reducing uncontrolled cell proliferation.
Smart Images

Figure 2023099116000001 
Figure 2023099116000002 
Figure 2023099116000003
Abstract
Description
Background Art
[0001] Receptor tyrosine kinase (RET) that is reconstituted during transfection is a single-pass transmembrane receptor belonging to the tyrosine kinase superfamily required for normal development, maturation, and maintenance of several tissues and cell types. The extracellular portion of the RET kinase contains four calcium-dependent cadherin-like repeats involved in ligand binding and a cysteine-rich region near the membrane necessary for proper folding of the RET extracellular domain, while the cytoplasmic portion of the receptor contains two tyrosine kinase subdomains. RET signaling is mediated by the binding of a group of 35 soluble proteins of the glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs), which also include neurturin (NTRN), artemin (ARTN), and persephin (PSPN). Unlike other receptor tyrosine kinases, RET does not bind directly to GFLs and requires an additional co-receptor, which can be one of four GDNF family receptor-α (GFRα) family members tethered to the cell surface by a glycosylphosphatidylinositol linkage. GFLs and GFRα family members form a binary complex that binds to RET in sequence and recruits it to the cholesterol-rich membrane subdomain where RET signaling occurs. Upon binding of the ligand-co-receptor complex, dimerization and autophosphorylation of RET at intracellular tyrosine residues recruits adapter and signaling proteins, activating multiple downstream pathways.
[0002]
[0003] This is stimulated. The adapter proteins that bind to these docking sites are Ras-M Activation of the APK and PI3K-Akt / mTOR signaling pathways, or RET-mediated CBL family of ubiquitin ligases that function during RET downregulation. This will lead to the mobilization of...
[0004] Genetic alterations in RET kinase, including protein-gene fusions and activation site mutations. The disruption of normal RET activity due to the resulting abnormal RET expression is caused by hyperactive RET signaling Uncontrolled cell proliferation, such as various types of cancer and irritable bowel syndrome (IBS). This can lead to certain gastrointestinal disorders, such as those associated with hyperactive RET signaling. The ability to inhibit abnormal RET activity in patients with other disorders would be extremely beneficial. Furthermore, genetic changes in several RET kinases affect the conformational structure of RET kinases. There are cases where a given RET kinase inhibitor is less effective (or ineffective). The goal is to change it to a certain extent. In such cases, a new modified RET kinase is effective. RET kinase inhibitors will likely bring significant benefits to patients. [Overview of the Initiative]
[0005] A compound of formula I, [ka] During the ceremony, A is C6-C 10 It is an aryl or C5-C6 heteroaryl, Each R1 independently contains hydrogen, halogen, C1-C6 alkyl, and C1-C6 heteroalkyl. -(C1-C4 alkyl)(C5-C6 heteroalkyl), -(C0-C4 alkyl) (C3-C7 cycloalkyl), -(C0-C4 heteroalkyl)(C3-C7 cycloalkyl) Lukil), -(C0-C4 alkyl)(C3-C7 cycloheteroalkyl), -(C0- C4 heteroalkyl)(C3-C7 cycloheteroalkyl), -(C0-C4 alkyl) (C4-C 10 Bicyclyl), -(C0-C4 alkyl)(C5-C6 aryl), -( C0-C4 alkyl)(C5-C6 heteroaryl), -(C0-C4 alkyl)(C4 -C 10 Heterobicyclyl), C5-C 12 Spiranil, C5-C 12 Heterospiranil dimethylphosphoryl, adamantyl, C1-C6 alkoxy, -(C1-C4 alkyl )-SO2-(C1-C4 alkyl), difluoromethylsulfanyl, or pentaph If it is ruolosulfanil and each R1 is either unsubstituted or substituted, R1 can be any of the following: halogen, cyano, hydroxyl, oxo, methyl, methoxy, or hydro hydroxymethyl, ethyl, ethoxy, hydroxyethyl, methylamine, N,N-dimethylmethyl Cylamine, mono-, di-, or trihalomethoxy, mono-, di-, or tri-halomethoxy One or more selected from the group consisting of methyl and C0-C3 alkylpyrrolidinyl. It is substituted with a substituent, and the pyrrolidinyl group is either unsubstituted or has 1, 2, or It is substituted with three independently selected halogen atoms, and two R1 groups are condensed, It can form a ring structure that includes part A and is optionally aromatic, and n is 1, 2, 3, 4, 5, or 6, X1, X2, X3, and X4 each operate independently as N, CH, C-CH3, C-CH2- It is OH, C-OCH3, C-CH2-OCH3, or C-halogen, R2 is C1-C6 alkyl, -(C0-C4 alkyl)(C3-C7 cycloalkyl ), -(C0-C4 alkyl)(C4-C7 heterocycloalkyl), -(C0-C4 alkyl) Lukil) (C4-C 10 It is a bicyclic compound, and each element can be arbitrarily selected from halogens, cyanoacrylates, and hydronitriles. Xyl, oxo, methyl, methoxy, hydroxymethyl, ethyl, ethoxy, hydroxy Ethyl, cyclopropyl, or one of mono-, di-, or tri-halomethyl The compounds that are substituted as described above, Or a pharmaceutically acceptable salt thereof is disclosed herein.
[0006] Methods using the compound of formula I or a pharmaceutically acceptable salt thereof are further disclosed herein. It is used to treat cancer, especially cancers with abnormal RET expression (e.g., thyroid cancer). For the treatment of medullary carcinoma or RET-associated cancers such as RET-fusion lung cancer, its pharmaceutical Compositions are also provided. The method involves a therapeutically effective amount of a compound of formula I or its pharmaceutically acceptable composition. This includes administering the salt to patients who require it.
[0007] Compounds of formula I or pharmaceutically acceptable salts thereof for use in therapy are also provided herein. It is provided for use in the treatment of cancer, particularly cancers with abnormal RET expression (e.g., type A). Formula I for the treatment of RET-related cancers such as medullary lung cancer or RET-fusion lung cancer Compounds or pharmaceutically acceptable salts thereof are further provided herein. In the manufacture of drugs for which a particular type of cancer involves abnormal RET expression (e.g., medullary thyroid carcinoma), The compound of formula I for use in the treatment of RET-related cancers such as RET-fusion lung cancer. The use of the substance or a pharmaceutically acceptable salt thereof is also provided herein.
[0008] explanation Novel RET kinase inhibitor compounds are described herein. These novel compounds Disorders associated with abnormal RET activity, such as IBS or cancer, particularly hyperactive RET sigma The need for powerful and effective treatments for cancers arising from nal transmission (i.e., RET-associated cancers) It can be addressed. More specifically, these new compounds can help treat lung cancer (e.g., small cell lung cancer). (or non-small cell lung cancer), thyroid cancer (e.g., papillary thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer) Differential thyroid cancer, recurrent thyroid cancer, or refractory differentiated thyroid cancer), multiple endocrine neoplasms Disease type 2A or 2B (MEN2A or MEN2B, respectively), goiter, endocrine disorders Adenoma, lung adenocarcinoma, bronchiololung cell carcinoma, multiple endocrine neoplasia type 2A or 2B ( (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer (bre) breast cancer, mammary cancer, mammary cancer breast carcinoma, breast neoplasms, colorectal cancer (e.g., metastatic colorectal cancer), breast Cephalic renal cell carcinoma, ganglionic neuroma of the gastrointestinal mucosa, inflammatory myofibroblastic tumor, or cervical cancer. This could address the need for powerful and effective treatments for RET-related cancers, such as cancer.
[0009] A compound of formula I, [ka] During the ceremony, A is C6-C 10 It is an aryl or C5-C6 heteroaryl, Each R1 independently contains hydrogen, halogen, C1-C6 alkyl, and C1-C6 heteroalkyl. -, -(C1-C4 alkyl)(C5-C6 heteroalkyl), -(C0-C4 alkyl) (C3-C7 cycloalkyl), -(C0-C4 heteroalkyl)(C3-C7 cyclo alkyl), -(C0-C4 alkyl)(C3-C7 cycloheteroalkyl), -(C0- C4 heteroalkyl)(C3-C7 cycloheteroalkyl), -(C0-C4 alkyl) (C4-C 10 bicyclil), -(C0-C4 alkyl)(C5-C6 aryl), -( C0-C4 alkyl)(C5-C6 heteroaryl), -(C0-C4 alkyl)(C4 -C 10 heterobicyclil), C5-C 12 spirainyl, C5-C 12 heterospirainyl , dimethylphosphoryl, adamantyl, C1-C6 alkoxy, -(C1-C4 alkyl )-SO2-(C1-C4 alkyl), difluoromethylsulfanyl, or penta fluorosulfanyl, and each R1 is unsubstituted or, when substitution is possible, R1 is independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, methyl, methoxy, hydro xymethyl, ethyl, ethoxy, hydroxyethyl, methylamine, N,N-dimethylme thylamine, mono-, di, or trihalomethoxy, mono-, di-, or tri-h romomethyl, and C0-C3 alkyl-pyrrolidinyl, and the pyrrolidinyl group is unsubstituted or is substituted with 1, 2, or 3 independently selected halogen atoms, and two R1 groups can condense to form a ring structure containing a moiety of A and optionally being aromatic, and n is 1, 2, 3, 4, 5, or 6, and X1, X2, X3, and X4 each operate independently as N, CH, C-CH3, C-CH2- It is OH, C-OCH3, C-CH2-OCH3, or C-halogen, R2 is C1-C6 alkyl, -(C0-C4 alkyl)(C3-C7 cycloalkyl ), -(C0-C4 alkyl)(C4-C7 heterocycloalkyl), -(C0-C4 alkyl) Lukil) (C4-C 10 It is a bicyclic compound, and each element can be arbitrarily selected from halogens, cyanoacrylates, and hydronitriles. Xyl, oxo, methyl, methoxy, hydroxymethyl, ethyl, ethoxy, hydroxy Ethyl, cyclopropyl, or one of mono-, di-, or tri-halomethyl The compounds that are substituted as described above, Or a pharmaceutically acceptable salt thereof is provided herein.
[0010] In some embodiments, the compounds of formula I and pharmaceutically acceptable salts are X1, X2, X 3, and at least one of X4 is CH. Sometimes X1, X2, X3, and X1 and X4 are each CH. Alternatively, at least one of X1, X2, X3, and X4 Another is N. In one embodiment, X1 is N, and each of X2, X3, and X4 These are CH. In another embodiment, X2 is N, and each of X1, X3, and X4 These are CH. In some compounds, at least one of X1 and X2 is It is C-Cl or CF. In other compounds, X1 and X2 are independently C-Cl It is selected from the group consisting of and CF. Furthermore, in other compounds, X1 and X2 are independently Then, selected from the group consisting of C-Cl and CF, X3 and X4 are both CH. Alternatively, X1 and X3 are independently selected from the group consisting of C-Cl and CF. In some compounds, X2 is either C-OCH3 or C-CH2-OH.
[0011] In some compounds of formula I and pharmaceutically acceptable salts, X2 and X3 are both It is N. In other compounds, both X2 and X3 are N, and X1 and X4 are independent. Then, selected from CH, C-Cl, CF, C-OCH3, and C-CH2-OH Furthermore, in other compounds, both X2 and X3 are N, and both X1 and X4 are It is also CH. Furthermore, in other compounds, both X2 and X3 are N, and X1 and X4 is independently CH, C-Cl, or CF. In some compounds, X1 is Both X1 and X4 are N. In other compounds, both X1 and X4 are N, and X 2 and X3 independently consist of CH, C-Cl, CF, C-OCH3, and C-CH2- It is selected from OH. Furthermore, in other compounds, both X1 and X4 are N, and X2 And X3 are both CH. Furthermore, in other compounds, X1 and X4 are both N And X2 and X3 are independently CH, C-Cl, or CF.
[0012] In some compounds of formula I and pharmaceutically acceptable salts, X1 and X3 are both N is N, and X2 and X4 are independently CH, C-Cl, CF, C-OCH3, and It is selected from C-CH2-OH. In other compounds, both X1 and X3 are N. In the other compound, both X2 and X4 are CH. And X2 and X4 are independently CH, C-Cl, or CF.
[0013] In the compound of formula I and its pharmaceutically acceptable salt, or its pharmaceutically acceptable salt, A -(R1) n teeth, [ka] And, In the formula, the dashed line indicates a connection to the skeleton, and the maximum value of n depends on the number of substitutable positions on ring A. do.
[0014] In one embodiment, the compound and salt of formula I are A-(R1) n teeth, [ka] And, The maximum value of n depends on the number of substitutable positions on ring A.
[0015] In one embodiment, for the compound of formula I and pharmaceutically acceptable salts, A-(R1) n teeth, [ka] And, The maximum value of n depends on the number of substitutable positions on ring A.
[0016] In another embodiment, for compounds of formula I and pharmaceutically acceptable salts, A-(R1) n teeth, [ka] That is the case.
[0017] In one embodiment, n is 5 or less. In a further embodiment, n is 1 to 3 or 1 ~2. In a further embodiment, when n is 3, each R1 group independently is halogen It is methyl or methoxy. In another embodiment, when n is 2, at least one One R1 is a halogen, and the other R1 is methyl or methoxy. Another implementation In this embodiment, n is 2, and R1 is CF3. In yet another embodiment, n is , and R1 is CF3, and the other R1 group is -CH2-piperazinyl Yes, piperazinyl can be optionally placed with a C1-C4 alkyl group such as methyl or ethyl. It has been replaced.
[0018] In some embodiments, the compound of formula I and its pharmaceutically acceptable salts are A-(R1) n teeth, [ka] And, The maximum value of n depends on the number of substitutable positions on ring A.
[0019] In some embodiments, the compound of formula I and its pharmaceutically acceptable salts are A-(R1) n teeth, [ka] And, The maximum value of n depends on the number of substitutable positions on ring A.
[0020] Compounds of formula I and pharmaceutically acceptable salts are combinations of formulas Ia, Ib, Ic, and Id. It includes chemically and pharmaceutically acceptable salts. [ka]
[0021] Compounds and pharmaceutically acceptable salts of formulas Ia, Ib, Ic, and Id contain X of formula I. 1, X2, X3, and X4 are CH.
[0022] Compounds of formula I and pharmaceutically acceptable salts of formula Ie, If, Ig, Ih, Ii, This includes compounds of Ij, Ik, and Il, and their pharmaceutically acceptable salts. [ka]
[0023] Compounds of formulas Ie to Il and pharmaceutically acceptable salts correspond to formula I, and X1, X2, X 3, and one of X4 is N, while the others are CH.
[0024] Compounds of formula I and pharmaceutically acceptable salts of formula Im, In, Io, Ip, Iq, This includes compounds of Ir, Is, and It, and their pharmaceutically acceptable salts. [ka]
[0025] Compounds and pharmaceutically acceptable compounds of the formulas Im, In, Io, Ip, Iq, Ir, Is, and It The salt to be accepted corresponds to the compound of formula I, where both X2 and X3 are N, while X1 Both X4 and X2 are CH, or both X2 and X3 are CH, while Therefore, both X1 and X4 are N.
[0026] Compounds of formula I also include compounds of formulas Iu, Iv, Iw, and Ix. [ka]
[0027] Compounds of formulas Iu, Iv, Iw, and Ix, and pharmaceutically acceptable salts, are compounds of formula I. Corresponding to objects, both X1 and X3 are N, while both X2 and X4 are CH. That is the case.
[0028] In compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts, R2 is -C1-C 6 alkyl, -C1-C4 alkyl-tetrahydrofuranyl, -C1-C6 hydroxy Lukil, -C1-C6 haloalkyl, -C1-C6 alkyl-O-C1-C2 alkyl, -C3-C6 cycloalkyl, tetrahydrofuranyl, pyranyl, -C1-C4 alkyl -Tetrahydropyranyl, -C1-C4 alkyl-C3-C6 cycloalkyl, and A Each is a zetidinyl, and each is either unsubstituted or independently a halogen, cyano, or hydride. Roxyl, oxo, methyl, methoxy, hydroxymethyl, ethyl, ethoxy, hydroxymethyl, ethyl, ethoxy, hydroxymethyl The group consisting of cycloethyl, cyclopropyl, or mono-, di-, or tri-halomethyl compounds. It is replaced with one or two groups selected from the following. In one embodiment, -C1-C6 The kill group is the ethyl group.
[0029] In one embodiment, in compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts, R2 is tert-butyl,-CH(CH3)-cyclopropyl,-2-tetrahydrofuranyl -3-tetrahydrofuranyl, -3-pyranyl, -4-pyranyl, -CH(CH3)C H2OH, -C(CH3)2CH2OH, -CH2-(2-tetrahydrofuranyl), - CH2-(3-tetrahydrofuranyl),-(CH2)3OH,-C(CH3)2CH2 OCH3, -CH(CH3)CF3, -CH2CF3, -C(CH3)2CH2OCH3 cyclopentyl, [ka] That is the case.
[0030] In one embodiment, in compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts, R2 is , [ka] That is the case.
[0031] In one embodiment, in compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts, R2 is , [ka] That is the case.
[0032] In one embodiment, in compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts, R2 is , [ka] That is the case.
[0033] In yet another embodiment, compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts R2 is, [ka] That is the case.
[0034] In yet another embodiment, compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts R2 is, [ka] That is the case.
[0035] In yet another embodiment, compounds of formulas I and Ia-Ix and pharmaceutically acceptable salts R2 is, [ka] That is the case.
[0036] In one embodiment, the compounds of formula I and pharmaceutically acceptable salts are those of formulas IIa to IIx and I This includes compounds IIa-IIIx and pharmaceutically acceptable salts. [ka]
[0037] Compounds of formulas IIa, IIb, IIc, and IId, and pharmaceutically acceptable salts thereof, are of formula Corresponding to compound I, X1, X2, X3, and X4 are CH, and R2 is isopropyl alcohol. It's a pill.
[0038] Compounds of formula I and pharmaceutically acceptable salts of formula IIe, IIf, IIg, and IIh are also included. This includes compounds of III, IIj, IIk, and IIl, and their pharmaceutically acceptable salts. . [ka]
[0039] Compounds of formulas IIe to IIl and pharmaceutically acceptable salts correspond to formula I, X1, X2 One of X3 and X4 is N, while the others are CH, and R2 is It is isopropyl.
[0040] Compounds of formula I and pharmaceutically acceptable salts of formula IIm, IIn, IIo, IIp This includes compounds of IIq, IIr, IIs, and IIt, and their pharmaceutically acceptable salts. . [ka]
[0041] Compounds of formulas IIm, IIn, IIo, IIp, IIq, IIr, IIs, and IIt The pharmaceutically acceptable salts correspond to the compounds of formula I, where both X2 and X3 are N. Yes, on the other hand, both X1 and X4 are CH, or both X2 and X3 are CH is present, while X1 and X4 are both N, and R2 is isopropyl.
[0042] The compounds of formula I also include the compounds of formulas IIu, IIv, IIw, and IIx. [ka]
[0043] Compounds of formulas IIu, IIv, IIw, and IIx, and pharmaceutically acceptable salts thereof, are of formula Corresponding to compound I, both X1 and X3 are N, while both X2 and X4 are N. Both are CH, and R2 is isopropyl. Compounds of formula I and pharmaceutically acceptable The salts are compounds of formulas IIIa, IIIb, IIIc, and IIId and their pharmaceutically acceptable substances. It contains salt that is tolerable. [ka]
[0044] Compounds of formulas IIIa, IIIb, IIIc, and IIId and pharmaceutically acceptable The salt corresponds to the compound of formula I, where X1, X2, X3, and X4 are CH, and R2 is [ka] That is the case.
[0045] Compounds of formula I and pharmaceutically acceptable salts of formula IIIe, IIIf, IIIg, Compounds IIIh, IIIi, IIIj, IIIk, IIIl and their pharmaceutically acceptable It contains salt. [ka]
[0046] Compounds of formulas IIIe to IIIl and pharmaceutically acceptable salts correspond to formula I, X1, One of X2, X3, and X4 is N, while the others are CH and R2 teeth, [ka] That is the case.
[0047] Compounds of formula I and pharmaceutically acceptable salts of formula IIIm, IIIn, IIIo, Compounds of IIIp, IIIq, IIIr, IIIs, and IIIt and their pharmaceutically acceptable It contains salt. [ka]
[0048] Formulas IIIm, IIIn, IIIo, IIIp, IIIq, IIIr, IIIs, and The compounds of IIIt and pharmaceutically acceptable salts correspond to the compounds of formula I, with X2 and X 3 is both N, while X1 and X4 are both CH, or X2 and Both X3 and X1 are CH, while both X1 and X4 are N, and R2 is [ka] That is the case.
[0049] The compound of formula I also encompasses the compounds of formulas IIIu, IIIv, IIIw, and IIIx. Includes. [ka]
[0050] Compounds of formulas IIIu, IIIv, IIIw, and IIIx and pharmaceutically acceptable The salt corresponds to the compound of formula I, where both X1 and X3 are N, while X2 and X 4 is either both CH, or both X2 and X4 are N, while X1 is Both X3 are CH, and R2 is [ka] That is the case.
[0051] In one embodiment, compounds of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx In the pharmaceutically acceptable salts, each R1 is independently hydrogen, C1-C6 alkyl, or C4 -C8 cross-linked bicycloalkyl, C5-C 12 It is a speedrun, and each R1 is optional, Halo Gen, cyano, hydroxyl, oxo, methyl, methoxy, hydroxymethyl, ethyl, Ethoxy, hydroxyethyl, methylamine, N,N-dimethylmethylamine, or mo It is substituted with one or more of the following: no-, di-, or tri-halomethyl groups.
[0052] In one embodiment, compounds of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx In the pharmaceutically acceptable salts, each R1 is independently 2-chloro-4-methylphenicol. Lu, 2,4-dichloro-3-fluorophenyl, 2-meth-4-chlorophenyl, 2 -Chloro-4-methoxyphenyl, 2-chloro-4-trifluoromethylphenyl, 2-Methoxy-4-chlorophenyl, 2,2-dimethylpropyl, 2-chloro-4- Luoro-phenyl, 2,4-dichlorophenyl, 1,1-dimethyl-2,2,2-triph Luoroethyl, 1,1-dimethylethyl, 1,1-dimethylpropyl, trifluoromethyl Lu, 1,1-dimethyl-2,2-difluoropropyl, 1,1-dimethyl-3,3,3- Trifluoropropyl, 1-methylcyclopropyl, (1-methylcyclopropyl)methyl L, 3-methylbicyclo[1.1.1]pentan-1-yl, 3-(trifluoromethyl ) Bicyclo[1.1.1]pentan-1-yl, or (3,3-dimethylcyclobutyl It is methyl.
[0053] In a further embodiment, equations I, Ia~Ix, IIa~IIx, and IIIa~IIIx In the compound and pharmaceutically acceptable salts, each R1 is independently unsubstituted or independent. Furthermore, one selected from the group consisting of C1-C4 alkyl, CF3, halo, and CN is also Alternatively, it is a C4-C8 crosslinked bicycloalkyl group substituted with two groups.
[0054] In another embodiment, the combination of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx In phytochemically and pharmaceutically acceptable salts, each R1 is independently unsubstituted or independently Then, one or two selected from the group consisting of methyl, ethyl, CF3, halo, and CN. It is a C4-C8 crosslinked bicycloalkyl group substituted with one group.
[0055] In some embodiments, formulas I, Ia~Ix, IIa~IIx, and IIIa~IIIx In the compounds and pharmaceutically acceptable salts, each R1 independently has the following cross-linked C4-C It is 8-bicycloalkyl. [ka]
[0056] In other embodiments, the combination of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx In phytochemically and pharmaceutically acceptable salts, each R1 is independently unsubstituted or independently Then, selected from the group consisting of =O, -OH, C1-C4 alkyl, -CF3, and halo C5-C which is substituted with one or two groups 12 It is a speedrun, and each R1 is independent , unsubstituted or independently =O, -OH, C1-C4 alkyl, -CF3, o C5-C is substituted with one or two groups selected from the group consisting of halos. 12 He It is Telospiran. C5-C 12 Spiran or C5-C 12 As an example of heterospiran The following are some examples: [ka]
[0057] In one embodiment, compounds of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx And in pharmaceutically acceptable salts, n is 1, and R1 is unsubstituted or methylated. Then, selected from the group consisting of =O, -OH, methyl, ethyl, CF3, and halo. C5-C substituted with one or two groups 12 It's Spiran.
[0058] In yet another embodiment, equations I, Ia~Ix, IIa~IIx, and IIIa~IIIx In the compounds and pharmaceutically acceptable salts, each R1 is independently a halogen, C1-C6 ion. Lukil, -(C0-C4 alkyl)(C3-C7 cycloalkyl), -(C0-C4 alkyl) (Cyl)(phenyl),-(C1-C4 alkyl)(C5-C6 heteroalkyl),-(C (C0-C4 heteroalkyl)(C3-C7 cycloheteroalkyl), or -(C0-C4 It is an alkyl (C5-C6 heteroaryl) group, and each R1 is arbitrarily selected, such as halogen or shear No, hydroxyl, oxo, methyl, methoxy, hydroxymethyl, ethyl, ethoxy, Hydroxyethyl, methylamine, N,N-dimethylmethylamine, and mono-, di- , or substituted with one or more substituents selected from the group consisting of tri-halomethyl .
[0059] In one embodiment, compounds of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx In the pharmaceutically acceptable salts, each R1 is unsubstituted. In alternative embodiments, each R1 This can be arranged with four or fewer bases, or three or fewer bases, or two or fewer bases, or just one base. It has been replaced.
[0060] In another embodiment, the combination of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx In phytochemically and pharmaceutically acceptable salts, each R1 is independently -CH2C(CH3)3, -C H(CH2CH3)2, -CF2CH3, -CH2CH2CF3, -C(CH3)2F, -C(CH3)2CF3, -CH2-cyclopentyl, -CH2-cyclohexyl, -C H2-Cyclopropyl, -CH2-Cyclobutyl, -CH2-Morpolinyl, -CH2- Pyrrolidinyl, phenyl, naphthyl, pyran-4-yl, 4-methylphenyl, 4-meth Xyphenyl, 2-fluorophenyl, 2-fluoro-4-chlorophenyl, 3-trif Luoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, cyclopropyl 2,4-Dimethicone chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-fluorophenyl, 3-chlorophenyl Lolophenyl, 2-methoxyphenyl, 4-difluoromethoxyphenyl, -C(CH3 )2SO2CH3,4-fluorophenyl,2,4-difluorophenyl,2,4-di Chlorophenyl, 3-chlorophenyl, methyl, ethyl, tert-butyl, isopropyl , trifluoromethyl, 3-methoxyphenyl, 3-bromophenyl, 4-bromophenyl L, 2,4,6-trifluoromethylphenyl, 3-tetrahydrofuranyl, -C(CH 3) 2CH2CH3, -C(CH3)2OH, 3,3-dimethylcyclobuta-1-yl, 2,3-Dichlorobenzyl, 3,3-Difluoromethylcyclobutyl, 2,2-Dimethyl Cyclopropyl-1-yl, 2,2-difluorocyclopropyl, N-methylimidazolyl , 2-methyl-4-chlorophenyl, 2,4-dichloro-3-fluorophenyl, -CH 2OCH3, -CH2CF3, -CF2CH3, -CF2C(CH3)3, -CH(CH 3) Cyclopropyl, 2,6-difluorophenyl, pyrido-2-yl, pyrido-3-yl Lu, pyrido-4-yl, 3-chloropyrido-2-yl, 2-methylpyrido-3-yl, 4 -methylpyrido-3-yl, 3,5-dichloropyrido-2-yl, 3,3-difluorosil Clopentyl, fluoro, chloro, bromo, 2-methoxy-4-chlorophenyl, 2- Fluoro-4-chlorophenyl, 3-fluoro-4-chlorophenyl, benzyl, piperi Dinyl, 4-methyl-piperidinyl, 4-methoxy-piperidinyl, N-methylpyrazole Ru-3-yl,-C(O)-piperidinyl,-OCHF2, [ka] That is the case.
[0061] In one embodiment, compounds of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx And in pharmaceutically acceptable salts, R1 is 2,2-dimethylpropyl or [ka] That is the case.
[0062] In a further embodiment, equations I, Ia~Ix, IIa~IIx, and IIIa~IIIx In the compound and pharmaceutically acceptable salts, R1 is 2,2-dimethylpropyl.
[0063] In further embodiments, equations I, Ia~Ix, IIa~IIx, and IIIa~III In compounds and pharmaceutically acceptable salts of x, R1 is [ka] That is the case.
[0064] In another embodiment, the combination of formulas I, Ia-Ix, IIa-IIx, and IIIa-IIIx In phytochemically and pharmaceutically acceptable salts, each R1 is independently, [ka] That is the case.
[0065] In different embodiments, the transformation of equations I, Ia~Ix, IIa~IIx, and IIIa~IIIx In compounds and pharmaceutically acceptable salts, R1 is either unsubstituted or independently halo Gen, C1-C6 alkyl, -(C0-C4 alkyl)(C3-C7 cycloalkyl), -(C0-C4 alkyl)(phenyl), -(C1-C4 alkyl)(C5-C6 hetero Alkyl), -(C0-C4 heteroalkyl), (C3-C7 cycloheteroalkyl), The groups are C0-C4 alkyl and C5-C6 heteroaryl, and each R1 is arbitrarily selected. And, halogen, cyano, hydroxyl, oxo, methyl, methoxy, hydroxymethyl, Ethyl, ethoxy, hydroxyethyl, methylamine, N,N-dimethylmethylamine, and one or more selected from the group consisting of mono-, di-, and tri-halomethyl It is a C1-C6 alkyl group that is substituted with a substitution group.
[0066] In yet another embodiment, the compounds of formula I and pharmaceutically acceptable salts are as follows: ru: [ka] [ka] .
[0067] In yet another embodiment, the compound of formula I and a pharmaceutically acceptable salt: [ka] .
[0068] definition The specific chemical nomenclature rules used herein are familiar to those skilled in the art of chemistry. This is the intention. Some terms are specifically defined for further clarity.
[0069] As used herein, the term alkyl refers to a saturated linear chain of 1 to 6 atoms or Branched-chain monovalent hydrocarbon radicals, for example, "C1-C6 alkyl". Zero is shown. In cases where this substituent is present, for example, in the case of C0-C4 alkyl or C0-C3 alkyl, The constituent elements may be absent, and therefore, the C5 heterocycloalkyl substituent of formula (I) If it is at the R2 position, the C5 heterocycloalkyl substituent is described for R2. Described by -(C0-C4 alkyl)(C3-C7 heterocycloalkyl) substituents. This is possible (i.e., the substituent becomes -(C0)(C5 heterocycloalkyl)). Example These include, but are not limited to, methyl, ethyl, propyl, 1-propyl, and isopylated Examples include propyl and butyl. Similarly, heteroalkyl as used herein. The term "alkyl" here refers to a heteroatom that replaces one or more carbon atoms in an alkyl chain. This refers to saturated linear or branched monovalent alkyl molecules as defined by [the relevant term]. Typically, hetero A lukyl group has four or fewer heteroatoms or three or fewer heteroatoms.
[0070] As used herein, the term aryl refers to a group of 6 to 10 carbon atoms, for example, C6-C 10 Contains aryls, or 5-6 carbon atoms, for example, C5-C6 aryls. Ally refers to a functional group or substituent derived from an aromatic ring that does not contain heteroatoms. Examples of the 'L' group include phenyl and naphthyl. When used herein, The term heteroaryl refers to a carbon atom as part of an aromatic ring and one or more heteroaryl atoms. Functional groups or substituents derived from aromatic rings containing children (e.g., nitrogen, oxygen, or sulfur) It refers to a molecule having 5 or 6 atoms, of which at least one is a heterogen. Examples of the child ring include these, but are not limited to these. Lysyl, pyrazinyl, pyrimidinyl, pyridadinyl, furanyl, pyrrolyl, thiophenyl Examples include imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, and thiazolyl. It is possible.
[0071] As used herein, the term C3-C7 cycloalkyl refers to a group of 3 to 7 carbon atoms. This refers to a cyclic alkyl molecule containing atoms. An example of a C3-C7 cycloalkyl molecule is this Examples include, but are not limited to, cyclopropyl, cyclobutyl, and cyclopentyl. Similarly, as used herein, heterocycloalkyl and cycloheteral The term "kill" refers to a total of 3 to 7 atoms, at least one of which is a heteroatom, as described in this specification. This refers to a cycloalkyl molecule as defined in the book. Heterocycloalkyl or cyclohete A ρalkyl group can be condensed with other groups such as a phenyl group. For example, condensed with phenyl Piperidine can form tetrahydroisoquinoline or tetrahydroquinoline.
[0072] As used herein, the terms bicyclic, biscuryl, and bicycloalkyl This refers to a group having two or more condensed or crosslinked rings. C4-C 10 Bicyclic, C4-C 10 Bisikrill, and C4-C 10 Bicycloalkyl groups contain 4 to 10 carbon atoms. When cyclic groups are condensed, the two rings share two adjacent atoms. When bicyclic groups are bridged... When cross-linked (also called a bicycloalkyl), the two rings share three or more atoms. The crosslinked bicycloalkyl group may have 4 to 10 carbon atoms or 4 to 8 carbon atoms. Such groups are, respectively, "C4-C 10 "Cross-linked bicycloalkyl" or "C4- These can be referred to as "C8-bridged bicycloalkyl molecules." All bicyclic molecules are aliphatic and all are aromatic. , or a mixture of aromatic and aliphatic compounds. C4-C 10 The term heterobicyclic , defined as C4-C including one or more heteroatoms 10 Refers to a bicyclic group. Compound of formula (I) Examples of useful cross-linked bicycloalkyl groups, including but not limited to these, are listed below. These are some examples. [ka]
[0073] C4-C 10 Examples of heterobicyclic structures include, but are not limited to, the following: . [ka]
[0074] When used herein, C5-C 12 Spiranil or spiran is a spirocyclic ring. Refers to the system. C5-C 12 Spiranil, C5-C 12 Spiran, and C5-C 12 Spira A spirocyclic ring system has 5 to 12 ring carbon atoms. It also contains two and up to four rings, of which at least two are connected via spirobonds. It must be done. C5-C 12 Spilan is non-substituted as described herein. Alternatively, it could be a substitution.
[0075] C5-C 12 A heterospiranil refers to a spiro ring system having 5 to 12 ring atoms, At least one of them is a heteroatom, i.e., not carbon. The nyl ring system contains 2 to 4 rings, at least 2 of which are connected via spirobonds. It must be done. C5-C 12 Heterospiran is, as described herein, It may be non-substitutable or substituted. Substitutable and non-substitutable C5-C 12 Spiran and C5-C1 Examples of two heterospirans include, but are not limited to, the following: [ka]
[0076] As used herein, the terms halogen or halo refer to fluoro(F), chloro(F), and chloro(F). It means chlorine (Cl), bromo (Br), or iodine (I).
[0077] As used herein, the term oxo refers to an oxygen atom double-bonded to a carbon atom. This means that this can be expressed as = O.
[0078] Compounds of formulas I, Ia-Ix, IIa-IIx, and / or IIIa-IIIx are: Deuterated or pulverized at one or more positions, such deuterated or pulverized form This is part of the present invention. Deuterium modification slows down the CYP-mediated metabolism of drugs, or Or, in an attempt to reduce the formation of undesirable metabolites, one or more hydrogen atoms of the drug are added. This includes replacing with hydrogen atoms. Tritium modification makes molecules radioactive, and researchers are using it in drugs. This makes it possible to determine where substances are deposited in the body and how they are metabolized.
[0079] Formulas I, Ia-Ix, IIa-IIx, and / or IIIa- Compounds of IIIx can form pharmaceutically acceptable salts. Formulas I, Ia~Ix, IIa~ Such pharmaceutically acceptable salts of compounds IIx and / or IIIa-IIIx It is intended to include pharmaceutically acceptable salts and for preparing them. General methods are well known in the art (e.g., P. Stahl, et al. Handbook of Pharmaceutical Salts: Propert ies, Selection and Use, 2 nd Revised Editio n (Wiley-VCH, 2011), S.M. Berge, et al., “Phar maceutical Salts,” Journal of Pharmaceuti cal Sciences, Vol. 66, No. 1, January 1977). ).
[0080] The compounds of Formula I, Ia-Ix, IIa-IIx, and / or IIIa- IIIx described herein are generally effective over a wide dosage range. For example, the daily dosage is in the range of about 0.01 mg / kg to about 200 mg / kg. Further, the compounds of Formula I, Ia-Ix, IIa-IIx, and / or IIIa-I IIx described herein are, for example, about 0.05 mg / kg to about 150, about 0.1 mg / kg to about 150, about 0.5 mg / kg to about 150 mg / kg, about 1 mg / kg to about 150 mg / k g, about 5 mg / kg to about 150 mg / kg, about 5 mg / kg to about 100 mg / kg, about 2 0 mg / kg to about 40 mg / kg, about 25 mg / kg to about 35 mg / kg, about 50 mg / kg to about 70 mg / kg, about 55 mg / kg to about 65 mg / kg, about 90 mg / kg to about 110 mg / kg, about 95 mg / kg to about 105 mg / kg, or about 50 mg / kg to about 150 mg / kg.
[0081] Alternatively, the compounds of Formula I, Ia-Ix, IIa-IIx, and / or Compounds IIIa to IIIx are, for example, approximately 0.1 mg / kg to approximately 15 mg / kg, The range is approximately 0.5 mg / kg to approximately 10 mg / kg, or 1 mg / kg to approximately 9 mg / kg, It can be administered in doses of approximately 2 mg / kg to approximately 8 mg / kg, or approximately 3 mg / kg to 7 mg / kg. Furthermore, formulas I, Ia-Ix, IIa-IIx, and / or described herein. Compounds IIIa-IIIx are, for example, approximately 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg. g / kg, 1.3mg / kg, 1.4mg / kg, 1.5mg / kg, 1.6mg / kg , 1.7mg / kg, 1.8mg / kg, 1.9mg / kg, 2mg / kg, 2.1mg / kg, 2.2mg / kg, 2.3mg / kg, 2.4mg / kg, 2.5mg / kg, 2.6mg / kg, 2.7mg / kg, 2.8mg / kg, 2.9mg / kg, 3mg / kg, 3.1mg / kg, 3.2mg / kg, 3.3mg / kg, 3.4mg / kg, 3 .5mg / kg, 3.6mg / kg, 3.7mg / kg, 3.8mg / kg, 3.9mg / kg, 4, mg / kg, 4.1 mg / kg, 4.2 mg / kg, 4.3 mg / kg, 4 .4mg / kg, 4.5mg / kg, 4.6mg / kg, 4.7mg / kg, 4.8mg / kg, 4.9mg / kg, 5mg / kg, 5.1mg / kg, 5.2mg / kg, 5. 3mg / kg, 5.4mg / kg, 5.5mg / kg, 5.6mg / kg, 5.7mg / kg, 5.8mg / kg, 5.9mg / kg, 6mg / kg, 6.1mg / kg, 6.2 mg / kg, 6.3mg / kg, 6.4mg / kg, 6.5mg / kg, 6.6mg / k g, 6.7mg / kg, 6.8mg / kg, 6.9mg / kg, 7mg / kg, 7.1m g / kg, 7.2mg / kg, 7.3mg / kg, 7.4mg / kg, 7.5mg / kg , 7.6mg / kg, 7.7mg / kg, 7.8mg / kg, 7.9mg / kg, 8mg / kg, 8.1mg / kg, 8.2mg / kg, 8.3mg / kg, 8.4mg / kg, 8.5mg / kg, 8.6mg / kg, 8.7mg / kg, 8.8mg / kg, 8.9m g / kg, 9mg / kg, 9.1mg / kg, 9.2mg / kg, 9.3mg / kg, 9 .4mg / kg, 9.5mg / kg, 9.6mg / kg, 9.7mg / kg, 9.8mg / kg, 9.9mg / kg, about 10mg / kg, about 15mg / kg, about 20mg / kg, Approx. 25mg / kg, approx. 30mg / kg, approx. 35mg / kg, approx. 40mg / kg, approx. 45m g / kg, approx. 50mg / kg, approx. 55mg / kg, approx. 60mg / kg, approx. 65mg / kg , about 70mg / kg, about 75mg / kg, about 80mg / kg, about 85mg / kg, about 90 mg / kg, approx. 95mg / kg, approx. 100mg / kg, approx. 105mg / kg, approx. 110m g / kg, approx. 115mg / kg, approx. 120mg / kg, approx. 125mg / kg, approx. 130m g / kg, approx. 135mg / kg, approx. 140mg / kg, approx. 145mg / kg, approx. 150m g / kg, approx. 155mg / kg, approx. 160mg / kg, approx. 165mg / kg, approx. 170m g / kg, approx. 175mg / kg, approx. 180mg / kg, approx. 185mg / kg, approx. 190m It can be administered in amounts of g / kg, approximately 195 mg / kg, or approximately 200 mg / kg. Daily dose The dosage may be once daily or multiple times daily, for example, twice daily (BID). For patients weighing >50kg, 160mg is taken orally twice a day, or for patients weighing <50kg For a patient of g, the dose may be 120 mg. The actual amount of compound administered depends on the condition being treated. The state, selected route of administration, the actual compound administered, the age, weight, and response of each individual patient. The answer, along with relevant circumstances including the severity of the patient's symptoms, is determined by the physician. It is understood that this is the case. Perhaps the involvement of the CNS / the need for increased CNS exposure is also typical. This will be taken into consideration.
[0082] Formulas I, Ia-Ix, IIa-IIx, and / or IIIa- The IIIx compound can be formulated as a pharmaceutical composition that can be administered via various routes. Such pharmaceutical compositions and processes for preparing them are prevalent in the art. It is knowledge (for example, Remington: The Science and Practice) ice of Pharmacy(A.Gennaro,et al.,eds.,21 (See st ed., Mack Publishing Co., 2005) Specifically, formulas I, Ia-Ix, IIa-IIx, and / or as described herein. Compounds IIIa to IIIx or their pharmaceutically acceptable salts may be one or more pharmaceutically acceptable compounds. It can be combined with a carrier, diluent, or excipient that is permissible. More specifically, Formula I, As specified herein by Ia-Ix, IIa-IIx, and / or IIIa-IIIx The compounds described herein can be formulated as pharmaceutical compositions. Furthermore, as described herein Compounds of formulas I, Ia-Ix, IIa-IIx, and / or IIIa-IIIx, Its pharmaceutically acceptable salts can be combined with one or more other therapeutic agents. For example, this Formulas I, Ia-Ix, IIa-IIx, and / or IIIa-I described in the specification The IIx compound or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable carrier 、 diluents, or excipients, and optionally one or more additional therapeutic agents, can be components of a pharmaceutical composition for the treatment of cancer. In combination therapy, when multiple driver mutations / changes are detected in a patient, such as when EGFR variations and clinically significant RET changes are detected, compounds of Formula I, Ia-Ix, IIa-IIx, and / or IIIa -IIIx can be administered in combination with a second therapeutic agent. Examples of combinations include, but are not limited to, compounds of Formula I, Ia-Ix, IIa-IIx, and / or IIIa-IIx and osimertinib. Other examples of combinations include, but are not limited to, compounds of Formula I, Ia-Ix, IIa-IIx, and / or IIIa-IIx in combination with one or more of a platinum-based chemotherapeutic agent, and / or a non-platinum-based chemotherapeutic agent. A pharmaceutical composition containing a compound of Formula I, Ia-Ix, IIa-IIx, and / or IIIa-IIx or a pharmaceutically acceptable salt thereof as described herein can be used in the methods described herein. As used herein, the term "treating" (or "treat" or "treatment") refers to suppressing, delaying, halting, or reversing the progression or severity of an existing symptom, condition, or disorder. As used herein, the term "irritable bowel syndrome" or "IBS" refers to, but is not limited to, diarrhea-predominant, constipation-predominant, or alternating bowel patterns, functional abdominal bloating, functional constipation, functional diarrhea, other functional bowel disorders, functional abdominal pain syndrome, chronic idiopathic constipation, and the like.
[0083]
[0084] , including functional esophageal disorders, functional gastrointestinal disorders, functional anorectal pain, and inflammatory bowel disease. It means intestinal disorder.
[0085] As used herein, the terms “cancer” and “cancerous” are typically used in their original form. This refers to or describes the physiological state of a patient characterized by the proliferation of their cells. This definition includes benign and malignant cancers. "Early-stage cancer" or "early-stage tumor" This refers to cancer that is not progressive or metastatic, or is classified as stage 0, I, or II cancer. It refers to a type of cancer. Examples of cancer include, but are not limited to, lung cancer (for example). (e.g., small cell lung cancer or non-small cell lung cancer), thyroid cancer (e.g., papillary thyroid carcinoma, thyroid cancer) Medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, or refractory differentiated thyroid cancer), multiple Endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), thyroid Adenoma, endocrine tumor, lung adenocarcinoma, bronchiololung cell carcinoma, multiple endocrine neoplasia type 2A or Type 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer breast cancer, mammary cancer, breast cancer (mammary carcinoma), breast neoplasm, colorectal cancer (e.g., metastatic colorectal cancer) Cancer, papillary renal cell carcinoma, ganglion neuroma of the gastrointestinal mucosa, inflammatory myofibroblastic tumor, Cervical cancer is another example.
[0086] As used herein, the term “RET-related disease or disorder” refers to the RET gene, R ET kinase (also referred to herein as RET kinase protein), or their capsules Dysregulation of the expression, activity, or level of any of the following (for example, one or more): If, then, RET gene, RET kinase, RET kinase domain, or as described herein A type of dysregulation in the expression, activity, or level of any of these. This refers to a disease or disorder that is related to or has any of the following conditions.
[0087] As used herein, the term “RET-related cancer” refers to the RET gene, RET kinase ZE (also referred to herein as RET kinase protein), or any of the above. Cancers associated with or having dysregulation of the expression, activity, or level of such cancers This refers to [a specific type of cancer]. Non-exclusive examples of RET-related cancers are described herein.
[0088] "Expression or activity of the RET gene, RET kinase, or any of the above" The phrase "or level of dysregulation" refers to a genetic mutation or change. RET gene, RET kinase, or any of the expression, activity, or level adjustment of any of them Examples of such gene mutations that cause segmental failure include, but are not limited to, fusions. RET gene translocations that result in protein expression are less frequent compared to wild-type RET protein. The RET gene, which results in the expression of the RET protein containing at least one amino acid deletion, A deletion, or a mutation in the RET gene resulting in the expression of the RET protein with one or more point mutations. Compared to heterologous or wild-type RET proteins, the RET protein has at least one amino acid Selective splicing of RET mRNA resulting in RET proteins with deficiencies in anoacids. Modification, or the kinase domain of RET protein in cells (e.g., RET RET leads to a pathological increase in the activity of the protein's constitutively active kinase domain. Autocrine activity resulting from protein overexpression or overexpression of the RET gene in cells One example is the amplification of the RET gene, which results from the RET gene, the RET protein, or Dysregulation of the expression, activity, or level of any of these is constitutively active or compared to the protein encoded by the RET gene that does not contain the mutation. This could be a mutation in the RET gene, which encodes the RET protein, resulting in increased activity. For example, the expression of the RET gene, the RET protein, or either of them. Dysregulation of activity or level is present in the second half / part of RET, and not in RET. The gene that results in the expression of a fusion protein containing the first half of several other genes This can result from chromosomal translocation. In some cases, the RET gene, RET protein, Or dysregulation of the expression, activity, or level of any of them is a certain R This could be the result of a gene translocation of the ET gene with another non-RET gene.
[0089] Formulas I, Ia-Ix, IIa-IIx, and / or IIIa- Treatment of RET-related diseases or disorders, particularly abnormal RET expression, using IIIx compounds. A method for treating IBS or cancer accompanied by abnormal RET expression is provided. Examples include the expression of the RET gene, RET kinase, or either of them. This includes cancers caused by dysregulation of activity or levels. Or one such method of treating RET-related diseases or disorders such as cancer is treatment Combinations of the formulas I, Ia~Ix, IIa~IIx, and / or IIIa~IIIx for the effective quantities This includes administering a substance or a pharmaceutically acceptable salt thereof to a patient in need. IB Another way to treat RET-related diseases or disorders such as S or cancer is a) trial from the patient In the material, the expression of the RET gene, RET kinase, or any of the two is also b) detecting dysregulation of activity or level, and the therapeutic effective dose formula I, Ia~I Compounds or pharmaceuticals of compounds x, IIa-IIx, and / or IIIa-IIIx This includes administering a moderately acceptable salt.
[0090] The expression or activity of the RET gene, RET kinase, or any of them Alternatively, dysregulation of the level can result in one or more chromosomal translocations or inverses leading to RET gene fusion. This can be the result of a positional translocation (i.e., the gene translocation is a residual from the non-RET partner protein). A fusion protein containing a group and a minimal functional RET kinase domain. (Provides the current protein). RET fusion partners and their associated cancers are not limited. Typical examples include ACBD5 (papillary thyroid cancer); AFAP1 (NSCLC); AFAP 1L2 (Papillary thyroid carcinoma); AKAP13 (Papillary thyroid carcinoma); BCR (Chronic myelomonocytic Leukemia; C10orf118 (Papillary thyroid carcinoma); CCDC6 (PTC1, D10S1) 70, also known as H4) (NSCLC, colon cancer, papillary thyroid cancer, adenocarcinoma, lung cancer) Adenocarcinoma, metastatic colorectal cancer, adenosquamous cell carcinoma, breast cancer; CCDC88C (NSCLC); CCDC186-RET, CEP55 (diffuse gastric cancer); CGNL1 (pancreatic cancer); C LIP1 (adenocarcinoma); CUX1 (lung adenocarcinoma); DLG5 (undifferentiated thyroid cancer); DO CK1 (NSCLC); EML4 (Papillary thyroid carcinoma); ERC1 (also known as ELKS) )(Papillary thyroid cancer, breast cancer); ETV6 (Salivary gland cancer); FGFR1OP (CMML, Primary myelofibrosis with secondary acute myeloid leukemia; FKBP15 (papillary thyroid carcinoma); FOXP4 (lung adenocarcinoma); BER4A (NSCLC); GOLGA5 (also called PTC5) (To be discovered) (Papillary thyroid carcinoma, Spitz-like neoplasm); H4L (various); HOOK3 (thyroid) Papillary thyroid cancer; HRH4-RET (thyroid cancer and / or papillary thyroid cancer); HTIF 1 (various); KIAA1217 (also called SKT) (papillary thyroid carcinoma, lung adenocarcinoma, N SCLC); KIAA1468 (also known as PTC9 and RFG9) (Papilla of the thyroid gland) Hmm, lung adenocarcinoma); KIF13A (NSCLC); KIF5B (NSCLC, ovarian cancer, S Pitts-like neoplasm, lung adenocarcinoma, adenosquamous cell carcinoma; KTN1 (also called PTC8) (A) Papillary thyroid carcinoma; MBD1 (also known as PCM1) (Papillary thyroid carcinoma); MP RIP (NSCLC); MYH10 (Infant Myofibromatosis); MYH13 (Medullary Thyroid Carcinoma) );NCOA4 (also known as PTC3, ELE1, and RFG) (Papillary thyroid carcinoma, NSCLC, colon cancer, salivary gland cancer, metastatic colorectal cancer, lung adenocarcinoma, adenosquamous cell carcinoma, thyroid cancer Adenomatous diffuse sclerosing papillary carcinoma, breast cancer, acinar cell carcinoma, mammary gland analogous secretory carcinoma); OLFM4 (small intestine) Cancer); PARD3 (NSCLC); PCM1 (Papillary thyroid carcinoma); PIBF1 (Bronchial carcinoma) Lung cell carcinoma; PICALM (NSCLC); PPFIBP2 (papillary thyroid carcinoma); PR KAR1A (also called PTC2) (Papillary thyroid carcinoma); PTC1ex9 (Novel CCD) C6 rearrangement) (metastatic papillary thyroid carcinoma); PTC4 (novel NCO4 / ELE1 rearrangement) Papillary thyroid carcinoma; RAB61P2 (papillary thyroid carcinoma); RASAL2 (sarcoma); RAS GEF1A (breast cancer); RBPMS (NSCLC); RFG8 (papillary thyroid cancer); RR BP1 (colon cancer); RUFY1 (colorectal cancer); RUFY2 (NSCLC; thyroid papilla h);RUFY3 (Papillary thyroid carcinoma);SLC12A2 (NSCLC);SORBS2 ( Papillary thyroid carcinoma; SPECC1L (papillary thyroid carcinoma, thyroid cancer); SQSTM1 ( Papillary thyroid carcinoma; TAF3 (pancreatic cancer); TBL1XR1 (papillary thyroid carcinoma, thyroid cancer) Cancer; TFG (pancreatic cancer); TIF1G (various); TRIM24 (also known as PTC6) (Papillary thyroid cancer); TRIM27 (also called RFP) (Papillary thyroid cancer); A KAP13 (papillary thyroid carcinoma); TRIM33 (also known as PTC7 and RFG7) Examples include (NSCLC, papillary thyroid carcinoma) and UEVLD (papillary thyroid carcinoma). The fusion protein could be, for example, KIF5B-RET. In addition, CCDC186-RET, ERC1-RET, KTN1-RET, and RUF Y3-RET was included. Further RET fusion proteins are listed herein. It may not be included or may not yet be known, however, formulas I, Ia Compounds of ~Ix, IIa~IIx, and / or IIIa~IIIx as specified herein The methods of use described therein are expected to be effective inhibitors.
[0091] The expression or activity of the RET gene, RET kinase, or any of them Dysregulation of the RET level is caused by one or more point mutations in the RET gene (compared to wild-type RET). This can be caused by mutations, insertions, or deletions in mature human RET protein. The array (sequence number 1) is provided below. MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAY WEKL YVDQAAGTPL LYVHALRDAP EEVPSFRLGQ HL YGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKL S VRNRGFPLLT VYLKVFLSPT SLREGECQWP GCARV YFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR P PGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAP DS LEVSTRWALD REQREKYELV AVCTVHAGAR EEVV MVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD ADVVPASGEL VRRYTSTLLP GDTWAQQ TFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR NLS ISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA QIGKVCVENC QAFSGI NVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KA LRRPKCAE LHYMVVATDQ QTSRQAQAQL LVTVEGSYV A EEAGCPLSCA VSKRRLECEE CGGLGSPTGR CEWRQ GDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI C PQDCLRGSI VGGHEPGEPR GIKAGYGTCN CFPEEEKC FC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSA FCIHCY HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP RKNLVLG KTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KEN ASPSELR DLLSEFNVLK QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSS SLDH PDERALTMGD LISFAWQISQ GMQYLAEMKL VH RDLAARNI LVAEGRKMKI SDFGLSRDVY EEDSYVKRS Q GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIV TLGGN PYPGIPPERL FNLLKTGHRM ERPDNCSEEM Y RLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDL AA STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPS TWIENK LYGMSDPNWP GESPVPLTRA DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS
[0092] The potential activation of RET kinase proteins compared to wild-type RET kinase. Non-specific examples of mutations, insertions, or deletions can occur at the following amino acid positions: 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 20, 32 (for example, S32L), 34 (for example For example, D34S), 40 (L40P), 56 (L56M), 64 (for example) , P64L), 67 (e.g., R67H), 114 (e.g., R114H), 136 (e.g., For example, from glutamate to the stop codon), 145 (for example, V145G), 180 (for example) , arginine (stop codon), 200, 292 (e.g., V292M), 294, 32 1 (e.g., G321R), 330 (e.g., R330Q), 338 (e.g., T338) I), 360 (e.g., R360W), 373 (e.g., alanine to valine (p.A3) 73V) Frame shift), D378-G385delinsE, 393 (for example, F 393L), 423 (e.g., G423R), 432, 446 (e.g., G446R), 505-506 (6-base pair in-frame germline deletion in exon 7), 51 0 (e.g., A510V), 511 (e.g., E511K), 513 (e.g., G513) D), 515 (e.g., C515R, C515S, C515W), 525 (e.g., R5 25W), 531 (e.g., C531R, or 9-base pair replication), 532 (e.g., replication) ), 533 (e.g., G533C, G533S), 550 (e.g., G550E), 59 1 (e.g., V591I), 593 (e.g., G593E), 595 (e.g., E595) D and E595A), 600 (e.g., R600Q), 602 (e.g., I602V) , 603 (e.g., K603Q, K603E), 606 (e.g., Y606C), 609 (For example, C609Y, C609S, C609G, C609R, C609F, C609W) , C609C), 611 (for example, C611R, C611S, C611G, C611Y, C611F, C611W), 616 (e.g., E616Q), 618 (e.g., C618 S, C618Y, C618R, C618T, C618G, C618F, C618W), 6 20 (For example, C620S, C620W, C620R, C620G, C620L, C62 0Y, C620F), 623 (e.g., E623K), 624 (e.g., D624N), 630 (for example, C630A, C630R, C630S, C630Y, C630F, C6 30W, C630G), 631 (e.g., D631N, D631Y, D631A, D63 1G, D631V, D631E), 632 (e.g., E632K, E632G), 632 -633 (6-base pair in-frame germline deletion in exon 11), 633 ( For example, 9-base pair replication), 634 (for example, C634W, C634Y, C634S, C6 34R, C634F, C634G, C634L, C634A, or C634T, This is an insertion ELCR, or a 12-base pair replication, or A640G, A641A, or A6 (Combination with 41T) (e.g., causes MTC), 634 / 852 (e.g., C 634R / I852M), 635 (e.g., R635G), 636 (e.g., T636P) , T636M), 648 (e.g., V648I), 649 (e.g., S649L), 66 4 (e.g., A664D), 665 (e.g., H665Q), 666 (e.g., K666) E, K666M, K666N, K666R), 675 (T675T, Silent Nucleo) (Cydro change), 686 (e.g., S686N), 689 (e.g., S689T), 691 ( For example, G691S), 694 (for example, R694Q), 700 (for example, M700L) , 706 (e.g., V706M, V706A), 713 splice variant (e.g., E713K), 732 (e.g., E732K), 736 (e.g., G736R), 748 (For example, G748C), 765 (For example, S765P), 766 (For example, P766S) , P766M6), 768 (e.g., E768Q, E768D), 769 (e.g., L7 69L), 770 (e.g., R770Q), 771 (e.g., D771N), 777 (e.g., For example, N777S), 778 (for example, V778I), 781 (for example, Q781R), 788 (e.g., I788I), 790 (e.g., L790F, L790T), 791 ( For example, Y791F, Y791N), 791 / 852 (for example, Y791F / I852M) ), 802, 804 (for example, V804L, V804M, V804E, V804G, V8 04S) (e.g., causes MTC), 804 / 918 (e.g., V804M / M9 18T, V804L / M918T), 805 (e.g., E805K), 804 / 805 ( For example, V804M / E805K), 806 (for example, Y806F, Y806C, Y80 6H, Y806Y), 810 (for example, G810R, G810S, G810A, G810 C, G810V), 818 (e.g., E818K), 819 (e.g., S819I), 8 23 (e.g., G823E), 826 (e.g., Y826M, Y826S), 833 (e.g., For example, R833C), 841 (for example, P841L, P841P), 843 (for example, E 843D), 844 (for example, R844W, R844Q, R844L), 848 (for example) , M848T), 852 (e.g., I852M), 865 (e.g., L865V), 87 0 (e.g., L870F), 873 (e.g., R873W), 876 (e.g., A876) V), 881 (e.g., L881V), 882, 883 (e.g., A883F, A883 P, A883S, A883T, A883Y), 884 (e.g., E884K), 886 ( For example, R886W), 891 (for example, S891A), 897 (for example, R897Q) , 898 (e.g., D898V), 900 (e.g., Y900F), 901 (e.g., E 901K), 904 (e.g., S904F, S904C), 905 (e.g., Y905F) ), 907 (e.g., K907E, K907M), 908 (e.g., R908K), 91 1 (for example, G911D), 912 (for example, R912P, R912Q), 918 (for example) For example, M918T, M918V, M918L, M918R (for example, causing MTC) ), 919 (e.g., A919V), 921 (e.g., E921K), 922 (e.g., S922P, S922Y), 930 (e.g., T930M), 961 (e.g., F961) L), 972 (e.g., R972G), 981 (e.g., Y981F), 982 (e.g., , R982C), 1009 (e.g., M1009V), 1015 (e.g., Y1015F) ), 1017 (e.g., D1017N), 1041 (e.g., V1041G), 1064 (e.g., M1064T), 1096 (e.g., Y1096F), Exxon 6 and 11 In-frame deletion in exon 15, 3bp in-frame deletion, nucleoti D position 2136+2 (for example, 2136+2T>G), del632-636 ins6 , and RET extracellular cysteine mutations (the following cysteine residues: 609, 611, 618 Defined as a mutation containing at least one of 620, 630, or 634. Other mutations include D631-liter633delinsE and E632-lit er633del, A883F, D631-liter633delinsV, L790 F, D898-E901del, D898_E901del+D903_S904del insEP, K666N, T636-V637insCRT, and D378-G385 This includes delinsE. Further mutations include D631-liter633deli nsE, E632-liter633del, A883F, D631-liter633 delinsV, L790F, D898-E901del, D898_E901del + D903_S904delinsEP, K666 N, T636-V637ins Includes CRT and D378-G385delinsE. RET kinase protein Qualitative point mutations / insertions / deletions include, for example, M918T, M918V, C634W, V804L , or V804M. Point mutations / insertions / deletions of other RET kinase proteins are However, there may be cases that are not included in the list herein or are not yet known, but While doing so, transform equations I, Ia~Ix, IIa~IIx, and / or IIIa~IIIx The compounds and the methods of use thereof described herein are expected to be effective inhibitors. It can be done.
[0093] In some embodiments, the RET gene, RET kinase, or any of the same Dysregulation of any expression, activity, or level is also a factor in the structure of the RET kinase domain. At least one residue is missing (compared to wild-type RET kinase) that contributes to its functional activity. R, which is an alternative splicing variant of RET, results in an expressed protein. This may include splice variations of ET mRNA.
[0094] The term "RET kinase inhibitor" as defined herein refers to the biological process described in the following examples. This refers to compounds that inhibit RET activity using measurements such as targeted assays.
[0095] In some cases, RET kinases containing mutations, insertions, or deletions are considered wild-type RET kinases. Compared to the kinase or RET kinase that does not contain the same mutation, one or more first RET It is more resistant to inhibition of its phosphotransferase activity by kinase inhibitors. Such mutations are those of formulas I, Ia-Ix, IIa-IIx, and described herein. / or treatment of compounds IIIa-IIIx for cancer cells possessing RET kinase Alternatively, it may not reduce tumor sensitivity (for example, certain RET inhibitor resistance mutations). (compared to cancer cells or tumors that do not contain it). In these cases, RET inhibitor resistance mutations are In the presence of the first RET kinase inhibitor, in the presence of the same first RET kinase inhibitor Compared to wild-type RET kinase or RET kinase without the same mutation, V max Increase in ATP K m The decrease of the first RET kinase inhibitor, K D Of the increase This can result in RET kinases having one or more copies.
[0096] In other cases, RET kinases containing mutations, insertions, or deletions are considered wild-type RET or Compared to RET kinases that do not contain the same mutations, Formulas I, Ia-Ix described herein , increasing resistance to compounds IIa-IIx and / or IIIa-IIIx In such cases, the RET inhibitor resistance mutation is represented by formulas I, Ia~ described herein. Fields in the presence of the same compound Ix, IIa-IIx, and / or IIIa-IIIx Compared to the bio-type RET kinase or RET kinase without the same mutation, as described herein. The combination of formulas I, Ia~Ix, IIa~IIx, and / or IIIa~IIIx listed In the presence of an object, V max Increase, K m The decrease, and K D Having one or more of the following decreases This can lead to the production of RET kinase.
[0097] Examples of RET inhibitor resistance mutations include, but are not limited to, gatekeeper residues, P-loop residues, DFG motifs or residues near them, and ATP cleft solvents The ATP binding site of the tertiary structure of RET kinase, including the front amino acid residue, and its attachment Possible examples include point mutations, insertions, or deletions in the vicinity. Further examples of these types of mutations These are not limited to these, but include residues in the activation loop and those near the activation loop. or residues that interact with it, residues that contribute to the active or inactive enzyme conformation, Changes in residues that can affect enzyme activity and / or drug binding, and advance the C helix. Changes include mutations, deletions, and insertions in the octaves and C helices. In certain residues or residue regions known to induce RET inhibitor resistance, this (Human wild-type RET protein sequence (Among these, but not limited to these, the following amino acids are included (Human wild-type RET protein sequence (Among these, Based on column number 1): 732 (e.g., E732K); 788 (e.g., I788N) ;804 (for example, V804M, V804L, V804E);804 / 805 (for example, V804M / E805K); 806 (e.g., Y806C, Y806E, Y806S, Y 806H, Y806N); 810 (e.g., G810A, G810C, G810R, G8 10S, G810V); and 865 (e.g., L865V). RET inhibitor resistance mutations. Further examples of amino acids include, but are not limited to, the following (in human fields) Based on the biological RET protein sequence (SEQ ID NO: 1): L730P, G731V, E73 2K, G733V, E734K, L760M, K761E, E762K, N763D, A 764V, S765N, P766A, S767C, E768K, L779M, I788M , M868R, K869E, L870Q, V871M, H872R, R873P, D87 4Y, L881R, L895M, S896N, R897C, D898Y, V899G, Y 900D, E901K, E902K, D903Y, S904C, Y905D, V906M , K907E, R908P, S909C, Q910R, G911C, and R912P. These mutations (changes in one or more amino acids, insertions within or adjacent to a sequence, etc.) Deletions (including those within or adjacent to the sequence) can cause steric hindrance and / or inhibitory reactions. It is thought to induce an active conformational effect that alters the synthesis properties.
[0098] Formulas I, Ia-Ix, IIa-IIx, and / or IIIa- The IIIx compound treats patients who develop cancer with certain RET inhibitor-resistant mutations. It may be useful for treatment. For example, amino acid position 804 (e.g., V804M, V80 This can lead to increased resistance to RET inhibitors, such as substitution with 4L or V804E. Resistance mutations, and / or resistance mutations to one or more other RET inhibitors as described above, may lead to concomitant administration. It can be treated either by administration or as follow-up therapy to existing drug treatments. For example, if a patient is treated with a first RET kinase inhibitor and the patient develops a RET inhibitor resistance mutation If the disease develops, the patient will then subsequently undergo the following treatments using formulas I, Ia-Ix, and IIa as described herein. Compounds of ~IIx and / or IIIa~IIIx or their pharmaceutically acceptable forms It can be treated with salt (formulas I, Ia-Ix, IIa-IIx, and as described herein) The compounds of type IIIa-IIIx are present in the presence of certain RET kinase inhibitor mutations. (Assuming it is a suitable inhibitor). As another example, a patient may have a change in a specific RET kinase inhibitor. If the patient is known to have a different (or multiple) mutation, the patient will have the present RETkina The following formulas I, Ia-Ix, and IIa described herein are effective against mutations of the enzyme inhibitor. Compounds of ~IIx and / or IIIa~IIIx or their pharmaceutically acceptable forms (Can be treated simultaneously with multiple RET kinase inhibitors containing salt). Currently known R Examples of ET kinase inhibitors include pazopanib, citravatinib, regorafenib, and mothe Sanib, RXDX-105, alectinib, BLU6864, cabozantinib, dovicinib B, foretinib, lenvatinib, ponatinib, pralcetinib, serpercatinib, so Examples include rafenib, sunitinib, and vandetanib.
[0099] Compounds of formulas I, Ia, Ib, Ic, and Id, and their pharmaceutically acceptable salts, are used. The types of cancer that can be treated with this method include blood cancers and solid tumor cancers. Formulas I, Ia~Ix, IIa~IIx, and / or IIIa~IIIx described below Examples of cancer types that can be treated with compounds include lung cancer (e.g., small cell lung cancer). (or non-small cell lung cancer), thyroid cancer (e.g., undifferentiated thyroid cancer, Haasle cell thyroid cancer) Adenocarcinoma, follicular thyroid cancer, poorly differentiated thyroid cancer, papillary thyroid carcinoma, medullary thyroid carcinoma, Differential thyroid cancer, recurrent thyroid cancer, or refractory differentiated thyroid cancer), multiple endocrine tumors Uterine ulcer type 2A or 2B (MEN2A or MEN2B, respectively), goiter, endocrine disorders Adenoma, lung adenocarcinoma, bronchiololung cell carcinoma, multiple endocrine neoplasia type 2A or 2B (and These include MEN2A or MEN2B, pheochromocytoma, parathyroid hyperplasia, and breast cancer (brea). (St. cancer), breast cancer (mammary cancer), breast cancer (mamma (Ry carcinoma), breast neoplasms, colorectal cancer (e.g., metastatic colorectal cancer), nipple Renal cell carcinoma, ganglion neuromas of the gastrointestinal mucosa, inflammatory myofibroblastic tumors, and cervical This could be the case. Specifically, the type of cancer could be lung cancer or thyroid cancer. Specifically, the cancer may be non-small cell lung cancer or medullary thyroid cancer. Compounds of formulas I, Ia-Ix, IIa-IIx, and / or IIIa-IIIx Further examples of cancer types that can be treated using this method include acute lymphoblastic cancer. Hematological cancers (ALL), acute myeloid leukemia (AML), adolescent cancers, adrenocortical carcinoma, anal cancer, Appendiceal cancer, astrocytoma, atypical teratoma-like / rhabdomyoform tumor, basal cell carcinoma, bile duct cancer, bladder Hmm, bone cancer, brainstem glioma, brain tumor, breast cancer, bronchial tumor, Burkitt lymphoma, cartilage Noid tumors, unknown primary cancers, cardiac tumors, cervical cancer, childhood cancers, chordomas, chronic lymphomas CLL (Chronic Leukemia), Chronic Myeloid Leukemia (CML), Chronic Myeloproliferative Neoplasms, Tumors by Site Tumors, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, bile duct cancer, non-invasive breast cancer Tubal cancer, embryonic tumor, endometrial cancer, ependymoma, esophageal cancer, nasal neuroblastoma, Ewing's meat Tumors, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic cholangiocarcinoma, eye cancer, fallopian tube cancer, fibrous bone Histiocytoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), Germ cell tumor, gestational trophoblastic disease, glioma, hairy cell tumor, hairy cell leukemia, head and neck cancer Thoracic tumors, head and neck tumors, CNS tumors, primary CNS tumors, cardiac cancer, hepatocellular carcinoma, tissue Choletropic disease, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, pancreatic neuroendocrine tumor Kaposi's sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, lip cancer Oral cancer, liver cancer, lung cancer, lymphoma, macroglobulinemia, malignant bone fibrous tissue Cystoma, osteosarcoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous cell carcinoma of the neck, median ductus Cancer, oral cancer, multiple endocrine adenoma syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome Group, myelodysplastic / myeloproliferative neoplasm, tumor by site, tumor, myeloid leukemia myeloid leukemia), myeloid leukemia, Myeloma, myeloproliferative neoplasms, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-holic myeloma Dikin lymphoma, non-small cell lung cancer, lung neoplasm, lung cancer, lung Tumors (pulmonary neoplasm), airway tumors, bronchial cancer, bronchial tumors, Oral cancer, oral cavity cancer r) Lip cancer, oral and pharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papilloma, paraganglioma, Sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary cancer, Plasma cell tumor, pleuroblastoma, pregnancy-related breast cancer, primary central nervous system lymphoma, primary peritoneal Hmm, prostate cancer, rectal cancer, colon cancer, colon tumor, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Salivary gland cancer, sarcoma, Sézary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma squamous cell carcinoma, squamous cell carcinoma of the neck, stomach cancer, T-cell lymphoma, testicular cancer, throat cancer thymoma and thymic carcinoma, thyroid cancer, renal pelvis and ureteral transitional cell carcinoma, unknown primary cancer These include urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilms' tumor. It can be done.
[0100] Formulas I, Ia-Ix, IIa-IIx, and / or IIIa- Examples of blood cancers that can be treated using IIIx compounds and methods include white blood cancer. Blood diseases, lymphoma (non-Hodgkin lymphoma), Hodgkin's disease (also called Hodgkin lymphoma) , and myeloma, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Chronic myelomonocytic leukemia (CMML), Chronic neutrophilic leukemia (CNL), Acute Anaplastic leukemia (AUL), anaplastic large cell lymphoma (ALCL), prolymphocytic leukemia (P ML), juvenile myelomonocytic leukemia (JMML), adult T-cell allergic leukemia (ALL), and triphyletic myelodysplasia. associated AML (AML / TMDS), mixed lineage leukemia (MLL), myelodysplastic syndrome (MD S) These include myeloproliferative disorders (MPD) and multiple myeloma (MM). Hematological cancers Further examples include polycythemia vera (PV), essential thrombocytopenia (ET), and myeloproliferative disorders (MPDs) such as idiopathic primary myelofibrosis (IMF / IPF / PMF) Examples include: In one embodiment, hematological cancers (for example, hematological cancers that are RET-related cancers) , AML or CMML.
[0101] Formulas I, Ia-Ix, IIa-IIx, and / or IIIa- Examples of solid tumor cancers that can be treated using IIIx compounds and methods include: Thyroid cancer (e.g., papillary thyroid carcinoma, medullary thyroid carcinoma), lung cancer (e.g., adenocarcinoma, thyroid cancer) Cellular lung cancer, pancreatic cancer, pancreatic ductal carcinoma, xanthogranuloma tumor, breast cancer, colon cancer, colorectal cancer, straight Intestinal neuroendocrine cancer, prostate cancer, renal cell carcinoma, head and neck tumors, neuroblastoma, and melanoma These are some examples.
[0102] This specification is intended for use in the treatment of RET-related diseases or disorders such as IBS or cancer. Formulas I, Ia~Ix, IIa~IIx, and / or IIIa~IIIx are described below. Compounds of or pharmaceutically acceptable salts thereof are also provided herein. Formulas I, Ia, I Treatment using compounds of b, Ic and / or Id or their pharmaceutically acceptable salts. The cancers that may occur are listed above in this specification. Treatment of RET-related diseases or disorders Furthermore, the step of performing an in vitro assay using biological samples from the patient, RET gene The expression, activity, or level of the child, RET kinase, or any of them. A step to determine the presence of dysregulation of the RET gene, RET kinase, or If there is a dysregulation of the expression, activity, or level of any of these , the therapeutically effective amounts of formulas I, Ia-Ix, IIa-IIx, and / or as described herein. The steps may include administering compounds of the IIIa-IIIx compounds to the patient. In this application, the biological sample may be a tumor sample, and tumor samples are used for genome / DNA sequencing. It can be analyzed using methods known to those skilled in the art, such as those mentioned above. Furthermore, in these applications The sample contains formulas I, Ia-Ix, IIa-IIx, and / or I as described herein. Compounds IIa-IIIx can be obtained from the patient before the first dose in therapy. Formulas I, Ia-Ix, IIa-IIx, and / or IIIa-I described herein In these applications of IIx compounds, the RET gene, RET kinase, or related Having a dysregulation of at least one of the following: expression, activity, or level This can be based on the patient being selected for treatment. Also, in these therapeutic applications , formulas I, Ia-Ix, IIa-IIx, and / or IIIa as described herein. The amount of compounds of type IIIx or their pharmaceutically acceptable salts is approximately 1 mg / kg to 200 mg / kg. It may be administered to patients in doses of kg (the sub-range of effective doses is indicated above in this specification). .
[0103] To clarify, in the following scheme, specific stereochemical centers are not identified. While certain substituents have been excluded, this is by no means intended to limit the scope of this scheme. This is not meant to illustrate. Furthermore, it does not illustrate individual isomers, enantiomers, and diastereomers. The present invention is obtained by selective crystallization techniques or methods such as chiral chromatography. Even if separated or divided by a person skilled in the art at any convenient point in the synthesis of the compound Good (for example, J. Jacques, et al., "Enantiomers, Rac emates,and Resolutions”,John Wiley and S. ons, Inc., 1981, and ELEliel and SHWilen ,”Stereochemistry of Organic Compounds”, Wiley-Interscience, 1994). "Isomer 1" and "Isomer 2" The specification states that, under the conditions described herein, chiral chromatography is performed as follows: This refers to the first and second eluting compounds, and chiral chromatography is initiated early in the synthesis. If so, the same specification applies to subsequent intermediates and examples. Furthermore, the following The intermediates described by Chiem may contain several nitrogen-protecting groups or oxygen-protecting groups. The protecting group may be the same in each appearance, depending on the specific reaction conditions and transformations performed. They may differ. The conditions for protection and deprotection are well known to those skilled in the art and are described in the literature. (For example, “Greene’s Protective Groups in O rganic Synthesis”, Fourth Edition, by Pete r GMWuts and Theodora W.Greene,John Wi (See ley and Sons, Inc. 2007).
[0104] Certain abbreviations are defined as follows: "ACN" refers to acetonitrile; "A "TP" refers to adenosine triphosphate; "bis(pinacolate)diborone" refers to 4,4, 4′,4′,5,5,5′,5′-Octamethyl-2,2'-bi-1,3,2-dioxa Refers to borolan; "Boc" refers to tert-butoxycarbonyl; "Boc2O" " is a di-tert-butyl dicarbonate; "BSA" is a bovine serum albumin. Refers to; "BTFFH" is fluoro-N,N,N′,N′-bis(tetramethylene)phor This refers to muamidinium hexafluorophosphate; "Bu" refers to butyl; "CO "MU (registered trademark)" is (1-cyano-2-ethoxy-2-oxoethylideneaminoox (c) Refers to dimethylamino-morpholino-carbenium hexafluorophosphate; "DCM" refers to dichloromethane or methylene chloride; "DIPEA" refers to N,N- Diisopropylethylamine or N-ethyl-N-isopropyl-propane-2-amine "DMAP" refers to 4-dimethylaminopyridine; "DMF" refers to N,N - Refers to dimethylformamide; "DMSO" refers to dimethyl sulfoxide; "DT "T" refers to dithiothreitol; "NMR" refers to ethyl acetate; "ee" is , refers to enantiomer excess; "Et2O" refers to diethyl ether; "EtOH" refers to , "FA" refers to formic acid; "GST" refers to gluten. This refers to tathione S-transferase; "HATU" is 1-[bis(dimethylamino )Methylene]-1H-1,2,3-Triazolo[4,5-b]pyridinium 3-oxide It refers to hexafluorophosphate; "HEK" refers to human fetal kidney; "hr" also "hrs" refers to time; "HOAc" refers to acetic acid; "HTRF" refers to uniform time. "IgG" refers to decomposition fluorescence; "IPA" refers to isopropyl Refers to alcohol or isopropanol; "IPAm" refers to isopropylamine. ; "iPr2O" refers to isopropyl ether; "[Ir(OMe)(1,5-co d)2" is di-mu-methanolatdiiridium(Ir-Ir)-cycloocta-1, 5-diene or (1,5-cyclooctadiene)(methoxy)iridium(I) dimer Alternatively, it refers to bis(1,5-cyclooctadiene)di-μ-methoxydiiridium(I). "KOAc" refers to potassium acetate; "LDA" refers to lithium diisopropylamide. "MeI" refers to methyl iodide or iodomethane; "MeOH" refers to meta It refers to methyl alcohol; "MeTHF" is 2-methyltetrahydrofurcation. "Mn" refers to min; "Mn(dpm)3" refers to manganese (3+) tris [(3Z)-2,2,6,6-tetramethyl-5-oxo-3-heptene-3-oleate ], Mn(TMHD)3, Shenvi hydrogenation catalyst, or Tris(dipivaloylmethana (T) refers to manganese; "NaOAc" refers to sodium acetate; "NaOMe" refers to na This refers to thorium methoxide; "NMI" refers to 1-methylimidazole or N-methylimidazole. This refers to midazole; the "Perkins catalyst" is a hydride (dimethylphosphinate-kP) [ This refers to hydrogen bis(dimethylphosphinite-kP) platinum(II), CAS #173416. -05-2; "PBS-T" is phosphate-buffered saline + Tween(registered trademark) Refers to 20; "Pd(dppf)Cl2)" is [1,1'bis(diphenylphosphinol) )ferrocene] refers to dichloropalladium(II); "Pd(dppf)Cl2)CH2 Cl2 is a [1,1'bis(diphenylphosphino)ferrocene]di conjugated with DCM. Chloropalladium(II) refers to chloropalladium; "PE" refers to petroleum ether; "PhSiH3" "RT" refers to phenylsilane; "RT" refers to room temperature; "SFC" refers to supercritical fluid chromatography. It refers to graphing; "tert-BuOH" refers to tert-butyl alcohol; "TBTU" is O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyl Tyluronium tetrafluoroborate or N,N,N′,N′-tetramethyl-O- (Benzotriazol-1-yl)uronium tetrafluoroborate refers to "TCF" H is N,N,N',N'-tetramethylchloroform amidinium hexafluoro "TEA" refers to phosphate; "TEA" refers to triethylamine; "TFA" refers to trifluor "THF" refers to tetrahydrofuran; "T3P (registered trademark)" refers to Propanephosphonic anhydride, 2,4,6-tripropyl-1,3,5,2,4,6-tri Refers to oxatriphospholinane-2,4,6-trioxide, or PPACA; "t ( R) " refers to the holding time, and "WT" refers to the wild type.
[0105] The compounds of the present invention or their pharmaceutically acceptable salts are well known in the art. These preparations may be prepared according to the following preparations and examples, which are understood to be appropriate. And preferred reaction conditions for the steps of the examples are well known in the art, Appropriate substitution of solvents and co-reagents is within the scope of the art in this field. Similarly, during synthesis... The interbody is isolated and / or purified by various well-known techniques as needed or desired. It is possible that, in many cases, various intermediates require little to no purification. Furthermore, it can be used directly in subsequent synthesis steps, as will be known to those skilled in the art. It will be understood as follows. For example, the compounds of preparation and examples are, for example, silica gel. It can be isolated by processing, and can be directly isolated by filtration or crystallization. Furthermore, those skilled in the art will know that in some situations the order in which the parts are introduced is not important. They will recognize the specific sequence of steps required to produce the compound of the present invention. The introduction, as is well known to those skilled in the art, describes the specific compounds being synthesized, starting It depends on the compound and the relative tendencies of the substituted moieties. All substituents are shown separately. Unless otherwise specified, all reagents are as previously defined and are used in the relevant art. It is knowledge and is understood.
[0106] In the following scheme, all substituents are defined previously unless otherwise specified. That is correct. Reagents and starting materials are generally readily available to those skilled in the art. These are standard organic and heterocyclic chemistry techniques similar to the synthesis of known structurally similar compounds. The following preparations and procedures described in the examples include techniques and any novel methods. Therefore, it can be prepared. Intermediates and p Rothes is intended to be included in this description.
[0107] [ka] Scheme 1 shows the preparation of compound (12). Those skilled in the art will be able to perform the preparation under typical Miyaura reaction conditions. Boronation of aryl bromide (1) can provide boronic acid ester (2). They will recognize the appropriate bromopirazole (3) and gold under Suzuki coupling conditions. By treating boronic acid ester (2) with a genus catalyst, aminopyrazole (9) can be obtained. can.
[0108] Alternatively, the aryl bromide (1) can be converted to palladium by carbon monoxide and benzyl alcohol. By carbonylation with a hydrogen catalyst, benzyl carboxylate (4) can be provided. Debenzylation of benzyl carboxylate (4) with a palladium catalyst results in the carboxylic acid ( 5) may be provided. Preparation of acid acyl chloride (5) and subsequent malo under basic conditions Reaction with nonitrile yields malononitrile (6). Vinyl alcohol The methylation of (6) is achieved using dimethyl sulfate, providing methoxy(7). This can be done. Appropriately substituted hydrazine (8) is used with dinitrile Michael acceptor ( By reacting with (7), aminopyrazole (9) can also be obtained.
[0109] Boro with appropriate bromopyrazole (10) and metal catalysts under Suzuki coupling conditions By treatment with ethanol ester (2), aminopyrazole (11) can be obtained. Bonic acid (12) can be obtained by saponifying ester (11) with a suitable nucleophilic base. It is possible.
[0110] Alternatively, carboxylic acids (12) can also be oxidized and saponified using peroxides and bases. It can be obtained from ester (9) in a two-step, one-pot reaction.
[0111] [ka] Scheme 2 is based on formulas I, Ia-Ix, IIa-IIx, and / or as described herein. The preparation of compounds IIIa to IIIx is shown. By saponification of ester (1), the scheme Carboxylic acid (14) is described in essentially the same style as carboxylic acid (12) in 1. A suitable amide cuprin can be supplied under conditions suitable for amide bond formation. Those skilled in the art will know that a suitable amide cuprin can be supplied. By using a reagent, an amide (15) is provided, thereby providing a carboxylic acid (14) and a It will be recognized that a quaternary amine (13) can be bonded. Typical Miyaura reaction strip Boration of aryl bromide (15) under the following conditions, followed by bromopy under Suzuki coupling conditions. Treatment of boronic acid esters in situ with rhazole (10) and a metal catalyst yields formulas I, I Compounds a-Ix, IIa-IIx, and / or IIIa-IIIx can be obtained. Cut.
[0112] Alternatively, by amide coupling of carboxylic acid (12) and primary amine (13) , in essentially the same format as described for the above amide (15), formulas I, Ia~Ix Compounds of types IIa-IIx and / or IIIa-IIIx may be provided.
[0113] [ka] Scheme 3 is based on formulas I, Ia-Ix, IIa-IIx, and / or as described herein. Alternatively, the preparation of compounds IIIa-IIIx is shown. Primary amines with appropriate protecting groups ( 16) Protection may provide a mono- or bis-protected aminopyrazole (17). Iridium-catalyzed CH borylation of pyrazole (17), followed by Suzuki coupling. Treatment of aryl bromide (1) and in-situ boronic acid esters with a metal catalyst under certain conditions By this, biaryl(18) can be obtained. By saponification of ester(18), scheme Carboxylic acid (19) is described in essentially the same style as carboxylic acid (12) in 1. A can be supplied for the amide coupling of a carboxylic acid (19) and a primary amine (13). Therefore, the amide (12) in scheme 2 is described in essentially the same style as the amide ( 20) may be provided. The nitrile portion of aminopyrazole (20) is processed by a metal catalyst. Under various conditions such as hydrolysis, acid hydrolysis, and oxidation, it is converted to carboxamide (21). It is possible. By removing the protecting group from the protected aminopyrazole (21), as described herein. Additional formulas I, Ia~Ix, IIa~IIx, and / or IIIa~IIIx A mixed dish may be offered.
[0114] [ka] Scheme 4 is a combination of formulas I, Ia-Ix, IIa-IIx, and / or as described herein. Alternatively, alternative preparations of compounds IIIa-IIIx are shown. Appropriately substituted hydrazine ( 8) is reacted with dinitrile Michael acceptor (22) to obtain Scheme 1 The description of aminopyrazole (9) is essentially in the same format as the description of aminopyrazole (23) can be obtained. Under Negishi coupling conditions, a suitable alkyl halogen sub By treating aryl bromide (23) with lead and metal catalysts, tert-butyl ester is obtained. Tert-butyl ester (24) can be obtained by acidic deprotection of tert-butyl ester (24). A carboxylic acid (25) may be provided.
[0115] Alternatively, by saponification of ester (9), the carboxylic acid (12) in scheme 1 can be described Carboxylic acid (25) can be supplied in essentially the same manner as listed. ) and amide coupling of primary amine (13) results in amide (12) of scheme 2 The amide (31) may be provided in essentially the same format as described for.
[0116] Alternatively, by amide coupling of carboxylic acid (26) and primary amine (13) , in essentially the same style as described for amide (12) in scheme 2, amide (27 ) may be provided. By saponification of ester (27), the carboxylic acid (12) of scheme 1 is Carboxylic acids (28) can be supplied in essentially the same manner as described below. Acid chloride Preparation of acyl(28) and subsequent reaction with malononitrile under basic conditions Malononitrile (29) can be obtained. Methylation of vinyl alcohol (29) This can be achieved using dimethyl sulfate and provide methoxy(30). The converted hydrazine (8) is reacted with dinitrile Michael acceptor (30). Therefore, it is essentially the same as described for aminopyrazole (9) in Scheme 1. The aminopyrazole (31) can be obtained using the formula.
[0117] The nitrile portion of aminopyrazole (31) undergoes hydration by a metal catalyst, acid hydrolysis, and Under various conditions such as oxidation, formulas I, Ia-Ix, IIa are used as described herein. It can be converted to additional compounds of ~IIx and / or IIIa~IIIx.
[0118] In any step, formulas I, Ia~Ix, IIa~IIx, and / or III The pharmaceutically acceptable salts of compounds a-IIIx are, under standard conditions, formula I, Ia-Ix, I Suitable free bases of Ia-IIx and / or IIIa-IIIx in a suitable solvent It can be formed by reaction with a suitable pharmaceutically acceptable acid. Furthermore, the formation of such salts. This can occur simultaneously with the deprotection of the nitrogen protecting group. The formation of such salts is prevalent in the art. It is knowledge and is understood. For example, Gould, PL, “Salt selec tion for basic drugs,”International Jour nal of Pharmaceutics,33:201-217(1986),Ba stin, RJ, et al. “Salt Selection and Opti mization Procedures for Pharmaceutical N ew Chemical Entities,”Organic Process Re Search and Development, 4:427-435 (2000), Berge, SM, et al., “Pharmaceutical Salt s,”Journal of Pharmaceutical Sciences,66 See 1-19, (1977). “Salt selection for basic,”International Journal of Ph drugs armaceutics,33:201-217(1986). Formula I, Ia~Ix, II Compounds a-IIx and / or IIIa-IIIx are pharmaceutically acceptable in salts. Those skilled in the art will understand that it can be easily converted and isolated as a pharmaceutically acceptable salt. cormorant.
[0119] Preparation and Examples Preparation 1 tert-butyl N-(tert-butoxycarbonyl)-N-(5-iodo-4-methyl (Lu-1,3-thiazole-2-yl)carbamate [ka] 5-iodo-4-methyl-1,3-thiazole-2-amine in THF (200 mL) (16.0g, 66.7mmol), Boc2O (32.0g, 146mmol), approximately The mixture of DMAP (0.81 g, 6.63 mmol) was stirred under N2 at room temperature for 2 hours. The mixture is concentrated under reduced pressure. The residue is then subjected to a PE:siRNA gradient of 12:1 to 5:1. The title compound (20.0 g, 68% is obtained as a yellow solid. ES / MS (m / z) 441.0 (M+H).
[0120] Preparation 2 5-(2,2-dimethylpropyl)-4-methyl-1,3-thiazole-2-amine [ka] Zinc chloride (5.84 mL, 4.09 mmol, 0.7 M in THF) was brominated at 0°C. 2,2-Dimethylpropyl)Magnesium (6.50 mL, 3.25 mmol, in THF) Add to a 0.5M solution and stir the mixture under N2 at 0°C for 30 minutes. tert-butyl N-(tert-butoxycarbonyl)-N-(5-iodo-4- Methyl-1,3-thiazole-2-yl)carbamate (1.20g, 2.73mmol) ) and Pd(t-Bu3P)2 (0.28g, 0.55mmol) were mixed at room temperature for 1 minute. Add gradually. Stir the mixture under N2 conditions at 100°C for a further 2 hours. Quench the substance by adding 20 mL of saturated NH4Cl aqueous solution at room temperature. Extract the mixture with ₹ (2 × 50 mL). Add the combined organic extract to brine ( Wash with 2 x 30 mL of water, dry with anhydrous sodium 2SO4, filter, and concentrate the filtrate under reduced pressure. The residue is dissolved in H2O (0.1% NH4HCO3) with a gradient of 45% to 52% ACN. The resulting compound (80m) was purified by reverse-phase chromatography (C18 column). g, 16%) is obtained as a yellow solid. ES / MS (m / z) 185.1 (M+H).
[0121] Preparation 3 Methyl 2-[4-bromo-3-(bromomethyl)phenyl]acetate [ka] Under N2 conditions, methyl 2-(4-bromo-3-methyl) in CCl4 (200 mL) at room temperature. - In a stirred solution of phenyl acetate (5.50 g, 22.6 mmol), 1-bromopy Roridine-2,5-dione (4.23g, 23.8mmol) and 2-[(E)-(1 -Cyano-1-methyl-ethyl)azo]-2-methyl-propanenitrile (1.30g, Next, add 7.92 mmol). Stir the reaction mixture at 80°C for 5 hours. Pour this into a NaHCO3 solution and extract the aqueous layer with DCM (2x). Combined organic extraction Wash the material with brine, dry it with Na2SO4, filter it, and concentrate it under reduced pressure. Silica gel chromatography elutes with a 2% to 10% phosphate gradient in cyclohexane. The title compound was purified by a fine to obtain a colorless oil (1.69 g, 23%). S / MS (m / z) 342 (M + Na).
[0122] Preparation 4 Methyl 2-[4-bromo-3-(methoxymethyl)phenyl]acetate [ka] Under N2 conditions, methyl 2-[4-bromo-3-(bromo) in MeOH (10 mL) at 5°C. In a stirred solution of methyl(phenyl)acetate (0.60 g, 1.86 mmol), add NaO Add Me (0.41 mL, 2.19 mmol, 30% by weight in MeOH). Mix the reaction. Stir the mixture at room temperature overnight. Concentrate the reaction mixture, add H2O to the residue, and mix the mixture. Extract with ethyl acetate (2x dilution). Wash the combined organic extract with brine and NaSO4. The mixture is dried in 4, filtered, and concentrated under reduced pressure to obtain the title compound as a pale yellow oil (0. 42g, 83%). ES / MS(m / z)274(M+H).
[0123] Preparation 5 Methyl 2-(4-bromo-3-chloro-2-fluorophenyl)acetate [ka] Under N2 conditions, 2-(4-bromo-3-chloro-2-fu in MeOH (15 mL) at 0°C (0.50g, 1.78 mmol) of ruolophenyl acetate, with thionyl chloride (0.39m Add L (5.33 mmol) dropwise. Warm the mixture to room temperature and stir for 16 hours. The mixture is concentrated under reduced pressure and dried under vacuum. The material is then mixed with heptane in a ratio of 25% to 100%. The title compound was purified by silica gel chromatography eluting with a DCM gradient. Obtain a colorless oil (0.50g, 100%).
[0124] The following compounds in Table 1 were reacted using an appropriate acid, and the reaction time was adjusted to determine when the reaction was complete. Chromatographic purification is performed where appropriate, and EtOH is used instead of MeOH if desired. Using this, an ethyl ester was prepared, and methyl 2-(4-bromo-3-chloro-2-fluorinated Prepare essentially as described for lo-phenyl acetate. [Table 1]
[0125] Preparation 7 Methyl 2-[4-bromo-3-(tert-butoxymethyl)phenyl]acetate [ka] Dry tert-BuOH (10 mL) and dry DCM (20 mL) protected from visible light Ag-trifluoromethanesulfonate (0.44 g, 1.71 mmol) in mL In the suspension, under N2 conditions, methyl 2-[4-bromo-3- Add a solution of (bromomethyl)phenyl acetate (0.50 g, 1.55 mmol). The reaction mixture is stirred at room temperature for 16 hours, and then poured into a saturated NaHCO3 aqueous solution. The aqueous layer is extracted with DCM (2x). The combined organic extract is dried with Na2SO4. The mixture is then filtered and concentrated under reduced pressure to obtain the title compound as a colorless oil (0.51 g, 95 %). 1 H NMR(d6-DMSO,400 MHz)δ(ppm)7.53(d,J =8.1 Hz,1H),7.39(d,J=2.2 Hz,1H),7.12(dd, J=8.1,2.3 Hz,1H),4.41(s,2H),3.70(s,2H),3 .62 (s, 3H), 1.25 (s, 9H).
[0126] Preparation 8 2-[(tert-butoxycarbonyl)[(tert-butoxycarbonyl)amino] [amino]-2-methylpropane-1-ol [ka] Stirring of Mn(dpm)3 (0.42g, 0.69 mmol) in IPA (150mL) In the solution, add metharyl alcohol (5.00 g, 69.3 mmol) and di-tert-butyl ether. Azodicarboxylate (24.0 g, 103 mmol), and PhSiH3 (7.5 Add 0g (69.3 mmol) dropwise under N2 conditions at 0°C. Refrigerate the mixture under N2 conditions. Stir at 0°C for 1 hour, and then at room temperature for 12 hours under N2. Remove the solvent under reduced pressure. The residue is eluted using silica gel chromatography with a PE:toluene gradient of 10:1 to 4:1. The compound was purified by a filtration method to obtain the title compound (15.0 g, 71%) as a white solid. 1 H NMR(CDCl3,300 MHz)δ 4.30-4.02(m,2H),3 .42-3.19(m,1H),1.59-1.42(m,24H).
[0127] Preparation 9 2-Hydrazinyl-2-methylpropane-1-ol 2HCl [ka] 2-[(tert-butoxycarbonyl)[( tert-butoxycarbonyl)amino]amino]-2-methylpropane-1-ol( In a solution of 15.0 g, 49.3 mmol, add HCl (50 mL, 4 parts 1,4-dioxane). Add N) and stir the mixture at room temperature for 2 hours. Concentrate the reaction under reduced pressure. Crude product. The material was ground with Et2O (30 mL) to obtain the title compound (4.4 g, 63%) as a white solid. To obtain as such. 1 H NMR(d6-DMSO,300MHz)δ 6.41(s,5H ), 3.40 (s, 2H), 1.14 (s, 6H).
[0128] Preparation 10 tert-butyl N-(1-methylcyclopropyl)-N-nitroso-carbamate [ka] DCM (20 mL) contains tert-butyl N-(1-methylcyclopropyl)carbame To a stirred solution of tert-butylnitrite (2.00g, 11.7mmol), add tert-butylnitrite (2 Add 0.40g (23.3 mmol) little by little at room temperature under N2 conditions, and then drain the mixture under N2 conditions. Then, stir at room temperature for 2 hours. Concentrate the mixture under reduced pressure, and separate the residue in a ratio of 25:1 to 20:1. Purified by silica gel chromatography eluting with PE:ammonium, and then titled The mixture (1.30g, 55%) is obtained as a brown liquid. 1 1H NMR (d6-DMSO) δ 1.59(s,9H),1.10(s,3H),0.86-0.84(m,2H), 0.70-0.65 (m, 2H).
[0129] Preparation 11 (1-methylcyclopropyl)hydrazine hydrochloride [ka] tert-butyl N-(1-methyl) in HCl (8 mL, 4N in 1,4-dioxane) Stirring of cyclopropyl)-N-nitroso-carbamate (1.20 g, 5.99 mmol) To the mixed solution, gradually add Zn (0.78g, 11.9 mmol) under N2 conditions at 0°C. Stir the mixture under N2 at room temperature for 12 hours. Filter the mixture and filter the cake. Wash with H2O (3 × 10 mL), concentrate the filtrate under reduced pressure to obtain the title compound (2.0 g). When the crude product is obtained as a grayish-white solid, it can be used directly without further purification. To use. 1 H NMR(d6-DMSO)δ 1.30(s,3H),0.77-0.7 3 (m, 2H), 0.54-0.50 (m, 2H).
[0130] Preparation 12 Methylspiro[2,2]pentane-2-carboxylate [ka] Spiro in Et2O (37.5 mL) and MeOH (7.5 mL) at 0°C [2.2 In a stirred solution of pentane-1-carboxylic acid (95%, 1.25g, 10.6 mmol), 2M diazomethyl(trimethyl)silane in hexane (6.9 mL, 13.8 mmol) Add the ions dropwise. Stir the reaction mixture at room temperature overnight. Remove the Et2O under reduced pressure. The reaction mixture is diluted with pentane (125 mL). The solution is then prepared as a saturated NaHCO3 aqueous solution. Wash with (2x), H2O (3x), and brine, dry with Na2SO4, and filter. Then, by concentrating under reduced pressure, the title compound (1.53 g, crude) is obtained as a yellow oil. It is used directly without further refinement.
[0131] Preparation 13 2-(trifluoromethyl)spiro[3,3]heptan-2-carbonyl chloride [ka] 2-(trifluoromethyl)spiro[3,3]heptane-2-carboxylic acid (1.02g Suspend (4.90 mmol) in DCM (40 mL) and DMF (0.10 mL). Cool the slurry to 0°C and add oxalyl chloride (3.0 mL, 6.00 mmol, DC). Add 2M of M. Stir the reaction mixture at 0°C for 5 minutes, then warm to room temperature and stir for 1 hour. Mix. Remove the solvent under reduced pressure to obtain a yellow residue. Do not further purify the residue. Use.
[0132] The following compounds in Table 2 should be mixed with an appropriate acid, oxalyl chloride (1-1.5 equivalents), and 0-5 Use a solvent (DCM, DMF) in the range of 0 mL and adjust the reaction time to determine when the reaction is complete. And, regarding 2-(trifluoromethyl)spiro[3,3]heptan-2-carbonyl chloride Prepare the mixture as described. The reaction temperature may be in the range of 0°C to 25°C. . [Table 2]
[0133] Preparation 17 Benzyl 2,2-dimethylcyclobutanecarboxylate [ka] Under N2 conditions, 2,2-dimethylcyclobutan-1-calcium in DCM (20 mL) at 0°C. To a stirred solution of bonic acid (1.50 g, 11.7 mmol), add oxalyl chloride (1.0 mL, Add 11.7 mmol of DMF (30 μL) dropwise. Stir the mixture slowly. Then warm to room temperature and stir for 5 hours. Benzyl alcohol (1.4 mL, 13.5 mmol) Add the mixture dropwise at 0°C, and slowly warm the reaction mixture to room temperature while stirring for 20 hours. Pour the mixture into a saturated NaHCO3 aqueous solution. Extract the aqueous layer with pentane (2x dilution). The combined organic extracts are washed with brine, dried with Na2SO4, filtered, and then removed under reduced pressure. The crude material is concentrated. The crude material is eluted in silica gel at a gradient of 5% to 50% DCM in pentane. The title compound (2.6g, 100%) was purified by chromatography to obtain a colorless oil. To obtain. ES / MS(m / z)219(M+H).
[0134] Preparation 18 2-[2-(3,3-dimethylcyclobutyl)-1,3-dioxolan-2-yl]acetate Tonitrile [ka] Under N2 conditions, 3-(3,3-dimethylcyclobutyl)- in DCM (8 mL) at 25°C 3-Oxo-propanenitrile (0.60 g, 4.00 mmol) is stirred with ethane. -1,2-diol (0.67 mL, 12.0 mmol) and chloro(trimethyl) cyanodiol Add ran (1.5 mL, 12.0 mmol). Stir the reaction mixture under reflux for 12 hours. Cool to room temperature. Add NaHCO3 (aqueous solution). Extract the aqueous layer with DCM. The combined organic extracts were washed with brine, dried with Na2SO4, filtered, and then removed under vacuum. Dry the residue. Elute the residue with a gradient of 10% to 30% siRNA in cyclohexane. The title compound (0.56 g, 72%) was purified by gel chromatography. It is obtained as a colored oil. 1 H NMR(d6-DMSO,400 MHz)δ(ppm)4. 09-3.98(m,2H),4.01-3.90(m,2H),2.79(s,2H) ,2.61(s,2H),1.79-1.57(m,6H),1.41(s,2H),1 0.12(s,3H), 1.01(s,3H).
[0135] Preparation 19 4-(1-methylcyclopropyl)-3-oxo-butanenitrile [ka] ACN (0.36 mL, 6.89 mmol) and benzyl 2-(1-methylcyclop Ropil acetate (1.27g, 6.22mmol) under N2 conditions, THF (15mL) Combine in the container and cool to -78°C. LDA (11.0 mL, 22.0 mmol, TH Add 2M of F dropwise and stir the reaction mixture at -78°C for 10 minutes. Heat to 21°C. Acidify the reactants with concentrated HCl to pH 1, and add the mixture to Et Extract with OAc (3 x 100 mL). Dry the combined organic extract with Na2SO4. Filter and concentrate to obtain the title compound (1.4 g, crude) as an orange oil. Materials It is used without further purification.
[0136] Preparation 20 3-Oxo-3-[2-(trifluoromethyl)spiro[3,3]heptan-2-yl] Propanenitrile [ka] ACN (0.28 mL, 5.36 mmol) and benzyl 2-(trifluoromethyl ) Spiro[3,3]heptan-2-carboxylate (1.40g, 4.69mmol) Combine the mixture in THF (15 mL) under N2 conditions and cool to -78°C. LDA(2.8 Add 2 mL of 5.64 mmol (2 M in THF) dropwise, and the reaction mixture is incubated at -78°C for 1 Stir for 0 minutes. Heat the reaction mixture to 21°C for 1 minute. Dilute the reaction mixture with concentrated HCl. Acidify the mixture with H1, and extract with toluene (3 x 100 mL). Combined organic extract The extract was dried with Na2SO4, filtered, and concentrated to obtain the title compound (1.05g, 97%). ) is obtained as an orange-colored oil. This material is used directly without further refinement.
[0137] The following compounds in Table 3 should be used in amounts of 1.2 to 4.2 equivalents of an appropriate base (hexane or THF). Using medium LDA or nBuLi, adjust the reaction time to determine the completion of the reaction, and 3- Oxo-3-[2-(trifluoromethyl)spiro[3,3]heptan-2-yl]pro Prepare it essentially as described for pannitrile. [Table 3]
[0138] Preparation 25 3-[3-methylbicyclo[1.1.1]pentan-1-yl]-3-oxopropane Trill [ka] In THF (5 mL), n-BuLi (1.71 mL, 4.28 mmol, 2.0% in THF). Add 5M ACN (0.2) in THF (5mL) to the mixture under N2 conditions at 0°C. Add 4 mL (4.59 mmol) dropwise over 5 minutes at -78°C under N2 conditions. Stir the mixture at -78°C for 1 hour. Add methyl 3-methionine to the mixture in THF (5 mL). Rubicyclo[1.1.1]pentane-1-carboxylate (0.40g, 2.85mm) Add (ol) dropwise under N2 at -78°C. Stir the mixture at room temperature for 1 hour. The reactants are quenched by adding saturated NH4Cl aqueous solution (20 mL) at 0°C. The mixture is acidified to pH 4 with a 1N HCl aqueous solution and extracted with DCM (3 x 50 mL). Wash the combined organic extracts with brine (2 x 100 mL) and then rinse with anhydrous Na2SO4. The mixture was dried, filtered, and concentrated under reduced pressure to obtain the title compound (0.36 g, 85%) as a brown liquid. Obtain it as a whole. Use the crude product without further purification.
[0139] Preparation 26 3-(3-fluorobicyclo[1.1.1]pentan-1-yl)-3-oxopropane Nitrile [ka] n-BuLi(2.0 mL, 2.5 M in n-hexane) in THF (20 mL) In a stirred solution of 0 mmol), add ACN (0.28 mL, 5.36 mm) in THF (4 mL). Add the solution of (ol) dropwise under N2 at -78°C. Allow the mixture to stand at -78°C for 30 minutes. Stir intermittently. Add methyl 3-fluorobicyclo[1.1.1] to the mixture in THF (4 mL). A solution of pentane-1-carboxylate (0.48 g, 3.33 mmol) is prepared at -78 Add dropwise over 10 minutes at °C. Warm the mixture to room temperature and stir for a further 3 hours. The reactants were quenched with saturated NH4Cl aqueous solution and acidified to pH 4 with 2N HCl aqueous solution. Then, extract with DCM (3 x 50 mL). Combine the organic extracts and brine (100 mL). Wash with (), dry with anhydrous Na2SO4, filter, concentrate under reduced pressure to obtain the title compound (0 0.50g (crude) is obtained as a brown oil. Use the crude product without further refinement. . 1 H NMR(CDCl3,300 MHz)δ 3.57(s,2H),2.50( d,6H).
[0140] Preparation 27 3-Oxo-3-[3-(trifluoromethyl)bicyclo[1.1.1]pentane-1- [Il] Propanenitrile [ka] n-BuLi (0.83 mL, 2.08 mmol, 2.5 M in hexane) is mixed with THF ( Add to 10 mL under N2 conditions at 0°C. ACN (0.12 mL) in THF (2 mL) Add 2.30 mmol) dropwise over 2 minutes at -78°C under N2 conditions, and react the product. Stir at -78°C for 1 hour. Methyl 3-(trifluoromethyl) methyl Cyclo[1.1.1]pentane-1-carboxylate (0.27g, 1.39mmol) Add the mixture dropwise at -78°C and stir the reaction mixture at room temperature for 12 hours. The reaction mixture was quenched and concentrated by adding saturated NH4Cl aqueous solution (20 mL). Acidify to pH 4 with HCl and extract with DCM (3 x 50 mL). Combine the organic extracts. Wash with brine, dry with anhydrous Na2SO4, filter, concentrate under reduced pressure, and title. A crude product (0.29 g) is obtained. The crude product is used without further purification. 1 H NMR(CDCl3,300 MHz)δ 3.54(s,2H),2.39(s,6 H).
[0141] The following compounds from Table 4 were used, and the reaction time was adjusted to determine the completion of the reaction. Purification was performed as appropriate. Regarding the matter, 3-oxo-3-[3-(trifluoromethyl)bicyclo[1.1.1]pentane Prepare the reaction as described for -1-yl]propanenitrile. After adding carboxylate, it can be heated to room temperature. n-BuLi is hex It may be present during Sun or THF. [Table 4]
[0142] Preparation 39 5-(2,5-dimethyl-1H-pyrrole-1-yl)-3-(1,1,1-trifluor Ro-2-methylpropan-2-yl)-1H-pyrazole [ka] 3-(1,1,1-trifluoro-2-methylpropane-2) in toluene (10 mL) -yl)-1H-pyrazole-5-amine (0.50g, 2.59 mmol), hexane -2,5-dione (0.91 mL, 7.76 mmol), and HOAc (0.015 mL) Stir the solution (L, 0.26 mmol) under N2 at 100°C for 2 hours. Reduce the amount of the mixture. Concentrate under pressure. Dissolve the residue in H2O (0.1% FA) with a gradient of 30% to 50% ACN. The resulting compound was purified by reverse-phase chromatography (C18 gel column) to obtain the title compound (0 0.61g, 87%) is obtained as a yellow solid. ES / MS (m / z) 272.1 (M+H ).
[0143] preparation 40 3-(2,5-dimethyl-1H-pyrrole-1-yl)-1-methyl-5-(1,1,1 (-trifluoro-2-methylpropan-2-yl)-1H-pyrazole [ka] 5-(2,5-dimethyl-1H-pyrrole-1-yl)-3- in ACN (10 mL) (1,1,1-trifluoro-2-methylpropan-2-yl)-1H-pyrazole(0 (0.50g, 1.84 mmol), MeI (0.46 mL, 7.39 mmol), and K A solution of 2CO3 (0.51g, 3.69 mmol) is stirred at 80°C for 4 hours under N2 conditions. The mixture is concentrated under reduced pressure. The residue is eluted with a 5:1 PE:siRNA solution. The title compound (95 mg, 18%) was purified by LC to obtain a white solid. / MS(m / z)286.2(M+H).
[0144] Preparation 41 1-Methyl-5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H -pyrazole-3-amine [ka] EtOH (1 mL) and KOH (53 mg, 0.94 mmol) in H2O (1 mL) l) A solution of hydroxylamine HCl (0.13 g, 1.8) in EtOH (2 mL) Add to a 7 mmol solution of 3-(2,5-dimethyl-1H-pyrrole-1-yl) -1-methyl-5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1 H-pyrazole (90 mg, 0.32 mmol) was added, and the mixture was heated under N2 conditions until 100°C. Stir at °C for 4 hours. Concentrate the mixture under reduced pressure. Remove the residue in H2O (0.1% FA). Reverse-phase chromatography (C18 gel column) with elution at a 10% to 30% ACN gradient. Purification by [method] yields the title compound (45 mg, 68%) as a white solid. ES / M S(m / z)208.1(M+H).
[0145] Preparation 42 3-[(1-methylcyclopropyl)methyl]isoxazole-5-amine [ka] 4-(1-methylcyclopropyl)-3-oxo-butanenitrile (1.40g, 10 Dissolve 0.2 mmol of NaOH in 15 mL of H2O. ( mmol) was added, followed by hydroxylamine sulfate (1.84 g, 11.2 ml) Add (mol). Adjust the pH using a 2M NaOH aqueous solution (5.0 mL, 10.0 mmol). Adjust to approximately 10. Heat the mixture at 100°C for 1.5 hours. Concentrated HCl (1 mL) Add and stir the mixture for 15 minutes. Dilute the mixture with H2O (30 mL) and EtO Extract with Ac (2 x 30 mL). Dry the combined organic extract with anhydrous NH2SO4. Concentrate under reduced pressure. Elute the residue with a gradient of 10% to 70% phosphate in hexane. The title compound (0.54 g, 35%) was purified by silica gel chromatography. Obtained. ES / MS (m / z) 153.0 (M+H).
[0146] Preparation 43 3-(3-fluorobicyclo[1.1.1]pentan-1-yl)isoxazole-5- Amine [ka] 3-(3-fluorobicyclo[1.1.1]pentan-1-I in MeOH (5 mL) In a stirred solution of (0.50 g, 3.26 mmol) hydroxypropyl alcohol, Droxylamine HCl (0.68g, 9.79mmol) and KOAc (0.96g) Add 9.78 mmol of the mixture under N2 conditions at 0°C. Allow the mixture to stand at room temperature under N2 conditions for 5 hours. Stir intermittently. Pour the mixture into H2O (50 mL) and extract with DCM (3 × 50 mL). The combined organic extracts are dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue is eluted in H2O (0.1% NH4HCO3) with a gradient of 25% to 45% ACN. The title compound (0.22g) was purified by reverse-phase chromatography (C18 column). 40% is obtained as a pale yellow solid. ES / MS (m / z) 169.1 (M+H).
[0147] Preparation 44 3-(Bicyclo[1.1.1]pentan-1-yl)isoxazole-5-amine [ka] 3-(bicyclo[1.1.1]pentan-1-yl)-3- in MeOH (10 mL) In a stirred solution of oxopropanenitrile (0.87 g, 6.44 mmol), hydroxyl Amine HCl (1.34 g, 19.3 mmol) and KOAc (1.89 g, 19.3 mmol) Add mmol) under N2 conditions at 0°C. Stir the mixture under N2 conditions at room temperature for 5 hours. Pour the mixture into H2O (50 mL) and extract with DCM (3 × 50 mL). The organic extract is dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue is then... Wash with hexane (2 × 5 mL) to obtain the title compound (0.73 g, 75%) as a pale yellow solid. It is obtained as follows: ES / MS (m / z) 151.3 (M+H).
[0148] Preparation 45 3-(3-methyl-1-bicyclo[1.1.1]pentanyl)isoxazole-5-amine hmm [ka] 3-[3-methylbicyclo[1.1.1]pentan-1-yl] in H2O (8 mL) -3-oxopropanenitrile (0.35 g, 2.35 mmol) and hydroxyl To a stirred mixture of mineHCl (0.18 g, 2.59 mmol), add NaOH (0.19 g, Add 4.75 mmol) little by little at room temperature under N2 conditions. Stir the mixture under N2 conditions for 10 minutes. Stir at 0°C for 1 hour. Cool the mixture to room temperature. Collect the precipitated solid by filtration. Wash with H2O (3 x 20 mL) and the title compound (0.30 g, 78%) is a pale yellow solid. Obtained as a physical substance. ES / MS (m / z) 165.1 (M+H).
[0149] Preparation 46 3-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)isopropyl Sazole-5-amine [ka] 3-Oxo-3-[3-(trifluoromethyl)bicyclo[1.1.1]pentane-1 -yl]propanenitrile (0.28g, 1.38mmol), hydroxylamine HCl A mixture of 1 (0.11 g, 1.58 mmol) and H2O (10 mL) contains NaOH ( Add 0.11 g (2.75 mmol) little by little at room temperature under N2 conditions. Mix the mixture for 10 minutes. Heat to 0°C for 1 hour. Cool the mixture to room temperature and extract with DCM (3 × 50 mL). The combined organic extracts are washed with brine, dried with anhydrous sodium 2SO4, filtered, and then removed under reduced pressure. The solid is concentrated. The resulting solid is ground with Et2O (10 mL). The solid is filtered. The sample was collected, washed with Et2O, and the title compound (0.22 g, 73%) was obtained. ES / MS(m / z)219.2(M+H).
[0150] The following compounds in Table 5 should be mixed in approximately 1 to 6 equivalents of an appropriate reagent (hydroxylamine sulfate). (or hydroxylamine HCl), a suitable solvent (EtOH, MeOH, H2O, or Approximately 1 to 6 equivalents of base (NaOH, NaOAc, or KOAc) in 1,4-dioxane. Using ), adjust the reaction time to determine the completion of the reaction and set appropriate chromatographic conditions. Alternatively, use a precipitate for purification, 3-(3-(trifluoromethyl)bicyclo[1.1 .1] As described regarding pentan-1-yl)isoxazole-5-amine, Prepare qualitatively. The reaction temperature may be in the range of 0 to 100°C, and the reaction mixture may be appropriate. The solution can be acidified during post-treatment. Add the reagents together at 0°C, either gradually or all at once. It is possible. [Table 5-1] [Table 5-2] [Table 5-3]
[0151] Preparation 74 3-(3,3-dimethylcyclobutyl)-4-fluoroisoxazole-5-amine [ka] 1-(chloromethyl)-4-fluoro-1,4-diazonia in a sealed vial Cyclo[2.2.2]octane;ditetrafluoroborate (0.46g, 1.30mm) ol) and 3-(3,3-dimethylcyclobutyl)isoxazole-5-amine (0. Add ACN (12 mL) to 20 g (1.20 mmol). Microwave the mixture. Irradiate at 100°C for 20 minutes under the specified conditions. Cool the reaction mixture to room temperature and concentrate under reduced pressure. The crude material is eluted in H2O (0.1% HOAc) with a reversed phase elution using a gradient of 0% to 100% ACN. Purify by chromatography (C18Aq column). Combine the desired fractions and concentrate. Then, remove the ACN. Add saturated NaHCO3 solution to the remaining aqueous solution to achieve a pH of 9. Add until [a certain amount]. Extract the mixture with DCM (2 x 10 mL). Combine the organic extracts. The mixture is dried with anhydrous Na2SO4, diatomaceous earth is added, and the mixture is concentrated under vacuum. Silica gel chromatography eluting with a 5% to 40% phosphate gradient in cyclohexane. Further purification by ES / MS (m) yields the title compound (48 mg, 22%). / z)185.3(M+H).
[0152] The following compounds in Table 6 were tested, and the completion of the reaction was determined using an appropriate controlled reaction time. Under the same purification conditions, 3-(3,3-dimethylcyclobutyl)-4-fluoroisoxazo Prepare essentially as described for ru-5-amine. [Table 6]
[0153] Preparation 77 5-(2-methylbutan-2-yl)-1,2-oxazole-3-amine [ka] 4,4-dimethyl-3-oxohexyl in MeOH (5 mL) and H2O (45 mL) Sannitrile (3.00 g, 21.6 mmol) and hydroxylamine sulfate To the stirred mixture of (3.89g, 23.7mmol), add NaHCO3 (4.53g, 53. Add 9 mmol) little by little at room temperature under N2. Allow the mixture to rise at 65°C under N2 for 5 minutes. Stir for a while. Cool the mixture to room temperature. Acidify the mixture to pH 1 with concentrated HCl, and add N 2. Stir under reflux for 20 minutes. Cool the mixture to room temperature and adjust the pH to 8 with NaOH. Extract the mixture with DCM (3 x 200 mL). The combined organic extract is brined. Wash with (2 x 200 mL), dry with anhydrous Na2SO4, filter, and concentrate under reduced pressure. The residue is eluted in H2O (0.1% NH4HCO3) with a gradient of 30% to 40% ACN. The title compound (1.20 g) was purified by reverse-phase chromatography (C18 column). 36% is obtained as a pale yellow solid. 1 ¹H NMR (CDCl3) δ 5.53(s) ,1H),1.66(q,2H),1.27(s,6H),0.82(t,3H).
[0154] Preparation 78 5-(3,3-dimethylcyclobutyl)isoxazole-3-amine [ka] In a sealed vial, add hydroxylamine HCl (0.5 mL) in MeOH (0.5 mL). 7M in 79g (11.4 mmol) and MeOH (2.0 mL, 14.0 mmol) Add NH3. Stir the suspension at 25°C for 30 minutes. In MeOH (0.5 mL) 2-[2-(3,3-dimethylcyclobutyl)-1,3-dioxolan-2-yl] Cetonitrile (0.56g, 2.87mmol) and quinoline-8-ol (42mg) Add a 0.29 mmol solution, stir the mixture at 65°C for 12 hours, and let it cool to room temperature. Discard. Filter the mixture, concentrate the filtrate under reduced pressure, and reconcentrate it with toluene (3 times). Intermolecular 2-[2-(3,3-dimethylcyclobutyl)-1,3-dioxolan-2-yl] -N'-hydroxyacetamidine is obtained as a yellow solid, which is then further purified. Use without any issues. In a sealed vial, 2-[2-(3,3-dimethylcyclobutyl [Lu)-1,3-dioxolan-2-yl]-N'-hydroxyacetamidine, Et Dissolve in OH (2 mL) and acidify to pH 1 with concentrated HCl. The reaction mixture is then heated at 80°C. Stir for 12 hours. Concentrate the mixture under reduced pressure, and dilute the residue with DCM. Saturated Na Add HCO3 aqueous solution until the solution becomes basic (pH 11). Separate the organic layer and add water. The phase is extracted using DCM. The combined organic extracts are washed with brine and dried with Na2SO4. The mixture is then filtered and concentrated under reduced pressure. The crude material is dissolved in DCM with a gradient of 0% to 5% MeOH. The title compound was purified by silica gel chromatography and obtained as a yellow solid. Obtained (30 mg, 6.3%). ES / MS (m / z) 167 (M+H).
[0155] Preparation 79 Methyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxymethyl Saborolan-2-yl)phenyl acetate [ka] Methyl 2-(4-bromo-2-methoxyphenyl)acetate (0.15g, 0.5 79 mmol), Bis(Pinacolato) Diboron (0.18 g, 0.709 mmol), KOAc (95%, 0.18g, 1.74mmol), Pd(dppf)Cl2 . CH2 Cl 2) (95%, 22 mg, 0.029 mmol), and 1,4-dioxane (2. Add 7 mL of the mixture together. Stir the reaction mixture at 80°C overnight. Dissolve the reaction product in H2O Quench the mixture and add DCM. Separate the two layers and add DCM (3 × 10 mL) to the aqueous phase. Extract. Dry the combined organic extract with Na2SO4, filter, and concentrate under reduced pressure. The title compound is obtained as a brown oil, which is then used crudely without further purification. ES / MS (m / z) 307.2 (M+H).
[0156] The following compounds in Table 7 were tested using appropriate reagents, and the reaction time was adjusted to determine when the reaction was complete. , if appropriate, purify by chromatography, and methyl 2-[2-methoxy-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl Prepare the acetate essentially as described. The reaction temperature is approximately 80-10°C. The temperature can be in the range of 0°C, filtered through talcum powder, and purified if appropriate. [Table 7]
[0157] Preparation 81 Methyl 2-[4-(5-amino-4-cyano-1-isopropylpyrazole-3-yl) -3-chlorophenyl acetate [ka] Methyl 2-(3-chloro-4-) in 1,4-dioxane:H2O (12 mL, 5:1) (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl ) Acetate (1.00g, 3.22mmol), 5-amino-3-bromo-1-isopropyl acetate Ropyrpyrazole-4-carbonilicate (0.73g, 3.22mmol), Pd(dp pf)Cl2 (0.47g, 0.64mmol), and K3PO4 (2.05g, 9. Stir the 66 mmol solution at 120°C for 2 hours under N2, then cool to room temperature. Filter through diatomaceous earth, wash with HCl (200 mL), filter again, and concentrate under reduced pressure. The residue is eluted using reverse-phase chromatography with a gradient of 10% to 50% ACN in H2O. The title compound (0.30 g, 28%) was purified by (C18 column) and obtained as a white solid. Obtained by doing this. ES / MS(m / z)333.1(M+H).
[0158] The following compounds in Table 8 were titrated by adjusting the reaction time to determine the completion of the reaction, and then titrated when appropriate. Alternatively, it can be purified by chromatography and obtained methyl 2-[4-(5-amino-4-cyano Regarding -1-isopropylpyrazole-3-yl)-3-chlorophenyl acetate Prepare the mixture as described. The reaction temperature may range from room temperature to 120°C. [Table 8]
[0159] Preparation 83 Methyl 2-[4-(5-amino-4-cyano-1-isopropylpyrazole-3-yl) -2,3-difluorophenyl acetate [ka] Methyl 2-(4-bromo-2,3-difluorophosphate) in 1,4-dioxane (30 mL) (Pinacolato) acetate (5.00g, 18.9mmol) and bis(pinacolato) dibo To the stirred mixture of ron (5.75g, 22.6mmol), add KOAc (3.70g, 37. 7 mmol) and Pd(dppf)Cl2CH2Cl2(1.54 g, 1.88 mmol) Add l) at room temperature. Stir the mixture under N2 at 80°C for 1 hour, then filter. - Wash the cake with 1,4-dioxane (5 mL). Add 5-amino-3-bromide to the filtrate. Mo-1-isopropylpyrazole-4-carbonitride (4.75g, 20.7mmol) ), Pd(dppf)Cl2CH2Cl2(1.54g, 1.88mmol), K2CO Add 3 (5.21 g, 37.7 mmol) and H2O (7 mL) at room temperature. Mix. Stir the mixture at 80°C for 1 hour. Cool the mixture to room temperature, then add the residue and PE in a 3:1 to 2:1 ratio. The title compound was purified by silica gel chromatography eluting with ammonium. 4.90g, 78%) is obtained as a yellow solid. ES / MS (m / z) 335.1 (M+ H).
[0160] Preparation 84 Benzyl 2-fluoro-4-(2-methoxy-2-oxoethyl)benzoate [ka] Methyl 2-(4-bromo-3-fluorophenyl)acetate in toluene (150 mL) (5.45g, 22.1mmol), TEA (9.2mL, 66.0mmol), Pd(dppf) was added to a solution of benzyl alcohol (2.5 mL, 24.0 mmol). Add Cl2 (0.32g, 0.44 mmol) in a pressure tank. Dissolve the mixture in N2. Purge for 1 minute, then pressurize with CO to 30 atmospheres. Dissolve the mixture in a CO atmosphere. Stir at 5°C for 24 hours. Cool the mixture to room temperature, filter, and place the filter cake in EtO Wash with Ac (2 x 50 mL). Concentrate the filtrate under reduced pressure and separate the residue in a 10:1-3: Purified by silica gel chromatography eluting with a PE:siRNA gradient of 1. The title compound (2.63 g, 39%) was obtained as a colorless oil. ES / MS (m / z) 32 0.05(M+NH3+H).
[0161] Preparation 85 2-Fluoro-4-(2-methoxy-2-oxoethyl)benzoic acid [ka] Benzyl 2-fluoro-4-(2-methoxy-2-oxo In a solution of (2.63g, 8.70 mmol) benzoate, Pd / C (10%, 0 Add 0.90g (0.85 mmol) under N2 conditions at room temperature. Drain the mixture under N2 conditions at room temperature. Stir at warm for 2 hours. Filter the mixture and add MeOH (2 × 10 mL) to the filter cake. Wash with [unclear], and concentrate the filtrate under reduced pressure to obtain the title compound (1.51 g, 82%) as a white solid. Once obtained, it is used without further refinement.
[0162] Preparation 86 Methyl 2-[4-(2,2-dicyano-1-methoxyes-1-en-1-yl)phen Acetate [ka] 4-(2-methoxy-2-oxoethyl)benzoic acid (40%) in DCM (300mL) In a stirred solution of 0g, 206 mmol) and a few drops of DMF, add oxalyl chloride (21.2mg). Add (L, 247 mmol) dropwise at 0°C. Stir the mixture at room temperature for 2 hours. The mixture is concentrated under reduced pressure to obtain the intermediate methyl 2-(4-(chlorocarbonyl)phenyl) Obtain acetate. In a separate container, add 13.6g of malononitrile in THF (100mL). A solution of 206 mmol of NaH (16.5 g, 412 ml) in THF (100 mL) Add dropwise to a stirred suspension of 60% of the mineral oil under N2 conditions at 0-10°C. Stir the mixture at room temperature for 20 minutes. Add methyl 2- in THF (200 mL) to this mixture. (4-(chlorocarbonyl)phenyl)acetate is added dropwise at 0-10°C. Stir the mixture at room temperature for 1 hour. Dimethyl sulfate (23.4 mL, 247 mmol) Add (1) and reflux the mixture under N2 at 80°C overnight. Add H2O (300 mL). Add the mixture and extract it with toluene (3 x 200 mL). The combined organic extract is then used in a bran. Wash with water, dry with Na2SO4, filter, and concentrate under reduced pressure. The residue is then separated into a 4:1 ratio. Purification by silica gel chromatography using a 1:1 PE:siRNA gradient. The title compound (42.0 g, 80%) is then obtained as a yellow solid. 1 1H NMR (CD) Cl3,400 MHz)δ 7.51-7.40(m,4H),3.96(s,3H) 3.75 (s, 3H), 3.74 (s, 2H).
[0163] Preparation 87 Methyl 2-[4-(5-amino-4-cyano-1-isopropylpyrazole-3-yl) Phenyl acetate [ka] Methyl 2-[4-(2,2-dicyano-1-methoxyes- in EtOH (40 mL) 1-en-1-yl)phenyl acetate (2.50 g, 9.76 mmol) and Sopropylhydrazine HCl (1.29 g, 11.7 mmol) and TEA (4.1 mg) Stir the solution (L, 29.4 mmol) under N2 at room temperature for 1 hour. Stir the mixture under reduced pressure. It is concentrated and extracted with ethyl acetate (3 x 100 mL). The combined organic extract is then prepared in a brightening solution. Wash with 2 x 100 mL, dry with anhydrous Na2SO4, filter, and concentrate under reduced pressure. The residue is purified by grinding with Et2O (50 mL) to obtain the title compound (2. 00g, 69% is obtained as a yellow solid. ES / MS (m / z) 299.0 (M+H) .
[0164] Preparation 88 Methyl 2-[4-(5-amino-4-carbamoyl-1-isopropyl-pyrazole-3 -yl)-2-methoxyphenyl]acetate [ka] Methyl 2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-diode Xaborolan-2-yl)phenyl acetate (67%, 0.21g, 0.460mm) ol), 5-amino-3-bromo-1-isopropyl-pyrazole-4-carboxamide (0.14g, 0.567mmol), K2CO3(0.13g, 0.941mmol) , and Pd(dppf)Cl2CH2Cl2 (19 mg, 0.0231 mmol), It was added together in a mixture of 1,4-dioxane (3.7 mL) and H2O (0.73 mL). Add. Heat the reaction mixture at 140°C for 1 hour under microwave irradiation. Filter through algae, wash with siRNA, and evaporate until dry. The crude material is then processed using DCM. Purified by silica gel chromatography with elution under a gradient of 0% to 8% MeOH. Then, the title compound (0.17 g, quantitative yield) is obtained. ES / MS (m / z) 347.2 M+H).
[0165] The following compounds in Table 9 were analyzed by adjusting the reaction time to determine the completion of the reaction, and then purified as appropriate. ,methyl 2-[4-(5-amino-4-carbamoyl-1-isopropyl-pyrazole- As described for 3-yl)-2-methoxyphenyl]acetate, essentially Prepare. [Table 9]
[0166] Preparation 90 tert-butyl N-tert-butoxycarbonyl-N-(4-cyano-2-isopropyl Pyr-pyrazole-3-yl)carbamate [ka] Preparation 91 tert-butyl N-(4-cyano-2-isopropyl-pyrazole-3-yl)carb Mate [ka] 5-amino-1-isopropyl-pyrazole-4-carbon in THF (205 mL) To a stirred solution of tolyl (4.80 g, 32.0 mmol), add N,N-dimethylpyridine-4 - Amine (0.38g, 3.11 mmol), TEA (13mL, 93.3 mmol), and tert-butoxycarbonyl tert-butyl carbonate (14.7g, 6 Add 7.4 mmol) of the reaction mixture. Stir the reaction mixture at room temperature overnight. Quench with saturated NH4Cl aqueous solution (15 mL), then extract with toluene (3 × 20 mL). The combined organic extracts are washed with brine, dried with Na2SO4, filtered, and reduced. Concentrate under pressure. Elute the residue with a gradient of 2% to 30% pharmaceutically acceptable phosphate in cyclohexane. Purified by silica gel chromatography, tert-butyl N-tert-butyrate Xycarbonyl-N-(4-cyano-2-isopropyl-pyrazole-3-yl)carb Mate was found as a grayish-white solid (7.67g, 68%), ES / MS (m / z) 37 As 3(M+Na), and tert-butyl N-(4-cyano-2-isopropyl- Pyrazole-3-yl)carbamate is a grayish-white solid (1.12g, 14%). ), obtained as ES / MS(m / z)251(M+H).
[0167] Preparation 92 Methyl 2-[4-[5-(tert-butoxycarbonylamino)-4-cyano-1-i Sopropyl-pyrazole-3-yl]-2,3-difluorophenyl]acetate [ka] THF (4.8 mL) is used with tert-butyl N-tert-butoxycarbonyl-N- (4-Cyano-2-isopropyl-pyrazole-3-yl)carbamate (0.79g, 2.25 mmol), Bis(Pinacolato)diboron (0.46 g, 1.81 mmol) [Ir(OMe)(1,5-cod)]2 (31 mg, 0.047 mmol), and 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine (26m Add to (g, 0.093 mmol) under N2 conditions. Stir the mixture under reflux for 4 hours. The mixture is cooled to room temperature and concentrated under reduced pressure. The residue is then mixed with DCM:siRNA in a 4:1 ratio. Dissolve in a mixture of (mL), and pass this solution through a silica gel (2g) pad. Wash with 3:1 DCM:siRNA (2 x 10 mL). Combine the filtrates and concentrate under reduced pressure. Shrink and dry under vacuum to obtain crude residue. Add 1,4-dioxane (1 Cs2CO3 (2.14 g, 6.57 mmol) and methyl 2-(4-) in 0 mL Romo-2,3-difluorophenyl)acetate (0.50g, 1.89mmol) Add the following: Pd(dppf)Cl2)CH2Cl2(0.10g, 0.123m Add (mol) and a 4Å molecular sieve under Ar. Heat the mixture overnight at 90°C. The mixture is cooled to room temperature, diluted with acetate, and filtered through diatomaceous earth. The filtrate is then converted to H2O. Dilute with ethyl alcohol, and extract the aqueous layer with ethyl alcohol (2x dilution). Combine the organic extracts and brine. Wash, dry with Na2SO4, filter, and concentrate under reduced pressure. The crude material is then heated in siRNA. Purified by silica gel chromatography with elution at a DCM gradient of 2% to 80%. The title compound (0.64 g, purity 94%, 73%) is obtained as a beige solid. ES / MS(m / z)435(M+H).
[0168] Preparation 93 Methyl 2-[4-[5-(tert-butoxycarbonylamino)-4-cyano-1-i Sopropyl-pyrazole-3-yl]phenyl]acetate [ka] tert-butylN-tert-butoxycarbonyl-N-(4-cyano-) under N2 2-Isopropyl-pyrazole-3-yl)carbamate (4.50g, 12.8mmo) l), bis(pinacolate) diborone (2.61g, 10.3mmol), [Ir(O me)(1,5-cod)]2 (0.18g, 0.267mmol), and 4-ter t-butyl-2-(4-tert-butyl-2-pyridyl)pyridine (0.15g, 0. Add THF (25 mL) to 535 mmol). Stir the mixture under reflux for 4 hours. The mixture is cooled to room temperature and concentrated under reduced pressure. The residue is then mixed with DCM:siRNA in a 4:1 ratio. Dissolve in a 20 mL mixture, pass the solution through a silica gel pad, and mix in a 3:1 ratio with DCM. Wash with dimethyl (2 x 10 mL). Combine the filtrates, concentrate under reduced pressure, and dry under vacuum. Dry to obtain a crude residue. Add Cs in 1,4-dioxane (50 mL) to the residue under N2. 2CO3 (10.5g, 32.2 mmol) and methyl(4-bromophenyl)acetate Add (2.50g, 10.9 mmol). Then add Pd(dppf)Cl2) CH2Cl2 (0.53 g, 0.642 mmol) and a 4 Å molecular sieve were added under Ar. The mixture is heated to 90°C for 12 hours, cooled to room temperature, diluted with ethyl acetate, and diatomaceous earth Filter through [a certain method]. Add H2O to the filtrate, extract the aqueous layer with SiO, and then [perform a brine test]. Wash, dry with Na2SO4, filter, and concentrate under reduced pressure. The brown crude oil is EtOA Purification by silica gel chromatography with elution at a gradient of 2% to 80% DCM in c. The title compound was then obtained as a white solid (3.80 g, 87%). ES / MS (m / z )399(M+H).
[0169] The following compounds in Table 10 were tested using appropriate reagents, and the reaction time was adjusted to determine when the reaction was complete. Then, if appropriate, purify by chromatography and methyl 2-[4-[5-(te rt-butoxycarbonylamino)-4-cyano-1-isopropyl-pyrazole-3- Prepare essentially as described for ylphenyl acetate. K2CO3 This can be used instead of Cs2CO3. The temperature for the second coupling reaction is The temperature range may be approximately 50-90°C. Mono and bis-tert-butoxycarbonylamino The compounds can be isolated and both can be processed in a later step to obtain a common product. [Table 10-1] [Table 10-2]
[0170] Preparation 103 2-[4-[5-(tert-butoxycarbonylamino)-4-cyano-1-isopropyl Pyr-pyrazole-3-yl]phenyl]acetic acid [ka] Methyl 2-[4-[5-(tert-butoxycarbonyl methyl Mino)-4-cyano-1-isopropyl-pyrazole-3-yl]phenyl]acetate (3.80g, 9.54 mmol) Stirring solution, 2M NaOH (14mL, 28mm Add ol). Stir the reaction mixture at 25°C for 1 hour. Concentrate the organic layer. H2O Add the following, and then add KHSO4 (3.92 g, 28.8 mmol) in H2O dropwise. The formed precipitate was filtered, washed with H2O, and dried under vacuum to obtain the title compound (2.8 Once 8g, 79% is obtained, it is used without further purification. ES / MS (m / z )385(M+H).
[0171] The following compounds in Table 11 are 2-[4-[5-(tert-butoxycarbonylamino) This document describes -4-cyano-1-isopropylpyrazole-3-yl]phenylacetic acid. The reaction is essentially prepared by adjusting the reaction time to determine when the reaction is complete. 1, 4-Dioxane can be used instead of MeOH, and NH4Cl can be used instead of KHSO4. It can be used, and the product can be extracted from H2O if appropriate. Mono and bister The t-butoxycarbonylamino compounds were isolated, and both were produced in a common way in a later step. It can be done to obtain something. [Table 11-1] [Table 11-2]
[0172] Preparation 112 2-[4-[5-(tert-butoxycarbonylamino)-4-cyano-1-isopropyl [pyr-pyrazole-3-yl]-2,3-difluorophenyl]acetic acid [ka] Methyl 2-[4-[5] in 1,4-dioxane (6.5 mL) and H2O (2 mL) -(tert-butoxycarbonylamino)-4-cyano-1-isopropylpyrazole [Lu-3-yl]-2,3-difluorophenyl]acetate (0.64g, 1.47mg) Add 1M LiOH hydrate (4.4 mL, 4.40 mmol) to (mol). Mix. Stir the mixture at room temperature overnight. Concentrate the reaction mixture, pour it into H2O, and wash with siRNA. The aqueous layer is acidified to pH 2-3 with a 1M KHSO4 aqueous solution, and then ammonium compounds are added. Extract at a 3x dilution. Wash the combined organic extract with brine and dry with Na2SO4. Then, filter and concentrate under reduced pressure to obtain a beige solid of the title compound (0.54g, purity 94%). The result is obtained as %, 82%. ES / MS(m / z)421(M+1).
[0173] Preparation 113 Methyl 4-([[3-(2,2-dimethylpropyl)-1,2-oxazol-5-yl Carbamoyl methyl benzoate [ka] [4-(methoxycarbonyl)phenyl]acetic acid (20.0g) in DMF (200mL) , 103 mmol) and 3-(2,2-dimethylpropyl)-1,2-oxazole- 5-amine (17.5 g, 113 mmol) and DIPEA (89.5 mL, 514 mL) In a stirred solution of mol, add T3P (registered trademark) (328g, 515 mmol, 50 in DMF) Add %) little by little at 0°C. Stir the mixture at 50°C for 2 hours. Add Et to the mixture. Add OAc (1 L). Wash the mixture with H2O (3 × 300 mL). Separate the organic layer. Separate, dry with anhydrous Na2SO4, filter, and concentrate under reduced pressure. The residue is divided into 8:1~4: Purified by silica gel chromatography eluting with a PE:siRNA gradient of 1. The title compound (31.0 g, 91%) is obtained as a pale yellow solid. ES / MS (m / z )331.2(M+H).
[0174] The following compounds in Table 12 were tested using appropriate reagents, and the reaction time was adjusted to determine when the reaction was complete. and use appropriate chromatographic conditions for purification, or further purification. Use without methyl 4-([[3-(2,2-dimethylpropyl)-1,2-oxazo As described regarding [5-yl]carbamoyl]methyl)benzoate, the essence Prepare it as described. The reaction temperature may be in the range of room temperature to 100°C. T3P (registered trademark) It can be added to DCM instead of DMF. [Table 12]
[0175] Preparation 117 4-([[3-(2,2-dimethylpropyl)-1,2-oxazole-5-yl]cal Bamoyl methyl benzoic acid [ka] Methyl 4-([[3-(2,2- Dimethylpropyl)-1,2-oxazole-5-yl]carbamoyl]methyl)benzo In a stirred solution of eth (31.0 g, 93.8 mmol), add LiOH (11.2 g, 468 mmol). Gradually add mmol) at room temperature. Stir the mixture overnight. Dissolve the mixture in 2N HCl. Acidify to pH 5 with 1 ml and extract with aryl (3 x 200 mL). Combined organic extracts. Wash with brine (3 x 50 mL), dry with anhydrous Na2SO4, filter, and under reduced pressure. Concentrated using ES / MS, the title compound (28.5 g, 96%) is obtained as a white solid. m / z) 317.2 (M+1).
[0176] The following compounds in Table 13 should be reacted using an appropriate ester, adjusting the reaction time to complete the reaction. Determine the pH, adjust it to 1-5 after completion, and collect by extraction or precipitation if appropriate. ,4-([[3-(2,2-dimethylpropyl)-1,2-oxazole-5-yl]ca Prepare essentially as described for 1,4-dibenzoic acid (rubamoylmethyl)benzoic acid. Use a solvent mixture of oxane / H2O or MeOH / H2O as needed for solubility. It can be done at a temperature that is approximately in the range of room temperature to 50°C. 1M NaOH, LiOH And can it be used instead of citric acid, or KHSO4 instead of HCl? It can be used for this purpose. [Table 13]
[0177] The following compounds in Table 14 were tested using appropriate reagents, and the reaction time was adjusted to determine the completion of the reaction. and use appropriate chromatographic conditions for purification, or further purification. Use without methyl 4-([[3-(2,2-dimethylpropyl)-1,2-oxazo As described regarding [5-yl]carbamoyl]methyl)benzoate, the essence Prepare it as described. The reaction temperature may be in the range of room temperature to 100°C. T3P (registered trademark) It can be added during DCM or ATP instead of DMF. [Table 14]
[0178] Preparation 129 2-[4-bromo-2-(hydroxymethyl)phenyl]-N-[5-(1-methylmethylphenyl] [Lopentyl)Isoxazole-3-yl]acetamide [ka] Under N2 conditions, TFA (16.6 mL), (2,2,2-trifluoroacetyl) 2,2 2-Trifluoroacetate (5.42 g, 25.8 mmol), and triethylsilamine In 1.0 mL (6.26 mmol), 2-[4-bromo in DCM (8.29 mL) -2-(tert-butoxymethyl)phenyl]-N-[5-(1-methylcyclopentyl] [Isoxazole-3-yl]acetamide (0.29g, 0.645mmol) is added. Add the mixture. Stir the reaction mixture for 4 hours. Concentrate the reaction mixture under reduced pressure and dry it under vacuum. Dissolve the ingredients in THF (9 mL) and H2O (4.5 mL). Saturated NaH Add 4 mL of CO3 aqueous solution and stir the mixture at room temperature for 1 hour. Then, under vacuum, the THF is subjected to a vacuum. Remove with Na2SO4. Dilute the mixture with DCM (10 mL), separate the organic layer, and remove the Na2SO4. Dry, filter, and concentrate under reduced pressure. The residue is then mixed with 1% to 10% MeOH in DCM. The title compound (0.20 g) was purified by silica gel chromatography using the elution method. 79% is obtained. ES / MS(m / z)394(M+H).
[0179] Preparation 130 5-amino-3-[2-(tert-butoxymethyl)-4-[2-[[5-(1-methyl Lucyclopentyl)isoxazole-3-yl]amino]-2-oxo-ethyl]phenyl [L]-1-isopropylpyrazole-4-carboxamide [ka] Bis(pinacolate)diborone (93 mg, 0.366 mmol), 2-[ 4-Bromo-3-(tert-butoxymethyl)phenyl]-N-[5-(1-methylmethyl] Clopentyl isoxazole-3-yl acetamide (0.15g, 0.334mg) 0.11g, 1.12 mmol), KOAc (0.11 g, 1.12 mmol), and Pd(dppf)Cl2C Add dried THF (4 mL) to H2Cl2 (28 mg, 0.033 mmol). Degas the reaction mixture with Ar for 15 minutes, then heat to 50°C. Stir at 65°C overnight, then at 80°C for 24 hours. Allow the reaction mixture to cool to room temperature. Cool. 5-amino-3-bromo-1-isopropyl pyrazol in THF (1.3 mL) Zol-4-carboxamide (0.11 g, 0.445 mmol) and H2O (1.3 Add K3PO4 (0.22 g, 1.04 mmol) in mL. Reaction mixture, A Degassed with r, and XantPhos Pd G3 (17 mg, 0.0167 mmol) was added. Heat the mixture at 50°C overnight. Filter the mixture through talcum powder. H2O is added to the filtrate, and the mixture is extracted with SiO2 (2x dilution). Combined organic extraction The material is washed with brine, dried with Na2SO4, filtered, and concentrated under reduced pressure. The residue is then removed. By silica gel chromatography, which elutes with a gradient of 1% to 10% MeOH in DCM... The compound is then purified to obtain the title compound as a brown powder (67 mg, 37%). ES / MS( m / z)537(M+H).
[0180] Preparation 131 2-[4-(2,2-dicyano-1-hydroxyes-1-en-1-yl)phenyl] -N-[3-(2,2-dimethylpropyl)-1,2-oxazol-5-yl]aceto Amido [ka] 4-([[3-(2,2-dimethylpropyl)-1,2-O [Xazol-5-yl]carbamoyl]methyl benzoic acid (32.0g, 101 mmol) ) and DMF (0.16 mL, 2.14 mmol) are stirred together in a mixed solution, and oxalyl chloride (1 Add 0.6 mL (124 mmol) dropwise at 0°C. Stir the mixture at room temperature for 2 hours. Mix. Concentrate the mixture under reduced pressure to obtain crude 4-([[3-(2,2-dimethylpropyl) [-1,2-oxazole-5-yl]carbamoyl]methyl)benzoyl chloride is obtained. In a solution of malononitrile (6.31 g, 95.5 mmol) in HF (100 mL), N Add aH (7.65g, 191 mmol, 60% of mineral oil) at 0°C. Stir the mixture for 15 minutes. Stir intermittently. 4-([[3-(2,2-dimethylpropyl)- in THF (150 mL) 1,2-Oxazol-5-yl]carbamoyl]methyl)benzoyl chloride (32.0g Add 95.6 mmol of the solution dropwise to a 0°C solution, stir the mixture for 2 hours, and allow it to cool to room temperature. Heat. Dilute the mixture with H2O (300 mL), acidify it to pH 5 with 2N HCl, Extract with à (3 x 200 mL). Combine the organic extracts and brine (3 x 10 Wash with 0 mL, dry with Na2SO4, filter, concentrate under reduced pressure to obtain the title compound ( 30.0 g, 82% is obtained. The crude product is used directly without further purification. ES / MS(m / z)365.1(M+H).
[0181] The following compounds in Table 15 are reacted under N2 conditions, if desired, and the reaction time is adjusted to complete the reaction. The decision was made to use 2-[4-(2,2-dicyano-1-hydroxyes-1-ene-1- [Phenyl]-N-[3-(2,2-dimethylpropyl)-1,2-oxazole-5 Prepare essentially as described for -yl]acetamide. THF and Na Malononitrile in H can be stirred for 15-30 minutes at 0°C to room temperature. The reaction mixture is then acidified. It may be concentrated until dry, and, if appropriate, by chromatography. It can be generated. [Table 15]
[0182] Preparation 136 2-[4-(2,2-dicyano-1-methoxyes-1-en-1-yl)phenyl]- N-[3-(2,2-dimethylpropyl)-1,2-oxazol-5-yl]acetate Mido [ka] 2-[4-(2,2-dicyano-1-hydroxyes-1- [E-1-yl)phenyl]-N-[3-(2,2-dimethylpropyl)-1,2-oxy Sazole-5-yl]acetamide (25.0g, 68.6mmol) and TEA (2 To a stirred solution of 8.7 mL, 206 mmol, add dimethyl sulfate (39.0 mL, 4 Add 11 mmol) dropwise under N2 at room temperature. Refrigerate the mixture under N2 at 50°C. Stir for 14 hours. Dilute the mixture with HCl (500 mL) and brine (3 x 50 mL). Wash with L), dry with anhydrous Na2SO4, filter, and concentrate under reduced pressure. Remove the residue, 8: By silica gel chromatography eluting with a PE:SiO2 gradient of 1-2:1 Purified, the title compound (9.0 g, 35%) is obtained as a pale yellow solid. ES / MS( m / z) 379.1 (M+H).
[0183] The following compounds from Table 16 were subjected to reaction time adjustments to determine the completion of the reaction, and purified as appropriate. Then, 2-[4-(2,2-dicyano-1-methoxyes-1-en-1-yl)phen [Lu]-N-[3-(2,2-dimethylpropyl)-1,2-oxazol-5-yl]a Prepare essentially as described for cetoamide. The temperature should be in the range of approximately 50-80°C. It could be an enclosure. [Table 16]
[0184] Preparation 141 Methyl 2-(4-(5-amino-4-cyano-1-(1-methylcyclopropyl)-1H -Pyrazole-3-yl)phenyl)acetate [ka] (1-methylcyclopropyl)hydrazine HCl (crude, 2) in EtOH (20 mL) Mix 0.00g, 16.3 mmol) and TEA (1.6 mL, 11.5 mmol) with stirring. The compound contains methyl 2-[4-(2,2-dicyano-1-methoxyes-1-en-1-yl) Phenyl acetate (0.48g, 1.87mmol) was slowly dissolved at room temperature under N2 conditions. Add the mixture. Stir the mixture under N2 conditions at 50°C for 2 hours. Cool the mixture to room temperature and reduce the volume. Concentrate under pressure. Dissolve the residue in H2O (0.1% NH4HCO3) with 30% to 50% ACN. Purified by reverse-phase chromatography (C18 column) with elution at a gradient, the title compound The substance (0.50g, 86%) is obtained as a white solid. ES / MS (m / z) 311.3 M+H).
[0185] The following compounds in Table 17 were tested using appropriate reagents, and the reaction time was adjusted to determine the completion of the reaction. Then, if appropriate, it is purified by chromatography to obtain methyl 2-(4-(5-amino -4-Cyano-1-(1-methylcyclopropyl)-1H-pyrazole-3-yl) Prepare the reaction essentially as described for nyl acetate. The reaction temperature is room temperature to 8°C. The temperature range may be in the 0°C range, the solvent may be THF if appropriate, and the base may be DIPEA or It could be tea. [Table 17-1] [Table 17-2]
[0186] Preparation 155 2-(4-(5-amino-4-cyano-1-(1-hydroxy-2-methylpropane-2 -yl)-1H-pyrazole-3-yl)phenyl)-N-(3-neopentylisoxyl) Zole-5-yl)acetamide [ka] 2-Hydrazino-2-methylpropan-1-ol HCl (43 mg, 0.306 mg) mol), EtOH (1.5 mL), TEA (0.12 mL, 0.861 mmol), 2-(4-(2,2-dicyano-1-methoxyvinyl)phenyl)-N-(3-neo Pentylisoxazole-5-yl)acetamide (0.11g, 0.291mmol) Add the mixture together and stir at 45°C for 18 hours. Dilute the mixture with H2O (1 mL), Extract with toluene (3 x 3 mL). Concentrate the organic extract under reduced pressure. Remove the residue and hexachloride. Silica gel chromatography elutes the substance with a gradient of 0% to 100% phosphate in the solution. The compound is then purified to obtain the title compound (39 mg, 30%) as a white solid. ES / MS( m / z) 451.3 (M+H).
[0187] Adjust the reaction time for the following compounds in Table 18 using 1 to 3 equivalents of appropriate hydrazine. The completion of the reaction is determined, and if appropriate, 2-(4-(5-amino-4-shea) is purified under purification conditions. No-1-(1-hydroxy-2-methylpropan-2-yl)-1H-pyrazole-3- (Iyl)phenyl)-N-(3-neopentylisoxazole-5-yl)acetamide Prepare essentially as described below. The reaction temperature can be in the range of room temperature to 45°C. THF can be used as a substitute for the solvent based on its solubility. [Table 18-1] [Table 18-2] [Table 18-3]
[0188] Preparation 173 2-(4-(5-amino-4-carbamoyl-1-isopropyl-1H-pyrazole-3 -yl)phenyl)acetic acid [ka] Methyl 2-[4-(5-amino-4-cyano-1-isopropylpyrazole-3-yl ) Phenyl acetate (7.40g, 24.8mmol), NaOH (5.96g, 1 (49 mmol), H2O (24 mL), DMSO (12 mL), and EtOH (60 mL) To the mixture of L, add H2O2 (38.0 mL, 372 mmol, 30% of H2O) at room temperature. Add. Heat the mixture to 40°C and stir for 6 hours. Mix the mixture with saturated Na2S2O3 Quench with an aqueous solution and adjust the pH to 4 with a diluted HCl aqueous solution. Add toluene (3) to the mixture. Extract with 200 mL of solution. Concentrate the combined organic extract under reduced pressure, and the resulting solid is E Grind with tOAc (20 mL). Collect the precipitated solid by filtration and rinse with water (3 × 60 mL). Wash with L) and dry under reduced pressure to obtain the title compound (4.30 g, 57%) as a yellow solid. Obtained by doing this. ES / MS (m / z) 303.1 (M+H).
[0189] Preparation 174 2-(4-(5-amino-4-carbamoyl-1-(1-methylcyclopropyl)-1H -Pyrazole-3-yl)phenyl)acetic acid [ka] Methyl 2-(4-(5-) in EtOH / H2O / DMSO (5mL / 2mL / 1mL) Amino-4-cyano-1-(1-methylcyclopropyl)-1H-pyrazole-3-yl Phenyl acetate (0.50g, 1.61mmol) and NaOH (0.32g To a stirred mixture of 8.00 mmol, add H2O2 (2.43 mL, 23.8 mmol, H Add 30% of the 2O dropwise at room temperature under N2 conditions. Stir the mixture overnight at 50°C. Quench the reaction mixture with saturated Na2SO3 aqueous solution (10 mL). Dissolve the residue in 1N H Adjust the pH to 4 with an aqueous Cl solution and extract with toluene (5 × 50 mL). Combine the organic extracts. Wash the residue with brine (2 x 100 mL), dry it with anhydrous Na2SO4, and filter it. The filtrate is concentrated under reduced pressure. The resulting solid is ground with dimethyl glycol (10 mL) and precipitated. The resulting solid was collected by filtration and washed with toluene (3 × 5 mL) to extract the title compound ( 0.20g, 40%) is obtained as a white solid. ES / MS (m / z) 315.2 (M+ H).
[0190] The following compounds in Table 19 were titrated by adjusting the reaction time to determine the completion of the reaction, and then titrated as appropriate. Alternatively, purify by chromatography to obtain 2-(4-(5-amino-4-carbamycin Lu-1-(1-methylcyclopropyl)-1H-pyrazole-3-yl)phenyl)acetic acid Prepare essentially as described. The reaction temperature is in the range of approximately room temperature to 50°C. Approximately 15-30 equivalents of H2O2 can be used. The reagents should also be added together at approximately 0°C. It is possible. [Table 19]
[0191] Preparation 180 2-(4-(5-amino-4-carbamoyl-1-(1,1,1-trifluoropropane -2-yl)-1H-pyrazole-3-yl)phenyl)acetic acid, isomer 1 [ka] Preparation 181 2-(4-(5-amino-4-carbamoyl-1-(1,1,1-trifluoropropane (-2-yl)-1H-pyrazole-3-yl)phenyl)acetic acid, isomer 2 2-(4-(5-amino-4-carbamoyl-1-(1,1,1-trifluoropropane (H-2-yl)-1H-pyrazole-3-yl)phenyl)acetic acid (0.500g, 1.4 0 mmol) under the following conditions: Column: CHIRALPAK IG, 2 × 25 cm, 5 μm; Mobile phase A: Hexane (0.1% TFA), Mobile phase B: Dissolved in 25% B in 12.5 minutes. Separation was performed by chiral HPLC using IPA at a flow rate of 20 mL / min, yielding a pale yellow solid. As a body, isomer 1, t (R) 6.7 min (0.240g, 48%), ES / MS (m / z) 357.1(M+H), [α] D 25 = -15.789 (C=0.304, MeOH), and isomer 2, t as a pale yellow solid (R) 9.5 minutes (0.210g, 42%), ES / MS (m / z) 357.1 (M+H), [α] D 25 =17.197(C=0.3 14. Obtain the title compound (MeOH).
[0192] Preparation 182 2-[4-(1-isopropyl-6,6-dimethyl-4-oxo-5,7-dihydropyra Zolo[3,4-d]pyrimidine-3-yl)phenyl]acetic acid [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl in acetone (5 mL) (-1H-pyrazole-3-yl)phenyl)acetic acid (0.100g, 0.331mmol) Add TFA (0.005 mL) to the mixture. Stir the mixture at 50°C for 2 hours under reduced pressure. The compound was concentrated below and dried under vacuum to obtain a yellow solid (0.113 g, 100%). When obtained as such, it is used without further refinement. ES / MS (m / z) 343. 2 (M+H).
[0193] The following compounds in Table 20 are 2-[4-(1-isopropyl-6,6-dimethyl-4-o Xo-5,7-dihydropyrazolo[3,4-d]pyrimidine-3-yl)phenyl]acetic acid As described, and by adjusting the reaction time to determine the completion of the reaction, essentially To manufacture. [Table 20]
[0194] Preparation 185 2-(4-(5-amino-4-cyano-1-(1-methylcyclopropyl)-1H-pyra Zole-3-yl)phenyl)acetic acid [ka] Methyl 2-(4-(5-amino-4) in THF (40 mL) and H2O (10 mL) -Cyano-1-(1-methylcyclopropyl)-1H-pyrazole-3-yl)phenyl ) Acetate (4.30g, 13.9mmol) and LiOH (1.66g, 69.3 Stir the solution of mmol) under N2 at room temperature for 3 hours. Concentrate the mixture under reduced pressure. Dilute with H2O (10 mL) and acidify to pH 3 with 1N HCl aqueous solution. Precipitate solid. The sample was collected by filtration and washed with H2O (3 × 30 mL) to obtain the title compound (4.00 g). 97% is obtained as a white solid. ES / MS (m / z) 297.3 (M+H).
[0195] The following compounds in Table 21 should be reacted using an appropriate ester, adjusting the reaction time to complete the reaction. Determine the pH, adjust it to 1-5 after completion, and collect by extraction or precipitation if appropriate. , 2-(4-(5-amino-4-cyano-1-(1-methylcyclopropyl)-1H- Prepare essentially as described for rhazol-3-yl)phenyl)acetic acid. 1, A solvent mixture of 4-dioxane / H2O or MeOH / H2O is used as needed for solubility. It can be used, and the temperature can be in the range of approximately room temperature to 50°C. 1M NaOH, L It can be used as a substitute for HCl and citric acid, or KHSO4 can be used as a substitute for HCl. It can be used as a substitute. [Table 21-1] [Table 21-2]
[0196] Preparation 200 2-[(4-bromo-2,3-difluorophenyl)(methoxy)methylidene]propane Dinitrile [ka] NaH (1.67g, 41.8mmol, 60% in mineral oil) and malononitrile (1. Add 37g (20.7 mmol) to THF (50mL) at 0°C. Dissolve the mixture in N2 Stir below at 0°C for 30 minutes. Add 4-bromo-2 in THF (10 mL) to this mixture. Add ,3-difluorobenzoyl chloride (5.30 g, 20.7 mmol) dropwise at 0°C. Add. Stir the mixture at room temperature for 1 hour. 2-[(4-bromo-2,3-difluoro The intermediate mixture of -phenyl)-hydroxy-methylene]propanedinitrile is further refined. Use directly without processing. ES / MS (m / z) 79 Br / 81 Br)282.9 / 284.9(MH). Dimethyl sulfate (2.4 mL, 25.3 mmol), 2-[(4-bromo-2,3-difluorophenyl)-hydro in THF (60 mL) In a solution of xy-methylene propanedinitrile (theoretically 5.90 g, 20.7 mmol) Add. Stir the mixture overnight under reflux under N2. Cool the solution to room temperature and under reduced pressure. Concentrate. Dissolve the crude product in alkyl hydroxide (200 mL) and add H2O (200 mL). Dilute and extract with toluene (3 x 300 mL). Remove the organic extract from brine (2 x 10 Wash with 0 mL, dry with anhydrous Na2SO4, filter, and concentrate under reduced pressure. Crude product The elution is performed using silica gel chromatography with a PE:siRNA gradient of 3:1 to 2:1. The compound was purified by [method] to obtain the title compound (3.00 g, 48%) as a yellow solid.
[0197] Preparation 201 5-amino-3-(4-bromo-2,3-difluorophenyl)-1-(1-methylcycline) Ropropyl)pyrazole-4-carbonitrile [ka] 2-[(4-bromo-2,3-difluorophenyl)(methoxymethyl phosphate) in THF (30 mL) (C) Methylidene]propanedinitrile (2.50g, 8.36mmol), (1-methyl Cyclopropyl)hydrazine HCl (3.07 g, 25.0 mmol), and TEA ( Stir the 5.8 mL (41.6 mmol) solution at room temperature under N2 for 1 hour. The residue is concentrated under reduced pressure, and silica is eluted using a PE:siRNA gradient of 3:1 to 2:1. Purified by gel chromatography, the title compound (2.50 g, 85%) was obtained as a pale yellow Obtained as a solid of color. ES / MS(m / z)( 79 Br / 81 Br)353.1 / 355 .1 (M+H).
[0198] Preparation 202 tert-butyl2-[4-[5-amino-4-cyano-1-(1-methylcyclopropyl [Pyrazole-3-yl]-2,3-difluorophenyl]acetate [ka] 5-amino-3-(4-bromo-2,3-difluorophenyl) in THF (20 mL) )-1-(1-methylcyclopropyl)pyrazole-4-carbonitride (1.80g, 5.10 mmol), tert-butyl 2-(bromodinose) acetate (3.98 g (15.3 mmol), and Pd(t-Bu3P)2 (0.26 g, 0.509 mmol) Stir the solution from (1) under N2 at 80°C for 1 hour, then cool to room temperature. Concentrate the solution under reduced pressure. Shrinkage and elution of the residue in silica gel chromatography using a PE:SiO2 gradient from 2:1 to 1:1. The title compound (0.50 g, 25%) was purified by fluoroscopy to obtain a yellow solid. . ES / MS (m / z) 389.2 (M+H).
[0199] Preparation 203 2-[4-[5-amino-4-cyano-1-(1-methylcyclopropyl)pyrazole- 3-yl]-2,3-difluorophenyl]acetic acid [ka] DCM (10 mL) contains tert-butyl 2-[4-[5-amino-4-cyano-1- (1-methylcyclopropyl)pyrazole-3-yl]-2,3-difluorophenyl] A solution of acetate (0.49 g, 1.26 mmol) and TFA (5 mL) was prepared under N2 conditions. Then, stir at room temperature for 2 hours and concentrate under reduced pressure. Dilute the mixture with Et2O (20 mL). The solution was then concentrated under reduced pressure to obtain the title compound (0.40 g, 96%) as a yellow solid. / MS(m / z)333.1(M+H).
[0200] Preparation 204 2-[4-[5-amino-4-cyano-1-(1-methylcyclopropyl)pyrazole- 3-yl]-2,3-difluorophenyl]-N-(3-[3-fluorobicyclo[1. 1.1]Pentan-1-yl]-1,2-oxazol-5-yl)acetamide [ka] 2-[4-[5-amino-4-cyano-1-(1-methyl Cyclopropyl)pyrazole-3-yl]-2,3-difluorophenyl]acetic acid (80 mg, 0.241 mmol), 3-(3-fluorobicyclo[1.1.1]pentane-1 -Isoxazole-5-amine (49 mg, 0.291 mmol), DIPEA ( 0.25 mL, 1.44 mmol), and T3P (registered trademark) (0.46 g, 0.72 A 3 mmol (50% in ethyl acetate) solution is stirred at 50°C for 1 hour under N2. The substance is cooled to room temperature and concentrated under reduced pressure. The residue is concentrated in H2O (0.1% FA) at a concentration of 40-60%. Purified by reverse-phase chromatography (C18 column) with elution using a % ACN gradient. The title compound (60 mg, 52%) was obtained as a yellow solid. ES / MS (m / z) 48 3.1 (M+H).
[0201] Preparation 205 2-[4-[5-amino-4-cyano-1-(1-methylcyclopropyl)pyrazole- 3-yl]-2,3-difluorophenyl]-N-(3-[3-methylbicyclo[1.1 .1]Pentan-1-yl]-1,2-oxazol-5-yl)acetamide [ka] 2-[4-[5-amino-4-cyano-1-(1-methylcyclo [Propyl)pyrazole-3-yl]-2,3-difluorophenyl]acetic acid (80 mg, (0.241 mmol), 3-[3-methylbicyclo[1.1.1]pentan-1-yl] -1,2-oxazole-5-amine (47 mg, 0.286 mmol), and DIP Add T3P (registered trademark) (0.46 g) to a solution of EA (0.13 mL, 0.746 mmol). Add 0.723 mmol (50% in phenylethylamine). Dissolve the reaction mixture in a sealed tube. Stir in a container at 50°C for 2 hours. Cool the mixture to room temperature and concentrate under reduced pressure. Residue In H2O (0.1% NH4HCO3), reversed phase elution occurs with a gradient of 40% to 60% ACN. Purified by chromatography (C18 column), the title compound (70 mg, 61%) was obtained. It is obtained as a white solid. ES / MS (m / z) 479.1 (M+H).
[0202] Preparation 206 2-(4-(5-amino-4-cyano-1-(1-methylcyclopropyl)-1H-pyra Zole-3-yl)phenyl)-N-(3-(2-chloro-4-fluorophenyl)iso Xazol-5-yl)acetamide [ka] 2-(4-(5-amino-4-cyano-1-(1-methylcyclopropyl)-1H-p Razole-3-yl)phenyl)acetic acid (60 mg, 0.202 mmol), DCM (0 Dissolve in 0.41 mL and mix with 3-(2-chloro-4-fluorophenyl)isoxazole. -5-amine (47 mg, 0.221 mmol), T3P (registered trademark) (0.77 g, 1 0.21 mmol, 50% in SiO2, and DIPEA (0.21 mL, 1.18 mL) Process at 0°C (mol). Stir the mixture for about 20 minutes, evaporate until dry, and then... It is used without further purification. ES / MS (m / z) 491.1 (M+H).
[0203] Preparation 207 2-[4-(5-amino-4-cyano-1-isopropylpyrazole-3-yl)phen [Lu]-N-[3-(pyridine-2-yl)-1,2-oxazol-5-yl]acetate Mido [ka] [4-(5-amino-4-cyano-1-isopropylpyrazole] in DCM (3 mL) -3-yl)phenyl]acetic acid (0.100 g, 0.352 mmol) and 3-(pyridyl)phenyl]acetic acid (-2-yl)-1,2-oxazole-5-amine (62 mg, 0.385 mmol) To the stirred mixture, add T3P (registered trademark) (0.337g, 0.530 mmol, HCl) Add 50% of the mixture and DIPEA (0.31 mL, 1.78 mmol). Stir at room temperature for 2 hours, then concentrate under reduced pressure. Dilute the residue with H2O (0.1% FA) at a concentration of 10%~ Purification by reverse-phase chromatography (C18 column) with elution using a 50% ACN gradient. Then, the title compound (70 mg, 47%) is obtained as a pale yellow solid. ES / MS (m / z)428.2(M+H).
[0204] The following compounds in Table 22 are mixed with approximately 1 to 6 equivalents of coupling reagent and approximately 1 to 4 equivalents of base. Using appropriate amines and carboxylic acids along with approximately 0.3-6 mL of solvent, the reaction time Adjust the reaction to determine completion, and if appropriate, purify under 2-[4-(5-amino-4 -Cyano-1-isopropylpyrazole-3-yl)phenyl]-N-[3-(pyridine) Please describe [-2-yl)-1,2-oxazole-5-yl]acetamide. Essentially, it is prepared. The reaction temperature can be in the range of -20°C to 50°C, T3P (registered trademark). The specified ingredient may be added to 50% SiO, 50% DMF, or 50% MeTHF. TCFH can be added gradually, and the reaction can be carried out in a sealed tube under N2 conditions. ru. *Coupling reagents: 1 T3P(registered trademark), 2 TCFH, 3 BTFFH, 4 C OMU (registered trademark), 5 TBTU, 6 TFFH, 7 HATU, 8 EDCI / HO BT Bases: a NMI, b Pyridine, c DIPEA Solvents: I toluene, II ACN, III DMF, IV DCM, V MeTHF [Table 22-1] [Table 22-2] [Table 22-3] [Table 22-4] [Table 22-5] [Table 22-6] [Table 22-7] [Table 22-8] [Table 22-9] [Table 22-10] [Table 22-11] [Table 22-12] [Table 22-13] [Table 22-14]
[0205] Preparation 278 tert-butyl N-[4-cyano-5-[4-[2-[[3-(2,2-dimethylpro Isoxazole-5-ylamino]-2-oxo-ethyl]-2,3-difluo [L-phenyl]-2-isopropylpyrazole-3-yl]carbamate [ka] 3-(2,2-dimethylpropyl)-1,2-oxazole-5-amine (58 mg, 0.376 mmol), 2-[4-[5-(tert-butoxycarbonylamino)-4 -Cyano-1-isopropylpyrazole-3-yl]-2,3-difluorophenyl Acetic acid (0.100 g, 0.238 mmol), and DIPEA (98 μL, 0.56 Add 3 mmol) to DMF (0.69 mL) under N2 conditions. T3P (Registered Trademark) Add the standard (0.454g, 0.713 mmol, 50% in MeTHF) and react the product. Stir at room temperature overnight. Quench the mixture with saturated NH4Cl aqueous solution and add EtOA to the aqueous layer. Extract using c (3x dilution). Wash the combined organic extract with brine and dry with Na2SO4. The mixture is then filtered and concentrated under reduced pressure. The residue is then mixed with 10% to 50% EtOA in cyclohexane. The title compound (45) was purified by silica gel chromatography eluting with a gradient of c. mg, 95% purity, 32% is obtained as a white solid. ES / MS (m / z) 557 (M +H).
[0206] Preparation 279 tert-butyl N-[4-carbamoyl-5-[4-[2-[[3-(2,2-dimethyl Isoxazole-5-ylaminopropyl-5-ylaminopropyl-2-oxoethyl-2,3-dipropyl-5-ylaminopropyl-2-oxoethyl-2,3-ethyl-2,3-ylamino Fluorophenyl]-2-isopropylpyrazole-3-yl]carbamate [ka] tert-butyl under N2 conditions N-[4-cyano-5-[4-[2-[[3-(2,2- Dimethylpropyl)isoxazole-5-yl]amino]-2-oxo-ethyl]-2, 3-difluorophenyl]-2-isopropylpyrazole-3-yl]carbamate (75 mg, 0.135 mmol) and Parkins catalyst (5.8 mg, 0.013 Mix 5 mmol of tert-BuOH (1.8 mL) and H2O (0.9 mL). Add the substance. Heat the mixture at 65°C for 16 hours. Cool the reaction mixture to room temperature, Et Dilute with OAc. Wash the organic layer with brine, dry with Na2SO4, filter, and reduce. Concentrate under pressure. Elute the crude material with a gradient of 1% to 10% DCM in MeOH. The title compound (48 mg, 62%) was purified by chromatography and obtained as a white solid. It is obtained as follows: ES / MS(m / z)597(M+Na).
[0207] Preparation 280 tert-butyl N-[4-carbamoyl-5-[4-[2-[[3-(2,2-dimethyl Lucyclopropyl)isoxazole-5-yl]amino]-2-oxo-ethyl]phenyl [L]-2-isopropylpyrazole-3-yl]carbamate [ka] tert-BuOH (10 mL) and tert-BuOH in H2O (5 mL) under N2 conditions Chil N-[4-cyano-5-[4-[2-[[3-(2,2-dimethylcyclopropyl) Isoxazole-5-yl]amino]-2-oxoethyl]phenyl]-2-isopropyl Stirring of pyr-pyrazole-3-yl]carbamate (0.365g, 0.704mmol) Add Parkins catalyst (15 mg, 0.0352 mmol) to the mixed solution. Stir the mixture at 60°C for 4 hours. Quench the reaction mixture with saturated NH4Cl aqueous solution. The aqueous layer is extracted with ethyl acetate (3 times). The combined organic extracts are washed with brine. Dry with Na2SO4, filter, and concentrate under reduced pressure. The material is then concentrated in cyclohexane at a rate of 30%. Purified by silica gel chromatography with an elution gradient of ~80% ammonium compounds. The title compound (0.363 g, 96%) was obtained as a white solid. ES / MS (m / z) 559.4 (M+Na).
[0208] The following compounds in Table 23 were used to determine the completion of the reaction by adjusting the reaction time, and t-BuOH and It uses 4:1 EtOH:H2O as the solvent and appropriate chromatography for purification. - Using the conditions, tert-butyl N-[4-carbamoyl-5-[4-[2-[[3 -(2,2-dimethylcyclopropyl)isoxazole-5-yl]amino]-2-oxy Regarding [so-ethyl]phenyl]-2-isopropyl-pyrazole-3-yl]carbamate Prepare essentially as described. The temperature may be in the range of approximately 60-70°C. [Table 23-1] [Table 23-2] [Table 23-3] [Table 23-4] [Table 23-5] [Table 23-6]
[0209] Preparation 314 3-(2,4-dichloro-3-fluorophenyl)-3-oxo-propanenitrile [ka] To a stirred solution of LDA (1.35 mL, 2.69 mmol) in THF (4 mL), AC Add N (0.13 mL, 2.47 mmol) dropwise under N2 conditions at -78°C. The mixture was stirred at -78°C for 1 hour, and then methyl 2,4-dichloro-3-flute in THF. Add the ruolobenzoate solution dropwise. Once the addition is complete, the reaction mixture should be left at room temperature for 2 hours. Stir intermittently. Quench the reaction mixture with saturated NH4Cl aqueous solution. Adjust the pH to HCl(1N). Adjust the pH to 5, then extract with ethyl acetate. Wash the organic layer with brine, then Na The mixture was dried with 2SO4, filtered, and concentrated to obtain the title compound (0.83 g). This crude material 3-(2,4-dichloro-3-fluorophenyl)isoxazole-5-amine It is used without further purification during preparation.
[0210] Preparation 315 3-(2,4-dichloro-3-fluorophenyl)isoxazole-5-amine [ka] 3-(2,4-dichloro-3) in EtOH (3.7 mL) and H2O (3.7 mL) -Fluorophenyl)-3-oxopropanenitrile (0.27g, 1.15mmo l) A solution of hydroxyamine HCl (0.40 g, 5.74 mmol) and KOA Treat with c (0.68 g, 6.89 mmol). Stir the mixture at 60°C for 1 hour. The reaction products are extracted with siRNA, and the organic layer is concentrated under vacuum. The residue is 0% in hexane. Fluorine elution is performed using a normal phase method with approximately 100% phosphate followed by 0%-20% MeOH in phosphate. The title compound (0.18 g, 65%) was obtained by purification by gel chromatography. . ES / MS (m / z) 247.0 (M+H).
[0211] Preparation 316 2-[5-(5-amino-4-cyano-1-ethyl-pyrazole-3-yl)-2-pyri Jill Acetate [ka] A reaction viar containing 1,4-dioxane (9.05 mL) and H2O (1.81 mL) 5-amino-3-bromo-1-ethyl-pyrazole-4-carbonitrile (233) .58mg, 1.09mmol), K2CO3 (299.78mg, 2.17mmol) , Pd(dppf)Cl2 (79.48 mg, 0.11 mmol), and methyl 2-[ 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2 A mixture of -pyridyl acetate (301 mg, 1.09 mmol) was sparged with nitrogen. Then, heat to 80°C for 90 minutes. Distribute the reaction mixture into DCM and H2O, and then add DCM (3 times). The mixture is then extracted using a phase separator. The organic matter is combined and concentrated in a vacuum. The residue is then processed in hexane. Purified by silica gel chromatography that elutes with 0% to 100% ammonium. The title compound (172 mg, 55.5%) was obtained. ES / MS (m / z) 286.1 (M +H).
[0212] Preparation 317 Methyl 2-[6-(5-amino-4-cyano-1-isopropylpyrazole-3-yl )-3-pyridyl acetate [ka] Methyl 2-(6-chloropyridine-3-yl) acetate (2.00g, 10.78mg) (mol), hexabutyldistannan (9.38 g, 16.16 mmol), and Pd (PPh3)4 (7.47g, 6.46mmol) was dissolved in N2 under 1,4-dioxane ( Combine the ingredients in 40 mL of water and stir the reaction mixture at 65°C for 3 days.
[0213] 5-amino-3-bromo-1-isopropylpyrazole-4-carbonitrile (0.7 5g (3.30 mmol) is added to a portion (25%) of the above reaction mixture under N2 conditions. Stir the reaction mixture at 75°C for 12 hours. Remove the solvent under reduced pressure. Divide the residue into 2:1-1 Purified by silica gel chromatography eluting with a PE:HCl gradient of :1. Then, the crude product is obtained. The product is mixed with 20% to 50% ACN in H2O (0.1% FA). Further purification is performed by reverse-phase chromatography (C18 gel column) which elutes in a specific direction, and then the sample is presented. The compound in question (0.12 g, 15%) was obtained as a yellow solid. ES / MS (m / z) 300 .2 (M+H).
[0214] Preparation 318 Methyl 2-[5-(5-amino-4-cyano-1-isopropylpyrazole-3-yl )-2-pyridyl acetate [ka] Methyl 2-(5-bromopyridine-2-yl) acetate (1.00g, 4.35mm) ol), bis(pinacol) diboron (1.33g, 5.22mmol), KOAc( 0.85g, 8.70mmol), Pd(dppf)Cl2(0.32g, 0.43mm Add ol) and 1,4-dioxane (30 mL) together. The reaction mixture is N2 Stir at 100°C for 2 hours. Filter the reaction mixture, and concentrate the filtrate under vacuum to obtain the intermediate solution. Obtain bodily fluids.
[0215] Residue 5-amino-3-bromo-1-isopropylpyrazole-4-carbonitrile (0 (0.99g, 4.33 mmol), potassium carbonate (1.19g, 8.60 mmol), Pd (dppf)Cl2 (0.32g, 0.43mmol), 1,4-dioxane (30mL) Add the following together: ), and H2O (7 mL). The reaction mixture is incubated under N2 at 100°C for 2 minutes. Stir for a while. Dilute the reaction mixture with H2O (50 mL) and add HCl (3 × 100 mL). Extraction is performed using [method]. The combined organic extracts are washed with brine (2 x 100 mL) and then Na2SO4. Dry in step 4, filter, and concentrate under vacuum. Dilute the residue with PE: dimethyl in a 6:1 to 2:1 ratio. The title compound (0.6) was purified by silica gel chromatography eluting at a gradient. 5g (50%) is obtained as a yellow solid. ES / MS (m / z) 300.1 (M+H).
[0216] The following compounds in Table 24 should be methyl 2-[5-(5-amino-4-cyano-1-isopropyl As described regarding [pyr-pyrazole-3-yl)-2-pyridyl]acetate, Furthermore, the reaction time is adjusted to determine when the reaction is complete, thereby essentially preparing the product. [Table 24]
[0217] Preparation 321 2-[6-(5-amino-4-cyano-1-isopropyl-pyrazole-3-yl)-3 -pyridyl acetate [ka] Methyl 2-[6-(5-amino-4] in methanol (2 mL) and H2O (2 mL) -Cyano-1-isopropyl-pyrazole-3-yl)-3-pyridyl]acetate (0 Add LiOH (0.024g, 1.00 mmol) to 0.10g, 0.33 mmol. Stir the mixture at 60°C for 2 hours. Dilute the reaction mixture with a 1M aqueous HCl solution to pH 5. Acidify the solution, then extract with ethyl acetate (2 x 30 mL). Combine the organic extracts. Wash with brine (2 x 20 mL), dry with Na2SO4, filter, and concentrate under reduced pressure. The residue is eluted using a reversed-phase chromatography method with a gradient of 5% to 60% ACN in H2O (0.1% FA). The title compound (0.080 g, 8) was purified by matrixing (C18 gel column). 0% is obtained as a yellow solid. ES / MS (m / z) 286.4 (M+H).
[0218] The following compounds in Table 25 are 2-[6-(5-amino-4-cyano-1-isopropyl- As described for pyrazole-3-yl)-3-pyridyl]acetic acid, and the reaction time The reaction is essentially prepared by adjusting the reaction to determine when it is complete. [Table 25]
[0219] Preparation 324 Lithium 2-[5-(5-amino-4-cyano-1-isopropylpyrazole-3- [Lu)-2-pyridyl acetate [ka] Methyl 2-[5-(5-amino-4- [Cyano-1-isopropyl-pyrazole-3-yl)-2-pyridyl]acetate (2. Add LiOH (0.17g, 7.20 mmol) to 40g, 8.00 mmol. Stir the mixture at room temperature for 2 hours. Dilute the reaction mixture with H2O (20 mL), and then... Then, wash with toluene (3 x 50 mL). Concentrate the aqueous layer under reduced pressure to obtain the title compound ( 1.50g, 65%) is obtained as a yellow solid. ES / MS (m / z) 286.1 (M+ H).
[0220] The following compounds in Table 26 are lithium 2-[5-(5-amino-4-cyano-1-isopropyl As described regarding [ropyr-pyrazole-3-yl)-2-pyridyl]acetate Furthermore, the reaction time is adjusted to determine the completion of the reaction, thereby essentially preparing the product. [Table 26]
[0221] Preparation 327 5-amino-3-(5-chloropyrazine-2-yl)-1-isopropylpyrazole- 4-Carbonitrile [ka] 5-chloropyrazine-2-carbaldehyde (0.30g, 2.1g) in DMF (4mL) (1 mmol) and isopropylhydrazine hydrochloride (0.26 g, 2.32 mmol) Add DIPEA (0.30 g, 2.32 mmol) to the stirred solution and stir slowly at room temperature under N2 conditions. Add the mixture. Stir the mixture at 80°C for 1 hour, then let it cool to room temperature. Add D to the mixture. Solution of N-bromosuccinimide (0.41 g, 2.32 mmol) in MF (4 mL) Add the mixture gradually over 5 minutes. Stir the mixture at room temperature for 2 hours.
[0222] Simultaneously, stir the malonitrile (0.15 g, 2.32 mmol) in EtOH (2 mL). Add sodium ethoxide (0.39 g, 5.80 mmol) to the mixed solution and store under N2 conditions at 0°C. Add the mixture. Stir the mixture at room temperature for 30 minutes.
[0223] Under N2 conditions, the first mixture is added dropwise to the second mixture at 0°C over a period of 30 minutes. Stir the reaction mixture at 80°C for 2 hours. Dilute the mixture with siRNA and wash with H2O. The organic layer is concentrated under vacuum. The residue is then subjected to a PE:siRNA gradient of 3:1 to 2:1. Purified by eluting silica gel chromatography, the title compound (0.26 g, 4 7% is obtained as a white solid. 1 1H NMR (d6-DMSO, 300 MHz) δ( ppm)8.88(d,1H),8.82(d,1H),6.80(s,2H),4.5 6 (m, 1H), 1.37 (d, 6H).
[0224] The following compounds in Table 27 are 5-amino-3-(5-chloropyrazine-2-yl)-1- As described for isopropyl-pyrazole-4-carbonitride, and at the reaction time The timing is adjusted to determine when the reaction is complete, essentially preparing the mixture. [Table 27]
[0225] Preparation 329 tert-butyl N-[5-(5-bromopyrimidine-2-yl)-4-cyano-2-yl] Sopropyl-pyrazole-3-yl]-N-tert-butoxycarbonylcarbame to [ka] 5-amino-3-(5-bromopyrimidine-2-yl)-1- in THF (10 mL) Isopropyl-pyrazole-4-carbonitride (0.35g, 1.14mmol), di -tert-butyl dicarbonate (0.50 g, 2.28 mmol), and DMAP Stir the mixture (0.029 g, 0.23 mmol) at room temperature for 4 hours. Reduce the amount of the mixture. Concentrate under pressure. Elute the residue with silica using a PE:siRNA gradient of 10:1 to 1:1. The title compound (0.40 g, 69%) was purified by gel chromatography and turned yellow. Obtained as a solid. ES / MS (m / z) 507.0, 509.1 (M+H).
[0226] Preparation 330 tert-butyl2-[2-[5-(tert-butoxycarbonylamino)-4-shea [N-1-isopropyl-pyrazole-3-yl]pyrimidine-5-yl]acetate [ka] tert-butyl N-[5-(5-bromopyrimidine-2-I) in THF (20 mL) [Lu)-4-cyano-2-isopropyl-pyrazole-3-yl]-N-tert-butoxy Cicarbonyl carbamate (0.39g, 0.77mmol), tert-butyl 2- (Bromodinsio)acetate (0.40g, 1.54mmol), and Pd(tB A solution of u3P)2 (0.079g, 0.15 mmol) was stirred at 80°C for 4 hours under N2. Mix and cool to room temperature. Concentrate the solution under reduced pressure and elute the residue with acetyl. The crude product is purified by Kagel chromatography. The product is then converted to H2O(0. Reverse-phase chromatography (C18) eluting with a gradient of 30% to 50% ACN in 1% FA. Further purification by column chromatography yielded the title compound (0.24 g, 71%) as a yellow solid. It is obtained as follows: ES / MS (m / z) 443.2 (M+H).
[0227] The following compounds in Table 28 are tert-butyl2-[2-[5-(tert-butoxyca [Rubonylamino)-4-cyano-1-isopropylpyrazole-3-yl]pyrimidine As described for -5-yl acetate, and by adjusting the reaction time, the reaction can be completed. Determine and essentially prepare it. [Table 28]
[0228] Preparation 332 2-[5-(5-amino-4-cyano-1-isopropyl-pyrazole-3-yl)pyra [Zin-2-yl]acetic acid [ka] tert-butyl2-[5-(5-amino-4-cyano-1-isopropyl-pyrazole [Lu-3-yl)pyrazine-2-yl]acetate (0.26g, 0.76mmol), Add TFA (10 mL). Stir the mixture at room temperature for 30 minutes, then concentrate under reduced pressure. When the title compound is obtained as a yellow solid (0.20 g, 91%), it is further purified. To use without hesitation.
[0229] Preparation 333 2-[2-(5-amino-4-cyano-1-isopropyl-pyrazole-3-yl)pyri Midine-5-yl acetate [ka] tert-butyl2-[2-[5-(tert-butoxycarbonylamino)-4-syl Ano-1-isopropylpyrazole-3-yl]pyrimidine-5-yl]acetate ( (0.22g, 0.50 mmol) in 4M HCl from 1,4-dioxane (10mL) Add the following: Stir the mixture at room temperature for 1 hour and concentrate under reduced pressure. Add the reaction product to saturated NaH Adjust the pH to 6 with an aqueous CO3 solution, then extract with toluene (3 x 50 mL). The organic extract is concentrated under reduced pressure. The residue is concentrated in H2O (0.1% FA) at a concentration of 30-40%. Purified by reverse-phase chromatography (C18 column) with elution using a % ACN gradient. The title compound (0.075 g, 53%) was obtained as a yellow solid. ES / MS (m / z) 287.1 (M+H).
[0230] Example 1 5-amino-1-isopropyl-3-(4-(2-((3-((1-methylcyclopropyl (L)methyl)isoxazole-5-yl)amino)-2-oxoethyl)phenyl)-1 H-pyrazole-4-carboxamide [ka] 3-[(1-methylcyclopropyl)methyl]isoxazole-5-amine (62mg) , 0.407 mmol) and 2-(4-(5-amino-4-carbamoyl-1-isopropyl Ropyr-1H-pyrazole-3-yl)phenyl)acetic acid (0.10g, 0.331mmo) l) HCl (0.38 mL), pyridine (0.64 mL), and ACN (0. Combine in 64 mL. Stir the mixture for 5 minutes and observe a cloudy suspension. Cool to -20°C, add T3P(registered trademark) (0.58 mL, 0.99 mmol, 5 in DMF) Add 0% dropwise. Stir the solution at -20°C for 45 minutes. Mix the mixture with H2O(50 Dilute (mL) and extract with ethyl acetate (2 x 50 mL). Combine the organic extracts and Na Dry with 2SO4, filter, and concentrate under reduced pressure. Dilute the residue in hexane at a concentration of 10% to 100%. Purified by silica gel chromatography eluting with an acetate gradient, and then title-formulated. A compound (28 mg, 19%) was obtained. ES / MS (m / z) 437.2 (M+H).
[0231] Example 2 5-amino-1-isopropyl-3-(4-(2-oxo-2-((5-(1,1,1- Trifluoro-2-methylpropan-2-yl)isoxazole-3-yl)amino) (Tyl)phenyl)-1H-pyrazole-4-carboxamide [ka] 5-(2,2,2-trifluoro-1,1-dimethylethyl)isoxazole-3- Amine (0.394g, 2.03 mmol) and 2-(4-(5-amino-4-cal) Bamoyl-1-isopropyl-1H-pyrazole-3-yl)phenyl)acetic acid (0.50 (0g, 1.65 mmol) is mixed with ACN (20mL), SiO (16mL), and pi Combine in lysine (2 mL). Stir the mixture for 2 minutes until a clear, colorless solution is obtained. Cool the solution to -20°C and add T3P(registered trademark) (1.89 mL, 3.23 mmol). Add 50% of the DMF dropwise. Stir the solution at -20°C for 30 minutes. Dilute with H2O (8 mL) and extract with HCl (2 × 10 mL). Combined organic extraction The material is dried with Na2SO4, filtered, and concentrated under reduced pressure. The residue is then concentrated in hexane at 0% concentration. 100% HCl, followed by 0%-10% MeOH (0.1% NH4) in HCl. Purified by silica gel chromatography with elution gradient (including OH), and then title-formulated. A composite (0.363g, 46%) was obtained. ES / MS (m / z) 478.8 (M+H).
[0232] Example 3 5-amino-1-isopropyl-3-(4-(2-((3-(1-methylcyclopentyl Isoxazole-5-yl)amino)-2-oxoethyl)phenyl)-1H-pyrazo 4-carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl in DMF (3mL) -1H-pyrazole-3-yl)phenyl)acetic acid (20 mg, 0.066 mmol), 3 -(1-methylcyclopentyl)isoxazole-5-amine (11 mg, 0.066 mg) mol), and [[(E)-(1-cyano-2-ethoxy-2-oxo-ethylidene) [amino]oxy-morpholino-methylene]-dimethyl-ammonium hexafluorophos A mixture of phosphate (34 mg, 0.079 mmol) and DIPEA (0.034 mL) Add 0.195 mmol) and stir the mixture at room temperature for 6 hours. Dilute (mL) and extract with ethyl acetate (2 x 20 mL). Mix the combined organic extract with bran. Wash with 20 mL of water, dry with Na2SO4, filter, and concentrate under reduced pressure. Residue This is eluted using silica gel chromatography with a gradient of 0% to 100% phosphate in hexane. The compound was purified by ES / MS (m / z). )451.2(M+H).
[0233] Example 4 5-amino-3-(4-(2-((3-(3-fluorobicyclo[1.1.1]pentane -1-yl)isoxazole-5-yl)amino)-2-oxoethyl)phenyl)-1 -Isopropyl-1H-pyrazole-4-carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl-1H-pyrazole- 3-(yl)phenyl)acetic acid (0.100g, 0.331mmol), 3-(3-fluoro)phenyl)acetic acid Bicyclo[1.1.1]pentan-1-yl)isoxazole-5-amine (61 mg, 0.363 mmol), T3P (registered trademark) (0.28 mL, 0.470 mmol, Et 50% in OAc, and DIPEA (0.17 mL, 0.976 mmol), sealed. Add together in 5 mL of DCM in a tube and stir under N2 conditions at room temperature for 10 hours. The mixture was concentrated under reduced pressure, and the residue was extracted from H2O (0.1% NH4HCO3) at a concentration of 20%. Elution is performed by reverse-phase chromatography (C18 column) with an ACN gradient of ~50%. Prepare the solution to obtain the title compound (67 mg, 45%) as a white solid. ES / MS (m / z )453.1(M+H).
[0234] Example 5 5-amino-3-(4-[[(3-[bicyclo[1.1.1]pentan-1-yl]-1 ,2-oxazol-5-yl)carbamoyl]methyl]phenyl)-1-isopropyl Pyrazole-4-carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl-1H-pyrazole-3- Il(phenyl)acetic acid (0.100g, 0.331mmol), 3-[bicyclo[1.1 .1]Pentan-1-yl]-1,2-oxazole-5-amine (60 mg, 0.40 (0 mmol), and DIPEA (0.17 mL, 0.976 mmol), DCM (1 Add together with (0 mL). T3P (registered trademark) (0.30 mL, 0.504 mmol) Add 50% of ethyl acetate and stir the mixture under N2 at room temperature for 2 hours. Concentrate under reduced pressure and redissolve in ACN (5 mL). Dissolve the residue in H2O (0.1% NH4). Reverse-phase chromatography (C18) eluting with a gradient of 20% to 60% ACN in HCO3. The title compound (24 mg, 17%) was purified by column chromatography to obtain a white solid. ES / MS (m / z) 435.3 (M+H).
[0235] Example 6 5-amino-1-(1-methylcyclopropyl)-3-[4-([[5-(1,1,1- [trifluoro-2-methylpropan-2-yl)-1,2-oxazole-3-yl] Rubamoyl methyl phenyl pyrazole-4-carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-(1-methyl) in ACN (5mL) Cyclopropyl)-1H-pyrazole-3-yl)phenyl)acetic acid (70 mg, 0.22 A stirred mixture of 3 mmol) and NMI (55 mg, 0.670 mmol) contains 5-(1 ,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazole-3 -amine (65 mg, 0.335 mmol) and TCFH (94 mg, 0.335 mmol) Add (ol) little by little under N2 conditions at room temperature. Stir the mixture under N2 conditions at 50°C for 2 hours. Mix. Cool the mixture to room temperature and concentrate under reduced pressure to obtain a residue. Dilute the residue with 100% E Purified by preparative TLC eluting with tOAc, with a gradient of 40%-50% ACN in H2O. Further purification was performed by reverse-phase chromatography (C18 column) to elute the title compound. The substance (20 mg, 18%) is obtained as a white solid. ES / MS (m / z) 491.2 (M +H).
[0236] Example 7 5-amino-1-isopropyl-3-[4-([[3-(1-methylcyclopropyl)- 1,2-Oxazol-5-yl]carbamoyl]methyl)phenyl]pyrazole-4- Carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl in DCM (10 mL) (-1H-pyrazole-3-yl)phenyl)acetic acid (0.300g, 0.992 mmol) ) and 3-(1-methylcyclopropyl)-1,2-oxazole-5-amine (0. To a stirred mixture of 151 g (1.09 mmol), add DIPEA (0.26 mL, 1.49 mL). mol) and T3P(registered trademark) (0.71 mL, 1.19 mmol, 5 phosphates) Add 0% gradually under N2 conditions at room temperature. Stir the mixture under N2 conditions at room temperature for 3 hours. Then, concentrate until dry. The residue is 30-40% in H2O (0.1% NH4HCO3). Purified by reverse-phase chromatography (C18 column) with elution using a % ACN gradient. The title compound (69 mg, 16%) was obtained as a white solid. ES / MS (m / z) 42 3.3 (M+H).
[0237] Example 8 5-amino-3-[4-([[1-methyl-5-(1,1,1-trifluoro-2-methyl Lupropan-2-yl)-1H-pyrazole-3-yl]carbamoyl]methyl)phenyl ]-1-(propan-2-yl)-1H-pyrazole-4-carboxamide [ka] 1-methyl-5-(1,1,1-trifluoro-2-methylpro) in DMF (2 mL) Pan-2-yl)-1H-pyrazole-3-amine (35 mg, 0.169 mmol), 2-(4-(5-amino-4-carbamoyl-1-isopropyl-1H-pyrazole-3 -yl(phenyl)acetic acid (56 mg, 0.185 mmol), HATU (96 mg, 0. Solutions of 252 mmol) and DIPEA (0.088 mL, 0.505 mmol) Stir the mixture under N2 conditions at room temperature for 2 hours. Add the mixture to H2O (0.1% FA) at a concentration of 50-70%. Purification by reverse-phase chromatography (C18 gel column) with elution using a % ACN gradient. The title compound (28 mg, 34%) was then obtained as a white solid. ES / MS (m / z) 492.3 (M+H).
[0238] Example 9 5-amino-1-isopropyl-3-[4-([[3-(1,1,1-trifluoro-2 [methylpropan-2-yl)-1,2-oxazole-5-yl]carbamoyl]methyl Phenylenol-4-carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl in DCM (5mL) -1H-pyrazole-3-yl)phenyl)acetic acid (0.150g, 0.496 mmol) ,3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxa Zole-5-amine (0.106g, 0.546mmol), DIPEA (0.35mL) , 2.01 mmol), and T3P (registered trademark) (0.59 mL, 0.991 mmol) A solution of 50% ethyl acetate is stirred at room temperature under N2 for 2 hours. The mixture is concentrated. The residue is eluted using reversed-phase chromatography with a gradient of 30% to 50% ACN in H2O (0.1% FA). The product is purified by tography (C18 gel column). The product is then converted to H2O (0.05% F). A) Reverse-phase preparative HPLC (Phenomenon) eluting with a gradient of 37% to 45% ACN Further purification was performed using a Gemini C6-Phenyl column to obtain the title compound ( 81 mg, 34% is obtained as a white solid. ES / MS (m / z) 479.3 (M+H ).
[0239] Example 10 5-amino-3-(4-(2-((5-(tert-butyl)isothiazol-3-yl )amino)-2-oxoethyl)phenyl)-1-isopropyl-1H-pyrazole-4 -Carboxamide [ka] 5-tert-butylisothiazole-3-amine (47 mg, 0.301 mmol) ) and 2-[4-(5-amino-4-carbamoyl-1-isopropyl-pyrazole- 3-yl)phenyl]acetic acid (60 mg, 0.198 mmol) in ACN (1.05 mL) Combine in phthalates (0.65 mL) and pyridine (0.31 mL). Stir for 2 minutes until a clear, colorless solution is obtained. Cool the solution to -20°C and pour into T3P (Registered Trademark) (0.26 mL, 0.437 mmol, 50% in ethyl) was added dropwise. Stir the solution at -20°C for 30 minutes. Dilute the reaction mixture with H2O (8 mL) and condense in DC. Extract with M (2 × 10 mL). Dry the combined organic extract with Na2SO4 and filter. Then, concentrate under reduced pressure. The residue is then mixed with 0% to 100% toluene in hexane, followed by Et Silica gel elutes in an OAc gradient of 0% to 20% MeOH (containing 1% NH4OH). The title compound (21 mg, 24%) was purified by chromatography and turned pale yellow. It is obtained as a physical substance. ES / MS (m / z) 441.2 (M+H).
[0240] Example 11 5-amino-1-isopropyl-3-(4-[[(3-[3-methylbicyclo[1.1. 1)Pentan-1-yl-1,2-oxazol-5-yl)carbamoyl]methyl] Phenyl)pyrazole-4-carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl in DCM (20 mL) (-1H-pyrazole-3-yl)phenyl)acetic acid (0.300g, 0.992 mmol) ) and 3-[3-methylbicyclo[1.1.1]pentan-1-yl]-1,2-oxy A stirred mixture of sazole-5-amine (0.163 g, 0.993 mmol) is mixed with DIPE A (0.52 mL, 2.99 mmol) and T3P (registered trademark) (0.89 mL, 1. Add 50 mmol (50% in ethyl acetate) at room temperature. Store the mixture in a sealed tube. Stir in a container under N2 conditions at 50°C for 1 hour. Concentrate the mixture under reduced pressure to obtain H2O(0. Reverse-phase chromatography eluting with a gradient of 30%-40% ACN in 1% NH4HCO3. The title compound (90 mg, 20%) was purified by (C18 column) and obtained as a white solid. Obtained by doing this. ES / MS (m / z) 449.2 (M+H).
[0241] Example 12 5-amino-1-isopropyl-3-(4-(2-oxo-2-((3-(2-(Trifol Luoromethyl)phenyl)isoxazole-5-yl)amino)ethyl)phenyl)-1 H-pyrazole-4-carboxamide [ka] 2-(4-(5-amine in phosphate (0.14 mL) and ACN (0.14 mL) No-4-carbamoyl-1-isopropyl-1H-pyrazole-3-yl)phenyl)vinegar Acid (75 mg, 0.248 mmol) and 3-[2-(trifluoromethyl)phenyl Isoxazole-5-amine (53 mg, 0.232 mmol), pyridine (0.1 4 mL) and T3P (registered trademark) (0.28 mL, 0.470 mmol, phosphate) Treat with 50%). Stir the mixture under N2 at 0°C for 20 minutes, then add H2O and E The mixture is partitioned into tOAc. The organic layer is concentrated, and 5% to 95% of A is added in H2O (0.2% TFA). The title compound (4.1 mg, 3) was purified by reverse-phase preparative HPLC eluting with a CN gradient. Obtain 0.4%. ES / MS(m / z)513.1(M+H).
[0242] The following compounds in Table 29 are mixed with approximately 1 to 6 equivalents of coupling reagent and approximately 1 to 4 equivalents of base. Using appropriate amines and carboxylic acids along with approximately 0.3 to 20 mL of solvent, during the reaction... Adjust the time to determine the completion of the reaction, and if appropriate, purify under the conditions of 5-amino-1-isopropyl alcohol. Pyr-3-(4-(2-oxo-2-((3-(2-(trifluoromethyl)phenyl) Isoxazole-5-yl)amino)ethyl)phenyl)-1H-pyrazole-4-cal Prepare the voxamide essentially as described. The reaction temperature should be -20°C to 50°C. It may be in the range of °C, and T3P (registered trademark) may be added to 50% ethyl acetate and 50% D MF and TCFH can be added in small amounts. *Coupling reagents: 1 T3P(registered trademark), 2 TCFH, 3 BTFFH, 4 C OMU (registered trademark), 5 TBTU, 6 TFFH, 7 HATU, 8 EDCI / HO BT Bases: a NMI, b Pyridine, c DIPEA Solvents: I HCl, II ACN, III DMF, IV DCM, V THF [Table 29-1] [Table 29-2] Table 29-3 Table 29-4 Table 29-5 Table 29-6 Table 29-7 Table 29-8 Table 29-9 Table 29-10 Table 29-11 Table 29-12 Table 29-13 Table 29-14 Table 29-15 Table 29-16 Table 29-17 Table 29-18 Table 29-19 [Table 29-20] [Table 29-21] [Table 29-22] [Table 29-23] [Table 29-24]
[0243] Example 153 5-amino-1-isopropyl-3-(4-(2-oxo-2-((3-(3-(Trifol Luoromethyl)bicyclo[1.1.1]pentan-1-yl)isoxazole-5-yl )amino)ethyl)phenyl)-1H-pyrazole-4-carboxamide [ka] 2-(4-(5-amino-4-carbamoyl-1-isopropyl-1H-pyrazole- 3-(yl)phenyl)acetic acid (196 mg, 0.65 mmol) and 3-(3-(trif Luoromethyl)bicyclo[1.1.1]pentan-1-yl)isoxazole-5-amine Combine (140.00 mg, 0.65 mmol) in DCM. DIPEA (25 1.36 mg, 1.95 mmol) and T3P (registered trademark) (536.32 mg, 0. Add 50% by weight of 84 mmol of ¼ ¼ ¼ ¼ dropwise at room temperature and under N2 conditions, and react. The mixture is stirred in a sealed tube at 50°C for 1 hour. The reaction mixture is concentrated under reduced pressure. The residue is eluted in H2O (0.1% NH4HCO3) with a gradient of 40% to 50% ACN. The title compound (1) was purified by reverse-phase flash chromatography (C18 column). Obtain 20 mg. Titrate the material with hexane (3 mL). Remove the precipitated solid by filtration. The sample was collected and washed with hexane (3 × 3 mL) to obtain the title product (85.1 mg, 34%). It is obtained as a white solid. ES / MS (m / z) 503.2 (M+H).
[0244] Example 154 5-amino-3-[4-[2-[[3-(2,2-dimethylpropyl)isoxazole- 5-yl]amino]-2-oxo-ethyl]-2,3-difluorophenyl]-1-yl Sopropylpyrazole-4-carboxamide [ka] tert-butyl N-[4-carbamoyl-5-[4-[ 2-[[3-(2,2-dimethylpropyl)isoxazole-5-yl]amino]-2- Oxo-ethyl]-2,3-difluorophenyl]-2-isopropyl-pyrazole- 3-yl]carbamate (45 mg, 0.078 mmol), TFA (0.23 mL, Add 3.12 mmol) at room temperature. Stir the mixture for 3 hours. Reaction mixture, under reduced pressure. The residue is concentrated, its pH is made basic with a saturated NaHCO3 aqueous solution, and then extracted with dimethyl. The organic extract is washed with brine and concentrated under reduced pressure. The residue is concentrated in DCM at a concentration of 1% to 10%. Purified by silica gel chromatography eluting with a % MeOH gradient, resulting in a white solution. A solid is obtained. This solid is ground in iPr2O at room temperature, filtered, and washed in iPr2O. Under vacuum, the compound (26 mg, 70%) was dried overnight at 80°C to obtain a white solid. Obtained by doing this. ES / MS (m / z) 475 (M+H).
[0245] Example 155 5-amino-3-(2,3-difluoro-4-(2-((3-(3-fluorobicyclo[ 1.1.1]Pentan-1-yl)isoxazole-5-yl)amino)-2-oxoyl (Tyl)phenyl)-1-isopropyl-1H-pyrazole-4-carboxamide [ka] DCM (2 mL) contains tert-butyl(4-carbamoyl-3-(2,3-difluoride) Ro-4-(2-((3-(3-fluorobicyclo[1.1.1]pentan-1-yl) Soxazol-5-yl)amino)2-oxoethyl)phenyl)-1-isopropyl -1H-pyrazole-5-yl)carbamate (30 mg, 0.051 mmol), T Add FA (0.39 mL, 5.10 mmol). Stir the reaction mixture at room temperature for 2 hours. The reaction mixture is quenched with a cold saturated NaHCO3 aqueous solution, and the aqueous layer is extracted with toluene. Dissolve. Wash the organic extract with brine, dry with Na2SO4, filter, and remove under reduced pressure. Concentrate the mixture. Elute the crude material with silica using a gradient of 10% to 100% methoxy in heptane. Purification by gel chromatography yields the title compound (10 mg, 40%). S / MS (m / z) 489.4 (M+H).
[0246] The following compounds in Table 30 were subjected to purification and / or / ma after the reaction time was adjusted to determine the completion of the reaction. Alternatively, use appropriate chromatographic conditions for titration in the appropriate solvent when necessary. 5-amino-3-(2,3-difluoro-4-(2-((3-(3-fluorobisic Ro[1.1.1]pentan-1-yl)isoxazole-5-yl)amino)-2-oxy Regarding soethyl(phenyl)-1-isopropyl-1H-pyrazole-4-carboxamide It is essentially prepared as described. TFA can also be added dropwise to the reactants. THF can be used as a substitute for DCM if its solubility is suitable. [Table 30-1] [Table 30-2] [Table 30-3] [Table 30-4] [Table 30-5] [Table 30-6] [Table 30-7]
[0247] Example 196 5-amino-1-isopropyl-3-[2-(methoxymethyl)-4-[2-[[5-( 1-Methylcyclopentyl)isoxazole-3-yl]amino]-2-oxoethyl ]phenyl]pyrazole-4-carboxamide [ka] 2-[4-bromo-3-(methoxymethyl)phenyl]-N-[ in THF (3 mL) 5-(1-methylcyclopentyl)isoxazole-3-yl]acetamide (0.13 0g, 0.319 mmol) contains bis(pinacolate)diborone (89 mg, 0.350 Add mmol) and KOAc (95 mg, 0.968 mmol). Degass with Ar for 10 minutes, then Pd(dppf)Cl2CH2Cl2(27mg, 0.032 Add mmol of THF, stir the mixture at 50°C overnight, and let it cool to room temperature. L) 5-amino-3-bromo-1-isopropylpyrazole-4-carboxamide (95 mg, 0.384 mmol) was added, followed by K3PO in H2O (1.2 mL). Add 4 (0.206 g, 0.970 mmol). Degas the mixture with Ar for 10 minutes. Add XantPhos Pd G3 (95%, 16 mg, 0.016 mmol). The mixture is heated at 50°C for 20 hours, cooled to room temperature, and filtered through talcum powder. The filtrate is diluted with ethyl acetate / H2O, and the aqueous layer is extracted with ethyl acetate (twice the amount). The organic extract is washed with brine, dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude material is eluted using silica gel chromatography with a gradient of 1% to 10% MeOH in DCM. The retrieval graph shows that the elution of the DCM is followed by a gradient of 90% to 100% ethyl acetate. 2. Chromatography, and 0% to 100% ACN (0.1% HOAc) in H2O. Purified by reverse-phase chromatography (C18Aq column) with elution at a gradient, Title The compound is obtained. The residue is dissolved in DCM and added dropwise to pentane. The suspension is cooled at room temperature for 2 minutes. Stir for a while and filter. Dry the solid under vacuum at 38°C for 3 days to obtain the title compound (35 Obtain mg, 22%). ES / MS (m / z) 495 (M+H).
[0248] The following compounds in Table 31 were subjected to reaction time adjustments to determine the completion of the reaction, and appropriate purification procedures were performed. Using chromatography conditions, 5-amino-1-isopropyl-3-[2-(me Toxymethyl)-4-[2-[[5-(1-methylcyclopentyl)isoxazole-3 -yl]amino]-2-oxo-ethyl]phenyl]pyrazole-4-carboxamide Prepare essentially as described below. The reaction temperature is in the range of approximately 50°C to 55°C. It is possible. [Table 31]
[0249] Example 199 5-amino-3-(4-(2-((3-(2-chloro-4-fluorophenyl)isoxa Zol-5-yl)amino)-2-oxoethyl)phenyl)-1-(1-methylcyclo Propyl)-1H-pyrazole-4-carboxamide [ka] 2-(4-(5-amino-4-cyano-1-(1-methylcyclopropyl)-1H-p Razole-3-yl)phenyl)-N-(3-(2-chloro-4-fluorophenyl) Soxazole-5-yl)acetamide (66 mg, 0.134 mmol) and Par Kins catalyst (69.2 mg, 0.161 mmol) and EtOH (1.0 mL) In H2O (1.0 mL), at 60°C for 4 hours, then at 50°C for 4 hours, and at room temperature... Stir the mixture overnight. Extract the reaction mixture with toluene and wash with H2O (3 times). Combine The organic extract is concentrated and then added to hexane at 0% to 100% pharmaceutically acceptable levels, followed by phosphate in hexane. Silica gel chromatography eluting with a gradient of 0% to 20% MeOH (including 1% NH4OH) Purified by Raffy to obtain the title compound (35 mg, 51%). ES / MS (m / z)509.1
[0250] The following compounds in Table 32 were analyzed by adjusting the reaction time to determine the completion of the reaction and then appropriately purified. Using the following chromatography conditions, 5-amino-3-(4-(2-((3-(2-) Rolo-4-fluorophenyl)isoxazole-5-yl)amino)-2-oxoethyl )phenyl)-1-(1-methylcyclopropyl)-1H-pyrazole-4-carbox Prepare it essentially as described for Mido. [Table 32-1] [Table 32-2] [Table 32-3] [Table 32-4]
[0251] Example 221 5-amino-3-[2,3-difluoro-4-[2-[[3-(3-fluoro-1-bicyl Chlo[1.1.1]pentanyl)isoxazole-5-yl]amino]-2-oxo-e [Tyl]phenyl]-1-(1-methylcyclopropyl)pyrazole-4-carboxamide [ka] 2-[4-[5-amino-4-cyano-1-(1-methylcyclopropyl)pyrazole -3-yl]-2,3-difluorophenyl]-N-(3-[3-fluorobicyclo[1 .1.1]Pentan-1-yl)-1,2-oxazol-5-yl)acetamide(6 0 mg, 0.124 mmol), NaOH in EtOH:DMSO (6 mL, 5:1) 25 mg, 0.625 mmol), and H2O2 (0.38 mL, 3.72 mmol, Add 30% of the H2O together and stir at 50°C for 1 hour. Cool the solution to room temperature and allow to saturated. Quench with Na2SO3 (10 mL) aqueous solution and extract with toluene (3 × 20 mL). The organic extract is dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue is H Reverse-phase chromatography eluting with a gradient of 40% to 60% ACN in 2O (0.1% FA). The compound was purified by (C18 column) to obtain the title compound (45 mg, 73%). ES / MS (m / z) 501.2 (M+H).
[0252] Example 222 5-amino-3-(2,3-difluoro-4-[[(3-[3-methylbicyclo[1.1 .1]pentan-1-yl)-1,2-oxazol-5-yl)carbamoyl]methyl ]phenyl)-1-(1-methylcyclopropyl)pyrazole-4-carboxamide [ka] 2-[4-[5-amino-4 in EtOH (3 mL) and DMSO (0.60 mL) -Cyano-1-(1-methylcyclopropyl)pyrazole-3-yl]-2,3-diflu Olophenyl]-N-(3-[3-methylbicyclo[1.1.1]pentan-1-yl] -1,2-oxazole-5-yl)acetamide (70 mg, 0.146 mmol) And in a solution of NaOH (29 mg, 0.725 mmol), add H2O2 (0.22 mL, 2 Add 0.15 mmol (30% of H2O). Stir the reaction mixture at 50°C for 1 hour. Mix Cool the substance to room temperature and quench it at 0°C with a saturated Na2SO3 (10 mL) aqueous solution. Extract with ethyl acetate (2 x 30 mL). Combine the organic extracts and brine (2 x 20 mL). Wash with (mL), dry with anhydrous Na2SO4, filter, and concentrate under reduced pressure. Remove the residue with H Reverse-phase chromatography eluting with a gradient of 40% to 60% ACN in 2O (0.1% NH4HCO3) The title compound (36 mg, 50%) was purified by tography (C18 column) and whitened. It is obtained as a solid of color. ES / MS (m / z) 497.3 (M+H).
[0253] Example 223 5-amino-1-isopropyl-3-[4-([[3-(pyridine-2-yl)-1,2 -Oxazol-5-yl]carbamoyl]methyl)phenyl]pyrazole-4-carb Xamide [ka] EtOH (1.5 mL), DMSO (0.30 mL), and H2O (0.60 mL) The 2-[4-(5-amino-4-cyano-1-isopropylpyrazole-3-yl) [enyl]-N-[3-(pyridine-2-yl)-1,2-oxazole-5-yl]acetate Toamide (60 mg, 0.140 mmol) and NaOH (28 mg, 0.700 mmol) To the stirred solution of (100 ml), add H2O2 (0.22 mL, 2.15 mmol, 30% of H2O). Add at room temperature. Stir the mixture at 40°C for 3 hours. Mix the reactants with saturated Na2SO3(1 Quench with 0 mL aqueous solution. Extract the mixture with toluene (3 × 100 mL). The combined organic extracts were washed with brine (100 mL) and dried with anhydrous sodium 2SO4. Filter the solution and concentrate the filtrate under reduced pressure. Dilute the residue with 10 units of H2O (0.1% NH3H2O). Purified by reverse-phase chromatography eluting with an ACN gradient of %~30%, and then title-formulated. The mixture (26 mg, 40%) is obtained as a white solid. ES / MS (m / z) 446.2 M+H).
[0254] The following compounds in Table 33 were tested using appropriate reagents, and the reaction time was adjusted to determine the completion of the reaction. Then, using appropriate chromatographic conditions for purification, 5-amino-1-isopropyl alcohol was used. Pyr-3-[4-([[3-(pyridine-2-yl)-1,2-oxazol-5-yl Carbamoyl methyl phenyl pyrazole-4-carboxamide, 0.3 formic acid Prepare essentially as described. Salt formation depends on purification conditions. H2O2 (Approximately 15-30 equivalents) can be added dropwise or little by little, and H2O can be added if necessary. The temperature can be increased to approximately room temperature or in the range of 50°C. [Table 33-1] [Table 33-2] [Table 33-3] [Table 33-4] [Table 33-5] [Table 33-6]
[0255] Example 258 5-amino-3-[4-[([3-[3-(trifluoromethyl)bicyclo[1.1.1 ]pentan-1-yl]-1,2-oxazole-5-yl]carbamoyl)methyl] [enyl]-1-[1,1,1-trifluoropropan-2-yl]pyrazole-4-cal Boxamide, isomer 1 [ka] Example 259 5-amino-3-[4-[([3-[3-(trifluoromethyl)bicyclo[1.1.1 ]pentan-1-yl]-1,2-oxazole-5-yl]carbamoyl)methyl] [enyl]-1-[1,1,1-trifluoropropan-2-yl]pyrazole-4-cal Boxamide, isomer 2 5-amino-3-[4-[([3-[3-(trifluoromethyl)bicyclo[1.1. 1]Pentan-1-yl]-1,2-oxazol-5-yl]carbamoyl)methyl] Phenyl]-1-[1,1,1-trifluoropropan-2-yl]pyrazole-4-ca Ruboxamide (70 mg) was administered under the following conditions: Column: Lux 5μ Cellulose -4, AXIA Packed, 2.12 × 25 cm, 5 μm, 80% hexane (0. Elute with 1% TFA and 20% IPA; flow rate 20 mL / min, 205 / 250 for 37 minutes. At nm, it was purified by Prep-CHIRAL-HPLC and obtained as a pale brown solid. Title compound t of type 1 (R) 18.6 minutes (15.4 mg, 22.0%, ee=100%) ES / MS (m / z) 557.2 (M+H), and isomer 2 as a pale brown solid. Title compound t (R) 29.8 minutes (14.9 mg, 21.2%, ee=99.5%), ES We obtain / MS(m / z)557.2(M+H).
[0256] The following compounds in Table 34 are 5-amino-3-[4-[([3-[3-(trifluoromethyl (Tyl)bicyclo[1.1.1]pentan-1-yl]-1,2-oxazol-5-yl ]Carbamoyl)methyl]phenyl]-1-[1,1,1-trifluoropropane-2- This section describes isomer 1 and isomer 2 of ylpyrazole-4-carboxamide. The sea urchin is essentially prepared by adjusting the purification system as appropriate. [Table 34-1] [Table 34-2] [Table 34-3] [Table 34-4] [Table 34-5] [Table 34-6] [Table 34-7] [Table 34-8]
[0257] Example 292 5-amino-1-isopropyl-3-[5-[2-oxo-2-[3-(trifluoromethyl [Cyl]anilino]ethyl]-2-pyridyl]pyrazole-4-carboxamide [ka] 2-[6-(5-amino-4-cyano-1-isopropyl-pyra in DMF (2mL)] Zole-3-yl)-3-pyridyl acetate (0.070 g, 0.24 mmol), 3-( Trifluoromethylaniline (0.047g, 0.29mmol), and DIPEA To a stirred solution of (0.16g, 1.22 mmol), add T3P(registered trademark) (0.46g, 0 Add 0.73 mmol (50% of DMF). Stir the mixture under N2 at room temperature for 2 hours. Next, concentrate under reduced pressure. The residue is then mixed with 40% to 60% A in H2O (0.1% FA). Purified by reverse-phase chromatography (C18 gel column) with elution using a CN gradient. 2-[6-(5-amino-4-cyano-1-isopropyl-pyrazole-3-yl)-3 -Pyridyl]-N-[3-(trifluoromethyl)phenyl]acetamide (0.050 g, 45%) is obtained as a white solid. ES / MS (m / z) 429.1 (M+H).
[0258] 2-[6-(5-amino-4) in EtOH:DMSO (1.2 mL, 5:1) at 0°C -Cyano-1-isopropyl-pyrazole-3-yl)-3-pyridyl]-N-[3-( [Trifluoromethyl)phenyl]acetamide (0.050g, 0.11 mmol) Add H2O2 (0.13g, 1) to a stirred solution of NaOH (0.13g, 0.58 mmol). Add 0.16 mmol (30% of H2O). Stir the mixture at 40°C for 4 hours. Cool the solution to 0°C, quench it with saturated Na2SO3 aqueous solution, and add toluene (2 × 10 mL). Extract with ). Wash the combined organic extract with brine (2 x 30 mL) and anhydrous sodium 2 Dry with SO4, filter, and concentrate under reduced pressure. Remove the residue from H2O (0.1% NH3H2O). ) Reverse-phase chromatography (C18 gel chromatography) that elutes with a gradient of 35% to 45% ACN. The title compound (0.021 g, 40%) is purified by (M) to obtain a white solid. ES / MS (m / z) 447.1 (M+H).
[0259] The compounds in Table 35 must be prepared using appropriate amines and carboxylic acids (or lithium salts). Adjust the reaction time as needed to complete the reaction, and 5-amino-1-isopropyl-3-[ 5-[2-oxo-2-[3-(trifluoromethyl)anilino]ethyl]-2-pyridyl Prepare essentially as described for [L]pyrazole-4-carboxamide. [Table 35-1] [Table 35-2] [Table 35-3] [Table 35-4] [Table 35-5] [Table 35-6] [Table 35-7]
[0260] Biological assays The following assays confirm that the compounds described herein are RET kinase inhibitors. This indicates.
[0261] Assay A: RET enzyme assay Compounds of formulas I, Ia-Ix, IIa-IIx, and / or IIIa-IIIx, Uses CisBio's HTRF® KinEASE®-TK assay technology. Therefore, they inhibit the wild-type, V804M, and G810S mutant RET kinases. Screen for capability. Eurofins (1.25nM RET; catalog) (a) N-terminal GST-tagged recombinant human RET cytoplasmic domain from (number 14-570M) a 658-terminus), or Millipore (1.25 nM enzyme; catalog number 14- N-terminal GST-tagged recombinant human V804M mutant RET cytoplasmic domain from 760) (aa 658 terminus), or N-terminal GST-tagged recombinant human G810S (aa-65 (8-terminal) (1.25 nM enzyme; produced in insect cells) was used as the test compound (0.4% in the assay). 10 μL of 1 nM DTT, 5 mM MgCl2, 0.0 (final DMSO) 1x Cisbuio enzyme buffer consisting of 0.4% BSA and 0.05% Tween20. The 62.5 nM TK-substrate biotin (CisBio, catalog number 62TK0PEC) is contained within. Incubate the compound with (part of) and 1 mM ATP. Typically, D Prepare by 3-fold serial dilution in MSO, add to the assay, and obtain the appropriate final concentration. 22°C Incubate for 40-60 minutes (40 minutes for V804M, 60 minutes for WT and G810S) After that, HTRF detection buffer (all from CisBio, catalog number 62TK0P) (Part of the EC) contains 7.8 nM streptavidin-XL665 and 0.5x TK-ab -By adding a quenching solution (10 μL) containing cryptate, the reaction products are quenched. Energize. 60-80 minutes at 22°C (60 minutes for WT, V804M and G810S) After incubation for 80 minutes, the reaction is observed at HT at 337 / 665 nm (excitation / emission). Determined using a PHERastar plate reader via RF detection. Inhibition per Cent showed 0% inhibition when compared to a control condition that did not contain the compound (0.4% DMSO only). And it is calculated as 100% inhibition expressed under conditions without enzymes. The inhibition value % is calculated using 4 parameters ICs that are fitted to and determined by the logistic curve 50 The value is the resistance at the inflection point of the fitted curve. Defined as the estimated concentration of the harmful agent. Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 153, 154, 199, 221, 222, 292, 293, 294, 299, 300, 301, 302, 303, 306, 308, 310, 311, 316, 317, 318, Compounds 321, 324, 329, 330, and 335 all performed well in these assays. At least one of the wild-type, V804M, and G810S mutant RET kinases And ICs with less than 150nM 50 The values were observed. This data indicates that these compounds are specified in this specification. As with the other compounds disclosed, it is shown to be a RET inhibitor.
[0262] Assay B: RET cell assay Compounds of formulas I, Ia-Ix, IIa-IIx, and / or IIIa-IIIx, RE at tyrosine 1062 when detected by In-Cell Western We will screen their ability to inhibit the intracellular autophosphorylation of T. Inducible expression of B-RET WT and RET mutant forms V804M and G810S HEK293 cells containing a doxycycline-inducible plasmid were subjected to black poly-D- Zimprecoat 384-well plate (Corning, catalog number 356697) Seedlings are seeded at 25,000 cells / well. KIF5B-RET expression is controlled at 1 μg / mL. The cells are induced with doxycycline and incubated overnight at 37°C. The compound is then DM After preparing the cells in 3-fold serial dilutions in SO, they were further diluted to 1:100 in culture medium before being added to the cells. (Final DMSO concentration 0.1%). The compound treatment is carried out at 37°C for 1 hour, followed by 4% HO Cells were fixed with lumaldehyde at room temperature for 20 minutes, then frozen in ice-cold MeOH at room temperature for 10 minutes. Cell permeabilization is performed. The cells are then placed in Intercept® blocking buffer. (Li-COR, catalog number 927-70010) Incubate at room temperature for 1 hour To do. Human phospho-RET (Y1062) (R&D, catalog number AF5009, 1 / (250 dilution) and human glyceraldehyde-3-phosphate dehydrogenase (clone 6 Primary antibody against C5, Merck, catalog number MAB374, 1 / 1000 dilution and Incubate the sample overnight at 4°C. Secondary antibody IRDye(registered trademark) 800CW Goat anti-rabbit IgG (Li-COR, catalog number 926-32211, 1 / 1000 dilution) (Translation) and IRDye (registered trademark) 680CW goat anti-mouse IgG (Li-COR, Cata) Incubation with log number 926-68070 (1 / 1000 dilution) at room temperature for 1 Perform for a specified time. All antibody dilutions include Intercept (0.05% Tween20). Performed using a blocking buffer (registered trademark). PBS-T (Cell Signaling) After washing the cells with technology (catalog number 9809), the image was taken with Li- Acquisitions were performed at 700 and 800 nm using a COR Odyssey LCx, with DMSO control. The percentage is 10 when compared to the control condition which does not contain the compound (0.4% DMSO only). Calculated using the 0% signal and the 0% signal represented under conditions including the control compound. DM The percentage relative to the SO control value was fitted to a 4-parameter logistic curve and determined the EC. 50 The value is defined as the estimated concentration of the inhibitor at the inflection point of the fitted curve. Examples 1, 2, and 3 ,4,5,6,7,8,9,10,153,154,199,221,222,292, 293, 294, 299, 300, 301, 302, 303, 306, 308, 310, The transformation of 311, 316, 317, 318, 321, 324, 329, 330, and 335 All of the formulations are from wild-type, V804M, and G810S RET mutant cell assays. At least one of the following, with an EC of less than 150 nM 50 The value of RET at tyrosine 1062 Intracellular autophosphorylation was inhibited. This data is based on the fact that these compounds are disclosed herein. Like other compounds, it demonstrates that it is a RET inhibitor.
Claims
1. A compound of the formula: 【Chemistry 1】 During the ceremony, A is phenyl or pyrimidinyl; Each R 1 are independently hydrogen, halogen, C 1 -C 6 Alkyl, cyclopropyl, -(C 0 -C 4 Alkyl) (C 3 -C 7 Cycloheteroalkyl), dimethylphosphoryl, C 1 -C 6 alkoxy, difluoromethylsulfanyl, or pentafluorosulfanyl; 1 is unsubstituted or can be substituted, R 1 is independently substituted with one or more substituents selected from the group consisting of halogen, methyl, and methoxy; and n is 1 or 2; X 1 CH, X 2 is CH or N, and X 3 is CH, and X 4 is CH, or C-halogen, R 2 is isopropyl, or a pharma- ceutically acceptable salt thereof.
2. The compound of claim 1, wherein A is phenyl.
3. The compound of claim 1, wherein A is pyrimidinyl.
4. The compound according to claim 1, wherein X 1 , X 2 , X 3 , and X 4 are all CH.
5. The compound according to claim 1, wherein at least one R 1 is CF 3 .
6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable carrier, diluent, or excipient.
7. A pharmaceutical composition for treating cancer in a patient, comprising an effective amount of a compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof.
8. The pharmaceutical composition described in claim 7, wherein the cancer is a RET-associated cancer.
9. The pharmaceutical composition of claim 7, wherein the cancer is selected from the group consisting of lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or type 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, colorectal cancer, papillary renal cell carcinoma, ganglioneuroma of the gastrointestinal mucosa, and cervical cancer.
10. The pharmaceutical composition described in claim 9, wherein the cancer is medullary thyroid cancer.
11. The pharmaceutical composition described in claim 9, wherein the lung cancer is small cell lung cancer, non-small cell lung cancer, bronchiolocarcinoma, RET fusion lung cancer, or lung adenocarcinoma.
